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Summary 
In diabetics, hyperglycemia, hyperlipidemia and inflammation potentiates the development of 
cardiovascular diseases (CVDs). These conditions provoke excessive generation of oxidative stress 
that has been implicated in the pathogenesis of diabetic cardiomyopathy (DCM). In the diabetic state, 
excessive generation of free radicals can cause oxidative damage to DNA and alter protein and lipids, 
leading to the activation of various death-induced signaling pathways. Activation of these death 
pathways result in structural and functional modifications to the myocardium. Current diabetic drug 
therapies do not protect the diabetic heart at risk from developing cardiovascular complications. Thus, 
in search for new therapeutics, we aim to unravel the molecular mechanisms associated with the 
protective effect of two major bioactive compounds from Aspalathus linearis, phenyl pyruvic acid-2-O-
β-D-glucoside (PPAG) and aspalathin against hyperglycemia-induced oxidative stress and apoptosis 
in H9c2 cardiomyocytes. 
The study showed that PPAG and aspalathin were able to decrease mitochondrial membrane 
depolarization and prevent hyperglycemia-induced myocardial apoptosis by increasing the Bcl2/Bax 
ratio. We revealed that while both compounds were able to reduce hyperglycemia-induced apoptosis, 
only aspalathin could ameliorate lipid toxicity and oxidative stress-associated with insulin resistance.  
An important feature of the failing heart is the observed shift in mitochondrial substrate preference that 
precedes the onset of oxidative damage. The current study revealed that aspalathin improved glucose 
metabolism by decreasing fatty acid uptake and subsequent β-oxidation. This was achieved through 
decreasing the expression of adenosine monophosphate-activated protein kinase threonine 172 
(pAMPK (Thr172)) and carnitine palmitoyltransferase 1 (Cpt1), while increasing that of acetyl-CoA 
carboxylase (Acc) and glucose transporter 4 (Glut4). Additionally, it is known that cardiomyocytes 
have a very low antioxidant capacity and a shift in mitochondrial substrate preference can result in 
accelerated oxidative damage. In this study, we showed that aspalathin ameliorated oxidative stress 
by increasing the antioxidant capacity of the cells through activation of the antioxidant response 
pathway, nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and its downstream target genes. 
Moreover, we showed that aspalathin was able to reverse lipid toxicity by increasing the expression of 
Adiponectin, C1Q and collagen domain containing (Adipoq) and concomitantly decreasing cluster of 
differentiation 36 (Cd36) and Cpt1 mRNA expression. We further observed that Adipoq negatively 
regulated sterol regulatory element binding transcription factor 1 (Srebf1), stearoyl-Coenzyme A 
desaturase 1 (Scd1) and solute carrier family 27 (fatty acid transporter), member 3/5 (Slc27a3/5). This 
led to reduced lipid accumulation in H9c2 cardiomyocytes, with an associated decrease in total 
cholesterol, triglycerides and low-density lipoprotein in leptin resistant db/db mice. This was 
accompanied by decreased mRNA expression of inflammation markers in H9c2 cells, including 
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interleukin 3 and 6 (IL3 and IL6), tumor necrosis factor receptor superfamily, member 1b and 13 
(Tnfrsf1b and Tnfsf13), Janus kinase 2 (Jak2) and mitogen-activated protein kinase 3 (Mapk3). 
Together our results infer that aspalathin can slow down the progression of DCM, and thus protect the 
myocardium against causal factors associated with the development and progression of CVD. 
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Opsomming 
In diabete, hiperglukemie, hiperlipidemie en inflammasie versnel die ontwikkeling van kardiovaskulêre 
siektes (CVDs). Hierdie toestande lei tot oormatige generasie van oksidatiewe stres wat betrokke is by 
die patogenese van diabetiese kardiomiopatie (DCM). In die diabetiese toestand, kan oormatige 
generasie van vrye radikale oksidatiewe skade aan DNA asook proteïne en vette verander, wat tot die 
aktivering van verskeie seldood seinpaaie kan lei. Aktivering van hierdie seldood seinpaaie 
veroorsaak strukturele en funksionele wysigings aan die miokardium. Huidige medikasie beskerm nie 
die diabetiese hart teen die ontwikkeling van kardiovaskulêre komplikasies nie. In die studie 
ondersoek ons die beskermende effek van twee hoof bioaktiewe verbindings van Aspalathus linearis, 
fenielpirodruiwesuur-2-O-β-D-glukosied (PPAG) en aspalatien, as nuwe terapeutiese middels, teen 
oksidatiewe stres en hiperglukemie-geïnduseerde apoptose in H9c2 kardiomiosiete en ontrafel ons die 
molekulêre meganismes wat betrokke is. 
Die studie het getoon dat PPAG en aspalatien mitokondriale membraan depolarisasie verminder en 
hiperglukemie-geïnduseerde miokardiale apoptose voorkom deur die Bcl2/Bax verhouding te verhoog. 
Die studie toon verder dat alhoewel beide verbindings in staat was om hiperglukemie-geïnduseerde 
apoptose te verminder, net aspalatien lipiedtoksisiteit en oksidatiewe stres, wat verband hou met 
insulien weerstand, verbeter. 
'n Belangrike kenmerk van hartversaking is die verskuiwing in mitokondrialesubstraat voorkeur wat die 
aanvang van oksidatiewe skade voorafgaan. Die huidige studie het getoon dat aspalatien glukose 
metabolisme verbeter deur vetsuuropname en daaropvolgende β-oksidasie te verminder. Dit word 
bereik deur die verlaagde uitdrukking van adenosienmonofosfaat geaktiveerde proteïenkinase 
threonien 172 (pAMPK (Thr172)) en karnitien palmitoyltransferase 1 (Cpt1), terwyl die ekspresie van 
asetiel-KoA karboksilase (Rek) en glukose transporter 4 (Glut4) verhoog word. Verder is dit bekend 
dat kardiomiosiete baie lae antioksidant kapasiteit het en gevolglik dat 'n verskuiwing in 
mitokondrialesubstraat oksidatiewe skade kan veroorsaak. Die studie wys dat aspalatien die 
antioksidantkapasiteit van die selle beskerm en oksidatiewe stres verlig deur aktivering van kernfaktor 
erythroïd-faktor (NF-E2)-verwante faktor 2 (Nrf2) antioksidant response element seintransduksie-pad. 
Aspalatien kon ook lipiedtoksisiteit verhoed deur adiponektien, C1Q en kollageen domein-verwante 
(Adipoq) ekspressie te verhoog met gepaardgaande afname van groepering van differensiasie 36 
(Cd36) and Cpt1 mRNA uitdrukking. Ons het verder opgemerk dat Adipoq sterol regulatoriese element 
bindende transkripsie faktor 1 (Srebf1), stearoyl-koënsiem A desaturase 1 (Scd1) en opgeloste stof-
draer familie 27 vetsuur transporter lid 3/5 (Slc27a3/5) ekspresie onderdruk, wat lipied akkumulasie in 
H9c2 kardiomiosiete teenwerk. In leptien weerstandige db/db muise het aspalatien totale cholesterol, 
trigliseriede en lae-digtheid lipoproteïen verlaag. Dit het gepaard gegaan met 'n afname in mRNA 
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uitdrukking van inflammasie merkers, wat interleukin 3 and 6 (IL3 and IL6), tumor nekrose faktor 
reseptor superfamilie, lede 1b and 13 (Tnfrsf1b and Tnfsf13), Janus kinase 2 (Jak2) en mitogen-
activated protein kinase 3 (Mapk3) insluit. 
In samevatting toon ons resultate dat aspalatien die ontwikkeling van DCM kan vertraag en daardeur 
die miokardium teen oorsaaklike faktore wat met die ontwikkeling en vordering van CVD verbind word, 
beskerm. 
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Introduction 
The prevalence of diabetes mellitus (DM) is increasing at an alarming rate worldwide. According to the 
International Diabetes Federation (IDF) the number of individuals living with DM is 415 million and this 
figure is estimated to reach 642 million by the year 2040 (IDF, 2015). The World Health Organization 
(WHO) lists three main types of diabetes: gestational DM, which can be defined as a degree of 
glucose intolerance during pregnancy; type 1 DM (T1DM), also known as juvenile or insulin dependent 
diabetes that is usually diagnosed in children and young adults; and type 2 DM (T2DM) which is 
related to obesity and represents approximately 90% of diabetes cases worldwide (WHO, 2012). DM 
is characterized by disturbances in insulin secretion and chronic hyperglycemia. Literature suggests a 
strong correlation between chronic hyperglycemia and micro- and macro- vascular complications, 
including retinopathy, nephropathy, neuropathy and cardiovascular diseases (CVDs) such as heart 
failure (HF) (Ginsberg and Mazze, 1994; Swan et al., 1997; Boudina and Abel, 2010).  
Chronic hyperglycemia remains the leading risk factor associated with HF in a diabetic state. Through 
various pathways, it is responsible for augmented production of oxidative stress (Fiordaliso et al., 
2004; Kukidome et al., 2006; Giacco and Brownlee, 2010; Mapanga and Essop, 2016). Oxidative 
stress may directly induce cardiac structural remodeling, a prominent sign of diabetic cardiomyopathy 
(DCM) (Watanabe, 1998). DCM is a distinct clinical entity that was first described about four decades 
ago (Rubler et al., 1972). The diagnosis of DCM remains nebulous and the precise mechanisms 
explaining DCM remain to be fully elucidated. Although therapeutic drugs certainly play a significant 
role in the treatment of DM and its co-morbidities, there is currently no treatment specific for DCM. 
Insulin and metformin are the first line antidiabetic drugs with known cardioprotective properties 
(Jonassen et al., 2001; Eurich et al., 2005; Yin et al., 2011). However, the rise in CVD related deaths 
in people with DM is still a major concern (Boudina and Abel, 2010; American Diabetes Association, 
2014). Furthermore, lifestyle interventions of caloric restriction and physical activity in patients with 
impaired glucose tolerance has been shown to improve CVD function. Nonetheless, most individuals 
do not adhere to such lifestyle interventions. On the other hand, antioxidants are among the leading 
therapies being investigated for their efficacy against various metabolic complications (Maritim et al., 
2003; Rahimi et al., 2005; Ford, 2006). In the last decade, there has been much interest in the 
potential health benefits of plant polyphenols such as resveratrol and mangiferin as dietary 
antioxidants (Sellamuthu et al., 2009; Szkudelski and Szkudelska, 2011; Wang et al., 2014). In 
addition, our laboratory has increasingly investigated and reported on the antidiabetic properties of 
compounds found in Aspalathus linearis (rooibos) (Muller et al., 2012; Mazibuko et al., 2013; 
Sanderson et al., 2014). However, the use of rooibos and its efficacy as a cardioprotective agent have 
not yet been investigated. 
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For this study we hypothesized that compounds specific to Aspalathus linearis (rooibos) protect the 
myocardium against hyperglycemia-induced oxidative injury by activating nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) antioxidant response pathway. Thus, we aim to investigate the mechanism by 
which phenylpyruvic acid-2-O-β-D-glucoside (PPAG) and aspalathin are able to protect the 
myocardium against oxidative stress associated with diabetes mellitus. 
 
This thesis is divided into the following themes which include: 
I. Literature review (Chapter 1) 
II. Phenylpyruvic acid-2-O-β-D-glucoside attenuates high glucose-induced apoptosis in H9c2 
cardiomyocytes (Chapter 2) 
III. Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high 
glucose-induced shifts in substrate preference and apoptosis (Chapter 3) 
IV. Aspalathin protects the heart against hyperglycemia-induced oxidative damage by up-
regulating Nrf2 expression (Chapter 4) 
V. Transcription profile unveils the cardioprotective effect of aspalathin against lipid toxicity 
(Chapter 5) 
VI. General conclusions (Chapter 6) 
 
Each chapter is structured according to the journal in which the article was published and if the results 
in a particular chapter have not been published yet, the specifications prescribed for the journal to be 
submitted to have been used. 
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Chapter 1: Literature review 
 
1.1. Cardiovascular diseases: a leading cause of death worldwide 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide (Fig. 1.) (World Health 
Organization [WHO], 2012). The continuous rise in non-communicable diseases such as diabetes 
mellitus (DM) and obesity remains a major burden causing an increase in CVDs worldwide (Boden 
and Salehi, 2013; WHO, 2014). Acute myocardial infarction (AMI) that may cause heart failure (HF) is 
often closely associated with risk factors such as DM, hypertension, obesity and smoking (Anand et 
al., 2000; Smith, 2007). Ischemic heart disease (IHD), also known as coronary artery disease (CAD), 
is the most common type of CVD (Reaven and Sacks, 2005; McCullough, 2007; Kealey, 2010). 
According to WHO, CAD was accountable for up to 42.3% of the 17.5 million CVD-related deaths 
reported in 2012, of which 9.2% was in the African region (Kengne et al., 2005; WHO, 2014). 
Moreover, diabetes can also affect cardiac structure and function independent of CAD, a condition 
identified as the diabetic cardiomyopathy (DCM) (Rubler et al., 1972; Boudina and Abel, 2010; Forbes 
and Cooper, 2013). 
 
1.2. Diabetic cardiomyopathy 
Cardiomyopathies are diseases of the myocardium that are characterized by a measurable 
deterioration of heart muscle function. As the condition worsens, less blood is pumped through the 
heart to maintain normal contractile function leading to a decrease in electrical rhythm and subsequent 
HF. According to a report by the American Heart Association (AHA), cardiomyopathies can be divided 
into 2 major groups based on predominant organ involvement (Maron et al., 2006). Primary 
cardiomyopathies are those exclusively or mainly limited to the heart muscle while secondary 
cardiomyopathies are a result of an underlying condition such as DM. Although they remain mainly 
non-ischemic, distinctively affecting the heart muscle, cardiomyopathies play a pre-dominant role in 
inducing HF and are one of the major causes of death in Africa (Kengne et al., 2008, 2005; Mbanya et 
al., 2010; Dalal et al., 2011). 
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Figure 1. The top 10 leading causes of mortality in 2012 (compiled by author, based on statistics by 
World Health Organization, 2014). Heart diseases are the leading cause of death in the world, with ischemic 
heart disease being the most prominent, followed by stroke. Heart failure is responsible for 3 in every 10 deaths 
worldwide and approximately 17.5 million deaths globally.  
 
DCM is a disease of the heart muscle in persons with DM. The prevalence of DCM is between 30-65% 
depending on the population under study (Miki et al., 2013; Dandamudi et al., 2014). DCM is 
characterized by left ventricular (LV) dysfunction accompanied by decreased systolic and diastolic 
function (Fonarow and Srikanthan, 2006). The precise mechanisms explaining LV impairment that is 
associated with systolic dysfunction in DCM remains to be fully elucidated. However, chronic 
hyperglycemia and hyperlipidemia, in the absence of CAD and hypertension is central in the etiology 
of DCM (Rubler et al., 1972; Poornima et al., 2006; Boudina and Abel, 2010). Epidemiological studies 
consistently report on a significantly increased LV wall thickness in both men and women with DM 
(Fig. 2.) (Devereux et al., 2000; de Simone et al., 2002). Moreover, these structural changes are 
distinctively identified in patients with DM but not in patients with impaired glucose tolerance (IGT) 
(Devereux et al., 2000; Adeghate and Singh, 2014; Cassidy et al., 2015). This indicates that 
myocardial modifications associated with a diabetic condition might not be an early defect but rather a 
result of prolonged exposure to hyperglycemia. In the diabetic heart, chronic exposure to 
Stellenbosch University  https://scholar.sun.ac.za
 7 
hyperglycemia can result in a shift in substrate preference leading to reduced cardiac efficiency 
(Stanley et al., 2005; Rijzewijk et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. An illustration of a hypertrophic heart from a diabetic patient compared to a normal heart from 
a non-diabetic individual. Hearts of patients with diabetes mellitus display irregularly enlarged left ventricular 
mass, which is a conspicuous sign of diabetic cardiomyopathy.  
 
1.3. Diabetic heart and energy substrate metabolism 
The derangement of cardiac energy substrate preference plays an important role during HF. In the 
normal heart, free fatty acids (FFAs) are the predominant energy substrate and are accountable for up 
to 70% of the energy supply (Stanley et al., 2005). The remaining proportions are mainly from glucose 
(up to 40%) and lactate oxidation (up to 10%) (Lei et al., 2004). Glucose is the preferred energy 
substrate for metabolism and ATP generation during diabetic-induced HF and this is attributable to its 
greater efficiency to produce high-energy products per oxygen consumed compared to the use of 
FFAs (Nagoshi et al., 2011). Insulin resistance inhibits this adaptive response, by almost exclusively 
using FFAs as an energy source, further contributing to the progression of ventricular remodeling and 
cardiac contractile dysfunction (Marfella et al., 2009).  
Stellenbosch University  https://scholar.sun.ac.za
 8 
FFAs enter cardiac cells either passively or actively using fatty acid transporters such as fatty acid 
translocase (FAT)/CD36 and fatty acid binding protein (FABP) (Lopaschuk et al., 2010). Upon entry, 
long chain FFAs can be converted to triacylglycerides (TAGs) by glycerolphosphate acyltransferase, 
resulting in an intramyocardial TAG pool; and this is simultaneous to increased accumulation of 
diacylglycerol (DAG) levels within heart cells in a diabetic state (Inoguchi et al., 1939; Schmidt et al., 
1999). DAG signaling may result in enhanced production of extracellular matrix proteins within a 
diabetic heart (Sharma and Ziyadeh, 1995; Zhao et al., 2014). Excess production of extracellular 
matrix proteins within the myocardium is closely associated with fibrosis, leading to adverse effects on 
cardiac structure and function (Mandavia et al., 2013). 
Increased intracellular DAG favours synthesis of dihydroacetone, a triose carbohydrate that is 
associated with increased free radical damage as well as the activation of protein kinase C (PKC) 
(Connelly et al., 2009; Geraldes and King, 2010). PKC exists in various isoforms and those known and 
most investigated in diabetes research include beta, alpha, gamma and delta isoforms. The main 
function of PKC is to control the function of target proteins through phosphorylation (Mochly-Rosen et 
al., 2012). Its inhibition through in vivo study models of diabetes reveals that PKC mediates a variety 
of activities including inflammation (Cameron et al., 1999; Brownlee, 2001; Connelly et al., 2009). In 
addition, its overexpression in the heart is implicated in the development of hypertrophy, leading to 
decreased ventricular compliance (Sentex et al., 2006). Treatment with antioxidants and decreased 
FFA uptake appears to attenuate DAG-PKC induced diabetic complications (Beckman et al., 2002; Xu 
et al., 2009). However, more clinical studies are required to investigate the precise role PKC plays in a 
diabetic heart and whether its inhibition can prevent diabetic associated vascular complications 
(Mapanga and Essop, 2016). 
 
1.3.1. Free fatty acid metabolism in the diabetic heart 
Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric protein composed of a 
catalytic α, non-catalytic β and γ subunits. The main function of this kinase is to preserve ATP or to 
promote alternative methods of ATP generation. It functions as a sensor during low energy states 
such as ischemia to change substrate utilization and thereby increase or decrease ATP synthesis. Its 
activation is controlled by an increase in the AMP:ATP ratio (Carling, 2004; Zungu et al., 2011). 
Stimulation of AMPK leads to phosphorylation of many target proteins important for ATP synthesis and 
utilization while concurrently inhibiting ATP-consuming pathways such as fatty acid synthesis. In the 
diabetic heart, AMPK activation is linked to phosphorylation of both acetyl-CoA carboxylase (ACC) 
and malonyl-CoA decarboxylase (MCD); however its association with the latter in the heart remains to 
be fully elucidated (Park et al., 2002, 2002; Sambandam et al., 2004; Brownsey et al., 2006). ACC and 
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MCD are both important for the interconversion of acetyl-CoA to malonyl-CoA. Phosphorylation of 
ACC by AMPK reduces the generation of malonyl-CoA; thus prompting more FFAs to enter 
mitochondria through carnitine palmitoyltransferase I (CPT1) for β-oxidation (Fig. 3.) (Makaula et al., 
2006). Resultant increased levels of ATP and citrate through β-oxidation are responsible for the 
allosteric inhibition of glycolysis through phosphofructokinase-1 (PFK1) (Randle et a., 1963, 1998). 
This causes accelerated reactive oxygen species (ROS) production and associated membrane 
peroxidation (Giacco and Brownlee, 2010; Rains and Jain, 2011). Hence, adequate control in the 
uptake and oxidation of FFAs remain crucial for optimal functioning of the myocardium, especially in a 
diabetic state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. AMPK is associated with the phosphorylation of both ACC and MCD to regulate myocardial 
energy metabolism in the heart muscle. Chronic hyperglycemia activates AMPK, resulting in the 
phosphorylation of ACC, releasing the inhibitory effect of malonly-CoA on CPT1 and subsequently leading to 
enhanced entry of FFAs via CPT1 into the mitochondria for β-oxidation. Abnormally increased β-oxidation is 
further accountable for mitochondrial membrane damage through peroxyl radicals. ACC: acetyl-CoA 
carboxylase; AMPK: 5’ adenosine monophosphate (AMP)-activated protein kinase; CPT1: carnitine 
palmitoyltransferase 1; FFA: free fatty acid; MCD: malonyl-CoA decarboxylase. 
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1.3.2. Glucose metabolism in the diabetic heart 
Under specific pathological conditions glucose becomes the preferred substrate in the heart, as it can 
provide greater efficiency by producing high energy products per oxygen consumed compared to 
FFAs (Nagoshi et al., 2011). However, insulin resistance impedes this adaptive metabolic shift. In the 
diabetic heart, myocardial glucose uptake is suppressed due to increased uptake and oxidation of 
FFAs (Fig. 4.) (Aroor et al., 2012). This of course more complex as high glucose uptake still continues 
in endothelial cells of the heart (Mapanga and Essop, 2016). Concurrently, the rate of oxygen (O2) 
consumption by the mitochondria is severely increased, causing the myocardium to be more 
susceptible to ischemic damage (How et al., 2006; Mandavia et al., 2013). Impaired myocardial 
glucose metabolism is observed in animal studies, where the rate of glycolysis was shown to be 
depressed by up to 48% in the hearts of untreated diabetic mice when compared to untreated lean 
control counterparts (Belke et al., 2000). A similar finding was reported in a study done on diabetic 
Zucker rats maintained on a high fat diet, showing an increased rate of fatty acid oxidation (FAO) with 
a concomitant decrease in glucose oxidation (Van den Brom et al., 2009, 2010).  
As part of cardiac substrate homeostasis, glucose transportation and sensing plays an integral role in 
the disease pathology of T2DM. Glucose transport into cardiomyocytes is mediated by two members 
of the glucose transporter family of proteins, glucose transporter 1 (Glut1) and glucose transporter 4 
(Glut4) (Fig. 4.). Glut1 is responsible for the basal uptake of glucose, whereas Glut4 is the main 
insulin-sensitive glucose transporter (Tsirka et al., 2001). For greater glucose demands, the 
stimulatory effect of insulin is responsible for the translocation of Glut4 to the plasma membrane for 
enhanced glucose uptake (Russell et al., 1999). When demand for glucose is lower Glut4 remains 
concealed in intracellular vesicles to a greater extent and less cycling to the plasma membrane. The 
potential association of Glut4 and increased glucose uptake is shown by various studies (Camps et 
al., 1992; Watson et al., 2004; Chen et al., 2007). Zisman and colleagues showed that mice lacking 
the Glut4 gene show signs of insulin resistance (Zisman et al., 2000). Furthermore, impaired 
myocardial substrate metabolism in the diabetic heart is associated with abnormally increased 
oxidative stress due to altered mitochondrial function (Lei et al., 2004; Joseph et al., 2014). This is 
characterized by morphological remodeling, occurring in parallel to contractile dysfunction (Boudina 
and Abel, 2007). Hence, the ideal ameliorative strategy to halt HF in DM should target moderately 
increasing intracellular glucose uptake while avoiding cardiac glucotoxicity. 
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Figure 4. Cardiac structural remodeling as a consequence of fatty acid and glucose oxidation. While 
Glut1 is responsible for the basal uptake of glucose, Glut4 is the main glucose transporter in the heart. Impaired 
substrate preference due to abnormally increased oxidation of FFAs is associated with inhibition of glucose 
oxidation and subsequent cardiac remodeling. ATP: adenosine triphosphate; FFAs: free fatty acids; Glut1: 
glucose transporter 1; Glut4: glucose transporter 4. 
 
1.4. Role of oxidative stress in a diabetic heart 
Altered cardiac energy substrate utilization and increased oxidative stress are linked to the onset of 
cardiac hypertrophy (Ingwall, 2009). Chronic hyperglycemia enhances oxidative stress and 
exacerbates myocardium injury, subsequent to the development of DCM (Boudina and Abel, 2010; 
Tarquini et al., 2011; Joseph et al., 2014; Mapanga and Essop; 2016). This has been confirmed by 
various laboratory studies showing strong correlation between oxidative stress and matrix remodeling 
in cardiomyocytes isolated from diabetic heart tissue (Uemura et al., 2001; Soliman et al., 2008; 
Dludla et al., 2014). Oxidative stress is aggravated by enhanced levels of ROS within cardiomyocytes 
(Rajamani and Essop, 2010; Essick et al., 2011). Abnormal ROS production elicits an increased pro-
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inflammatory response resulting in myocardial apoptosis (Sabri et al., 2003; Kim et al., 2005). Some of 
the well-known reactive oxygen substances, associated with myocardial damage include superoxide 
anion (O2• −) and hydrogen peroxide (H2O2). Generation of ROS is generally a cascade of reactions 
that starts with the formation of O2• − (Sharma et al., 2012). Superoxides rapidly dismutate to H2O2 
either spontaneously or catalytically by superoxide dismutase (SOD), while H2O2 is decomposed to 
water (H2O) and O2 through catalase (Cat).  
The mitochondrial electron transport chain (ETC) and the actions of the nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH oxidase) enzymes remain the foremost sources of stress in 
cardiomyocytes (Giacco and Brownlee, 2010; Kuroda et al., 2010; Sovari et al., 2013). Augmented 
activity of NADPH oxidase is demonstrated in the myocardium of a failing heart at the same rate as 
oxidative damage (Kuroda et al., 2010). Correspondingly, mitochondrial structural modification is 
affiliated with reduced endogenous antioxidant status in cardiomyocytes from diabetic heart tissue 
(Sivitz and Yorek, 2010; Ansley and Wang, 2013). 
 
1.4.1. Mitochondrial stress 
The mitochondrion remains an essential organelle for intracellular energy production. However, an 
increased capacity of the mitochondrion to produce energy is associated with increased ROS 
production. Given that a diabetic heart has a diminished mitochondrial antioxidant capacity (Huynh et 
al., 2014), it is therefore not surprising that minor alterations in mitochondrial structure or function 
induced by increased ROS are associated with major changes in the heart muscle (Marín-García et 
al., 2013; Zorov et al., 2014). Increased ROS and mitochondrial depolarization, subsequent to diastolic 
dysfunction has been reported in patients with metabolic disturbances (Sack, 2009; Montaigne et al., 
2013). Though the precise role of mitochondrial dysfunction in a diabetic heart is still lacking, 
consensus is that defects in ETC and its oxidative status play a major role in impaired mitochondrial 
morphology and function. 
Simultaneous to energy generation, there is constant generation of O2• − within mitochondria (Zamzami 
et al., 1995). Accumulation of these radical substances result in the induction of the mitochondrial 
permeability transition (MPT) pore (Baines, 2009). MPT occurs at the same time with altered redox 
state of the mitochondria (Crompton, 1999; Zorov et al., 2014). With diseased states, the MPT pore is 
unique for being nonselective and allowing for the accumulation of excessive calcium (Ca2+) and other 
toxic compounds (Lemasters et al., 1998). Recent literature shows that the fate of the cell after an 
insult depends on the extent of the MPT pore formation (Orrenius et al., 2003; Kwong and Molkentin, 
2015; Morciano et al., 2015). If MPT pore formation occurs to only a limited extent, the cell may 
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recover through cell recovery mechanisms such as activation of mitophagy/ubiquitination, whereas if 
pore formation is exacerbated it accelerates apoptosis (Galluzzi et al., 2014). If it occurs to an even 
larger degree, the cell is likely to undergo necrotic cell death. Thus prevention of mitochondrial 
membrane depolarization may play a role in reducing myocardial injury associated with chronic 
hyperglycemia. 
 
1.4.2. NADPH oxidase 
NADPH oxidase (Nox) is an important enzyme that plays a notable role in the generation of ROS in 
many cell types, including cardiomyocytes. Nox generates intracellular ROS by transferring electrons 
from NADPH across the cell membrane and coupling these to molecular oxygen to produce O2• −. Nox 
exists as different isoforms, from Nox1 to Nox4 and those predominant in the heart muscle are Nox2 
and Nox4 (Bedard and Krause, 2007; Mapanga and Essop, 2016). Nox1 has been identified to be the 
major source of ROS production in vascular tissues, resulting in low levels of nitric oxide (Paravicini 
and Touyz, 2008; Fu et al., 2014). Decreased levels of nitric oxide are associated with impaired 
endothelium-dependent vasodilatation of coronary arteries (Stockklauser-Färber et al., 2000). Human 
aortic endothelial cells exposed to high glucose, display upregulated expression of Nox1, concomitant 
to enhanced oxidative stress and pro-inflammatory markers (Gray et al., 2013). The same study 
showed that diabetic mice lacking Nox1 had a profound anti-atherosclerotic outcome related to 
reduced ROS and inflammation. Although Nox2 and Nox4 are predominant in the heart muscle, these 
ROS generating enzymes are also co-expressed in other cell types and are implicated in agonist-
stimulated redox-sensitive signal transduction (Bedard and Krause, 2007). Nox2 has been shown to 
play a central role in insulin resistance-mediated oxidative damage in vascular tissue (Sukumar et al., 
2013; Kowluru and Kowluru, 2014). Nox2 knockout transgenic mice with endothelial-specific insulin 
resistance present enhanced ROS production and vascular dysfunction (Guichard et al., 2006; 
Sukumar et al., 2013). On the other hand, the Nox4 isoform is specifically expressed in mitochondria 
of cardiomyocytes; and mice lacking Nox4 gene show accelerated free radical damage coupled by 
mitochondrial dysfunction (Kuroda et al., 2010; Maalouf et al., 2012). Its overexpression in the mouse 
heart deteriorates cardiac dysfunction by initiating apoptosis, leading to cytochrome-c release (Kuroda 
et al., 2010).  
 
1.5. Inflammation as a precursor for apoptosis 
Inflammation is the initial protective biological response of the body against harmful stimuli. There are 
various risk factors linked with the onset of inflammation; namely age, obesity, stress and smoking 
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(Willerson and Ridker, 2004; Sastre et al., 2011). However, hyperglycemia is one condition that has 
been shown to activate various pro-inflammatory transcription factors, including nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) (Esposito et al., 2002; Castello et al., 2010). NF-κB is 
the most significant regulator of pro-inflammatory gene expression and is strongly associated with 
fibrosis in heart tissue (Miguel-Carrasco et al., 2010; Lorenzo et al., 2011). Overexpression of NF-kB 
accelerates apoptosis in a diabetic state (Cameron and Cotter, 2008; Kumar et al., 2013). By contrast, 
its inhibition in diabetic mice ameliorates ROS-induced damage through improving mitochondrial 
structural integrity (Mariappan et al., 2010; Gordon et al., 2011). 
Recent literature suggests that hyperglycemia-induced cardiomyocyte apoptosis is further deteriorated 
by the increased stimulation of inflammatory cytokines (Esposito et al., 2002; Pickup, 2004; King, 
2008). Tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL6) are significantly increased in 
patients with uncontrolled hyperglycemia (Goyal et al., 2008). The activation of c-Jun N-terminal 
kinases (JNKs) pathway acts as a direct inducer of apoptosis in heart cells (Turner et al., 1998; Liu et 
al., 2004); and it triggers enhanced expression of pro-inflammatory cytokines (Lysiak et al., 2003; 
King, 2008). It is well known that inflammatory cytokines and chemokines are predictive makers for 
most cardiovascular events (Melter et al., 2001; Inoue et al., 2008). TNF-α is released by a variety of 
immune cells and is a prognostic marker for MI (Ridker et al., 2000). The reduced expression of TNF-α 
in the heart signals improved myocardial performance (Saini et al., 2005). Other well-known cytokines 
and chemokines include interleukin-1 beta (IL1β), Interleukin-8 (IL8), IL6, chemokine (C-C motif) 
ligand 3 (CCL3), and monocyte chemotactic protein 1 (MCP1) (Melter et al., 2001; Shanmugam et al., 
2003). These cytokines not only stimulate adhesion molecules within vascular tissue in DM, but can 
indirectly cause AMI via the inhibition of the PKB pathway (Kidd et al., 2008). A number of studies 
support the concept that IL1β and IL18 might be implicated in the pathogenesis of DCM (Van Linthout 
et al., 2007; Westermann et al., 2007; Lorenzo et al., 2011). The major mechanism by which such pro-
inflammatory cytokines may be associated with the development of DCM has been through initiating 
apoptosis (Wang et al., 2010; Wen et al., 2013). Inhibition of JNK phosphorylation, along with 
cytokines such as TNF-α and IL1β has been shown to deter high glucose-induced inflammation and 
apoptosis in cardiomyocytes from diabetic tissue (Thomas et al., 2014; Yu et al., 2016). 
 
1.6. The role of apoptosis in the diabetic heart  
Apoptosis is a regulated process of programmed cell death that forms a vital component in various 
biological systems. In a diabetic state, persistent hyperglycemia is understood to be the key mediator 
of myocardial apoptosis (Cai et al., 2002; Rajamani and Essop, 2010). Apoptosis signaling varies with 
different cell types and there are two main types of apoptotic pathways: intrinsic and extrinsic. 
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Literature has shown that both intrinsic and extrinsic apoptotic pathways in the diabetic myocardium 
are involved in HF and DCM (Li et al., 2007; Giacco and Brownlee, 2010; Kim and Kang, 2010). The 
intrinsic apoptotic pathway is mediated mainly through intracellular signals that involve the 
mitochondrion. Stimuli for the intrinsic pathway include generation of free radical species leading to 
alteration in the inner mitochondrial membrane resulting in loss of transmembrane potential, causing 
the release of pro-apoptotic proteins (Rajamani and Essop, 2010). This mitochondrial membrane 
depolarization is linked to a number of disturbances within the myocardium, including ATP depletion 
and bioenergetic failure (Johnson et al., 2016). In addition, deterioration of the proton-translocating 
ATPase and intracellular Ca2+ overload may occur concurrent the release of cytochrome-c (Webster, 
2012).  
Cytochrome-c is a vital component of the mitochondrial-ETC, acting as an electron shuttle during 
redox generation of ATP (Boekema and Braun, 2007). Its release and mitochondrial depolarization are 
considered key physiological events of apoptosis (Elmore, 2007). Earlier evidence shows that loss of 
cytochrome-c from mitochondria is one of the earliest changes in mitochondria during heart ischemia 
(Borutaite and Brown, 2003). In high glucose exposed cardiomyocytes, independent of mitochondrial 
depolarization status, cytochrome-c release is enough to cause apoptosis (Yu et al., 2008). However, 
once released into the cytosol, cytochrome-c may form an apoptosome by interacting with apoptotic 
protease activating factor 1 in the presence of deoxyadenosine triphosphate (dATP). This process 
results in the activation of pro-caspase-9 and caspase-3, respectively. Conversely, an extrinsic 
apoptotic pathway similarly lead to the cleavage of caspase-3, however the initial stimuli is usually 
external, such as pro-inflammatory cytokines (Elmore, 2007). Generally, myocardial remodeling is 
affiliated with increased activity of caspase-3, -7, and -9 (Schwarz et al., 2006). These observations 
are consistent with mitochondrial dysfunction found in heart cells of diabetic mice (Cai et al., 2002). 
Caspases are proteases that become incongruously activated as zymogens and may prompt 
apoptosis by activating poly (ADP-ribose) polymerase (PARP) proteins (Boulares et al., 1999). PARP 
activation plays a central role in the pathogenesis of diabetic cardiovascular dysfunction by inducing 
cardiac hypertrophy and fibrosis in the hearts of diabetic animals (Boulares et al., 1999; Joseph et al., 
2014).  
Pro-apoptotic proteins associated with accelerated myocardial damage are not only restricted to the 
cysteine-aspartic-specific caspases. B-cell lymphoma 2 (Bcl2) protein homologs are also needed for 
the modulation of apoptotic actions. These proteins can induce either pro-apoptosis or cellular survival 
depending on the cell’s fate. This family of proteins consists of two classes: anti-apoptotic Bcl2 
proteins or the pro-apoptotic proteins such Bax and Bad. Bax translocation and cytochrome-c release 
are regarded as two significant upstream molecular events of apoptosis (An et al., 2004). Bax is 
confined in the cytoplasm as a monomer and can be triggered by the BH3-only proteins such as Bim 
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and Puma, causing it to translocate into the mitochondria where it induces changes in mitochondrial 
membrane potential (An et al., 2004). Accumulative data suggests that drug agents that inhibit either 
Bax translocation or activation of caspases may alleviate MI induced by DM (Webster, 2012; Dludla et 
al., 2015; Johnson et al., 2016). Therefore, interventions that could inhibit pro-apoptotic proteins and 
mitochondrial cytochrome-c release could salvage myocardial injury. 
 
1.7. Endogenous cardiac protective mechanisms 
Free radicals within mitochondria are generally removed by mitochondrial SOD, thereby generating 
H2O2. This process allows H2O2 to be further reduced to water by glutathione (GSH)/thioredoxin (Txn) 
peroxidase or Cat enzymes. GSH remains an important intracellular antioxidant to prevent free radical 
damage. GSH and thioredoxins (Txns) can easily be oxidized to their disulfide form during oxidation 
reactions; thus, NADP transhydrogenase enzymes remain important to maintain the reduced form of 
these co-factors (Revollo et al., 2007). NADP transhydrogenase functions by transferring electrons 
from a reduced form of nicotinamide adenine dinucleotide (NADH) to NADP+ in order to regenerate 
GSH and Txn (Rydström, 2006). Txns are proteins that act as antioxidants and they serve as electron 
donors for enzymes such as ribonucleotide reductases (Berndt et al., 2008). The antioxidant 
mechanism of Txns involves facilitating protein reduction through cysteine thiol-disulfide exchange. 
Thioredoxin reductase (Txnrd) is the only known enzyme to reduce Trxn and is crucial during 
embryogenesis (Jakupoglu et al., 2005). Reduced expression of both GSH and Txns is consistently 
reported in experimental models investigating a diabetic heart (Chen et al., 2009; Giacco and 
Brownlee, 2010; Dludla et al., 2014). This is confirmed when investigated in either type 2 diabetic 
subjects or mice that are chronically subjected to hyperglycemia and hyperlipidemia, respectively 
(Bhatt et al., 2013; Marnewick et al., 2011).  
 
1.7.1. Activation of Nrf2 within the diabetic heart 
Expression of most antioxidant response genes, including GSH and Txns is regulated by the redox-
sensitive transcription factor, nuclear factor erythroid-2-related factor 2 (Nrf2) (He et al., 2009). Nrf2 is 
a transcriptional regulator that is activated in response to intracellular stress (Bryan et al., 2013). 
Genes activated by Nrf2 can be classified into numerous groups including phase II detoxifying and 
cytoprotective enzymes (Fig. 5.). Nrf2 resides in the cytoplasm, where it is subjected to continuous 
degradation by the ubiquitin-proteasome (Kobayashi et al., 2006). However, under stressful conditions 
such as ischemia or oxidative stress, it is activated by disassociating from its negative regulator Kelch-
like ECH-associated protein 1 (Keap1) and translocate to the nucleus. Once in the nucleus, it forms a 
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heterodimer with Maf protein before binding to the antioxidant response element (ARE) to initiate and 
activate antioxidant defence genes (Bai et al., 2013). Activation of Nrf2 in epithelial cells has been 
shown to induce GSH synthesis and thus protect against oxidative stress (Kode et al., 2008). In 
addition to its negative regulation of Nrf2, Keap1 also acts as a sensor for a wide array of stressors 
that could activate Nrf2.  
Antioxidant response components linked with Nrf2 activation include heme oxygenase-1 (Hmxo1/HO-
1), Txnrd, glutathione-S-transferase (Gst), and NAD(P)H:quinone oxidoreductase (Nqo1) (Chen et al., 
2009). Nrf2 also mediates gene expression of SOD, Cat, and nonenzymatic scavengers such as GSH 
and sulfiredoxin, which are vital for the reduction of oxidized protein thiols (Dinkova-Kostova and 
Abramov, 2015). Significant down-regulation of cardiac Nrf2 expression is concomitant to increased 
ROS and reactive nitrogen species damage in hearts of diabetic animals (Kode et al., 2008; He et al., 
2009; Bai et al., 2013; Dinkova-Kostova and Abramov, 2015). Thus, agents that can significantly up-
regulate Nrf2 expression have a potential to protect cardiomyocytes against high glucose induced 
apoptosis.  
 
1.7.1.1. Nrf2 and mitochondrial function 
Increased mitochondrial oxidative phosphorylation is associated with increased ROS production within 
the diabetic heart (Giacco and Brownlee, 2010). In a recent study, heart muscle cells exposed to H2O2 
display increased uncoupling protein 3 (UCP3) expression simultaneous to nuclear accumulation of 
Nrf2 (Anedda et al., 2013). However, silencing of Nrf2 significantly reduced UCP3 expression in these 
cells resulting in enhanced oxidative damage. There are few studies linking activation of Nrf2 and 
reduction of ROS by transcriptional upregulating uncoupling proteins which influences mitochondrial 
biogenesis. Uncoupling proteins (UCPs) are a family of proteins that are located in the inner 
mitochondrial membrane of mammalian cells (Dinkova-Kostova and Abramov, 2015). They act as 
proton transporters within the mitochondrial matrix to disintegrate increased membrane potential 
(Kadenbach, 2003). These transporter proteins are expressed in a variety of cell types, whereas 
UCP1 and UCP2 are predominantly found in the heart muscle where they act as negative regulators 
of mitochondrial derived ROS production (Kadenbach, 2003; Essop et al., 2004). Although it has been 
shown that UCPs may ameliorate mitochondrial stress by modulating mitogen-activated protein 
kinases (MAPK) pathways and preserving Ca2+ homeostasis (Boudina and Abel, 2006; Valouskova 
and Modriansky, 2008), it has been reported that mitochondrial membrane potential is significantly 
increased in the absence of Nrf2 (Dinkova-Kostova and Abramov, 2015). Enhanced mitochondrial 
membrane potential and accelerated rate of oxidative respiration are constant with increased levels of 
mitochondrial free radical damage leading to increased MPT pore opening. However, this increased 
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ROS production is neutralized by the Nrf2-dependent transcriptional upregulation of UCP3 which 
improves proton conductance of the mitochondrial inner membrane and consequently decreases the 
production of O2• −.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The role of Nrf2 in response to increased ROS within a diabetic heart. Nox and mitochondrial-
ETC cause augmented production of O2‒, which damages the cell through ROS/RNS. The cell reacts by 
activating the Nrf2-mediated antioxidant response system. Activated Nrf2 causes it to dissociate from Keap1 and 
migrate into the nucleus where it binds ARE and causes increased expression of cytoprotective genes and 
phase II detoxifying enzymes to combat ROS/RNS. ARE-antioxidant response element; ETC-electron transport 
chain; GPx2- glutathione peroxidase 2; Gst- glutathione S-transferase; Gclc- glutamate-cysteine ligase catalytic 
subunit; Keap1- Kelch-like ECH-associated protein 1; Nqo1- NADPH dehydrogenase [quinone] 1; Nox- NADPH 
oxidase; O2‒ superoxide ion; Txn- thioredoxin; Txnrd1- thioredoxin reductase 1; HO-1- Heme oxygenase 1; 
Nrf2- nuclear factor (erythroid-derived 2)-like 2; RNS-reactive nitrogen species; ROS-reactive oxygen species. 
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1.8. Current antidiabetic agents and cardiac protection 
Primary interventions that may salvage a diabetic heart at risk from MI include lifestyle changes and 
maintaining blood sugar levels (American Diabetes Association, 2014). While such interventions are 
achievable and beneficial to the heart; adherence to lifestyle changes such as maintaining physical 
activity, remains a big challenge. Therefore, antidiabetic agents that could suppress postprandial and 
chronic hyperglycemia may be effective in decreasing the risk of HF. Although substantial work is 
required to confirm its long-term cardiac protective effect; metformin displays strong blood glucose 
lowering and potential cardiac protective effects (Kahn et al., 2006; Khurana and Malik, 2010; Yin et 
al., 2011). 
Despite overwhelming evidence on the efficacy of other antidiabetic drugs such as beta statins and 
dipeptidyl peptidase-4 (DDP4) inhibitors (Magkou and Tziomalos, 2014), metformin remains the 
leading first line antidiabetic drug for T2DM individuals with known cardiac complications (Khurana 
and Malik, 2010; Messaoudi et al., 2011). In addition to its accomplished antidiabetic properties (Kahn 
et al., 2006; Yin et al., 2011), metformin is associated with improved clinical outcomes in diabetic 
patients with heart failure (Eurich et al., 2005). It enhances the efficacy of a number of synthetic drugs 
and novel medicinal compounds currently screened for metabolic benefits (Eurich et al., 2013; Dludla 
et al., 2016; Johnson et al., 2016). Metformin monotherapy or its use as an add-on effect to 
glibenclamide improves the intracellular antioxidant status of the myocardium in streptozotocin (STZ)-
induced Sprague-Dawley rats (Erejuwa et al., 2010). Previous work also found that the benefit of 
metformin in the heart can be mediated through AMPK activation and improved antioxidative capacity 
(Gundewar et al., 2009; Johnson et al., 2016). However, there is an increasing toll of mortality due to 
cardiovascular complications within a diabetic population.  
 
1.9. Polyphenols as a cardioprotective intervention 
In recent years, more research has focused on the use of plant-derived products as a cardioprotective 
therapy (Marnewick et al., 2011; Muller et al., 2012; Chen et al., 2013; Mazibuko et al., 2013). Ideally, 
every plant has a potential medicinal use while for every disease there is likely a perfect natural cure. 
Medicinal plants have been extensively used in the pharmaceutical industry for the production of novel 
drugs to counteract various illnesses (Mukhtar and Ahmad, 2000; Pandey and Rizvi, 2009). Most 
medicinal plants contain a variety of compounds termed phytochemicals. Polyphenols are naturally 
occurring phytochemicals with variable phenolic structures. A polyphenol is classified according to the 
number and characteristics of the phenolic structure it contains. These functional phenol structures are 
unique to each class of polyphenols, giving it their distinct chemical and biological property. 
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Polyphenols are predominantly found in vegetables, fruits and teas. Furthermore, a profound 
relationship between a diet rich in polyphenols and health has given hope to long-term effective 
interventions that could prolong the onset of diabetes and it co-morbidities (Marnewick et al., 2011; 
Mazibuko et al., 2013; Sanderson et al., 2014).  
 
1.10. The major polyphenolic compounds present in rooibos 
Aspalathus linearis (Brum.f) Dahlg. (Fabaceae), commonly known as rooibos, is a popular South 
African plant that is used to make one of the leading herbal teas on the market. Rooibos tea is well 
known for its robust antioxidant activity and this has resulted in increased interest in its commercial 
value (Raynolds and Ngcwangu, 2010). Rooibos tea exists in two forms: a fermented one which is an 
oxidized form; and an unfermented one which is an unoxidized form. The fermentation process gives 
fermented rooibos its distinctive reddish-brown colour, while unfermented rooibos tea maintains its 
green color (Von Gadow et al., 1997). In addition to catechin, epicatechin, gallocatechin, and 
epigallocatechin; esters of gallic acid, catechin gallate, epicatechin gallate, gallocatechin gallate and 
epigallocatechin gallate are distinct polyphenolic compounds found in unfermented rooibos (Del Rio et 
al., 2013). Other bioactive compounds found in rooibos with ameliorative effect against various 
metabolic diseases, include its dihydrochalcones (aspalathin and nothofagin), flavones (orientin, 
isoorientin, luteolin, and apigenin), flavonols (quercetin, rutin), and the infrequently occurring 
phenylpyruvic acid-2-O-β-D-glucoside (PPAG) (Joubert et al., 2013). Therefore, due to their growing 
interest, it is important to assess the beneficial effects of major polyphenols from rooibos against 
oxidative-induced myocardial injury. 
 
1.10.1. Cardioprotective potential of flavanols present in rooibos 
The unfermented rooibos is unique from the fermented form by containing an additional group of 
flavonoids termed flavanols. This polyphenolic group is characterized by a 2-phenyl-3,4-dihydro-2H-
chromen-3-ol skeleton and flavanols found in abundance in unfermented rooibos include epicatechin, 
epicatechin gallate and epigallocatechin gallate (Fig. 6.) (Snijman et al., 2009). Accompanying its well-
documented antioxidant capacity (Von Gadow et al., 1997; Bramati et al., 2003; Joubert et al., 2004); 
unfermented rooibos has been shown to decrease body fat mass and levels of oxidized lipids in fat 
cells and human subjects, respectively (Marnewick et al., 2011; Sanderson et al., 2014). An 
aspalathin-enriched green rooibos extract (GRE) has been shown to display potential as an agent to 
induce hypoglycemia by inhibiting α-glucosidase in vitro and suppressing fasting plasma glucose 
(FPG) levels in Wistar rats; and ameliorate palmitate induced insulin resistance when tested in skeletal 
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muscle cells (Muller et al., 2012; Mazibuko et al., 2013; Mikami et al., 2015). In cultured skeletal 
muscle cells and pancreatic β-cells, GRE promotes GLUT-4 translocation to the plasma membrane 
and suppresses advanced glycation end products (AGEs)-induced ROS, respectively (Kamakura et 
al., 2015). In addition, this study shows that subchronic feeding with GRE for five weeks lowered the 
increased FPG levels found in a type 2 diabetic mouse model. In the heart, an aqueous extract of 
GRE protects against ischemic-induced reperfusion injury by modulating the phosphatidylinositol 3-
kinase/protein kinase B (PI3K-Akt) pathway (Pantsi et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The chemical structure of major flavanols present in Aspalathus linearis (rooibos). Unfermented 
rooibos is distinct by containing an additional group of flavonoids termed flavanols that is characterized by a 2-
phenyl-3,4-dihydro-2H-chromen-3-ol skeleton. 
 
In addition to the aforementioned synergistic amelioration of DM-associated complications by GRE, 35 
day treatment of STZ-induced diabetic rats with epigallocatechin gallate at doses of 15 and 30 mg/kg, 
respectively, significantly improved FPG levels and combats oxidative stress by increasing 
antioxidants such as GSH, Cat, SOD and glutathione peroxidase (Sabarimuthu Darlin Quine, 2005). In 
Wistar rats, administration of epigallocatechin gallate at a dose of 25 mg/kg for eight weeks displays a 
hypoglycemic effect in addition to attenuating oxidative stress (Roghani and Baluchnejadmojarad, 
2009, 2010). This flavanol further protects type 2 diabetic rats against hyperglycemia-induced 
oxidative stress by reducing the degree of autophagy (Kim et al., 2013). Other mechanisms by which 
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unfermented rooibos/GRE and its flavanols may protect the heart against diabetes-induced damage 
include regulating cardiac lipid metabolism, directly increasing intracellular antioxidants, and 
modulating the activation of AMPK (Pantsi et al., 2011; Mazibuko et al., 2013; Kamakura et al., 2015;). 
 
1.10.2. Cardioprotective potential of dihydrochalcones present in rooibos 
Dihydrochalcones are a family of bicyclic flavonoids containing two distinct benzene rings joined by a 
saturated three-carbon bridge (Fig. 7.). Dihydrochalcones, aspalathin and nothofagin are the unique 
polyphenolic compounds found in rooibos with potent therapeutic properties. These two compounds 
primarily have known antioxidant properties (Von Gadow et al., 1997; Snijman et al., 2009; Van Der 
Merwe et al., 2010; Chen et al., 2013) and are found in abundance in GRE (Manley et al., 2006). The 
biological of activity of aspalathin and its structural analog, nothofagin, is associated with 
antithrombotic activity (Ku et al., 2015) and display an ameliorative effect against high glucose-
induced inflammation when tested in endothelial cells from human umbilical vein and mice (Ku et al., 
2015; Lee and Bae, 2015).  
 
 
 
 
 
 
 
Figure 7. The chemical structure of major dihydrochalcones present in Aspalathus linearis (rooibos). 
Aspalathin and its structural analogue, nothofagin belong to a family of bicyclic flavonoids containing two distinct 
benzene rings joined by a saturated three-carbon bridge. 
 
Aspalathin has demonstrated an even greater efficacy to prevent diabetes-associated complications. 
This is evident through its potential antidiabetic properties when tested in in vitro muscle cells and an 
in vivo type 2 diabetic mouse model (Kawano et al., 2009). There was further confirmation of its 
hypoglycemic activity after it was tested in obese mice (Son et al., 2013). Our laboratory has 
presented recent evidence that aspalathin reverses palmitate-induced insulin resistance in cultured 
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adipocytes; while it prevents apoptosis by improving substrate metabolism and recuing oxidative 
stress in H9c2 cardiomyocytes (Mazibuko et al., 2015; Johnson et al., 2016). Despite limited literature 
on the in vivo cardioprotective activity of aspalathin, the molecular mechanism of protection is 
associated with activation of AMPK (Mazibuko et al., 2015; Johnson et al., 2016). Optimal modulation 
of AMPK within the diabetic heart is crucial in the regulation of myocardial substrate preference 
(Johnson et al., 2016). 
 
1.10.3. Cardioprotective potential of flavones present in rooibos 
Flavones, in general, appear as crystalline compounds and they provide yellow or white pigments in 
certain plants. The group of flavones present in rooibos includes orientin, isoorientin, luteolin and 
apigenin (Fig. 8.) (Schloms and Swart, 2014). The number of functional hydroxyl groups on the 
structure of luteolin is directly correlated to its scavenging effect of hydroxyl radicals (Brown et al., 
1998). In addition to its antidiabetic properties (Liu et al., 2013; Kim et al., 2014; Kwon et al., 2015), 
luteolin and its glycoside, luteolin-7-glucoside, attenuate myocardial oxidative damage and diabetic 
nephropathy by upregulating cellular antioxidants and inhibiting apoptosis (Fang et al., 2011; Qi et al., 
2011; Hwang et al., 2013; Madhesh and Vaiyapuri, 2013). They further reverse early onset of DCM by 
hindering the destructive actions of aldose reductase and nitrogen oxide synthase (NOS) in diabetic 
animals (Wang et al., 2012, 2013). Transgenic mice broadly overexpressing the human aldose 
reductase gene have been shown to display enhanced ROS production concurrent to MPT pore 
opening and ischemic injury (Ramasamy and Goldberg, 2010). The effect of luteolin in preventing 
ischemia/reperfusion injury in diabetic rats has also been reported to be associated with upregulation 
of myocardial nitric oxide synthase (Sun et al., 2012). Furthermore, there is very limited on the 
cardioprotective effect of orientin and isoorientin; except for a few studies which have reported on the 
inflammatory properties of both compounds when tested in either cultured adipocytes or endothelial 
cells (Alonso-Castro et al., 2012; Ku et al., 2015).  
Apigenin on the other hand has the unique ability to activate the transient receptor potential cation 
channel subfamily V member 4 (TRPV4) gene in endothelial cells (Ma et al., 2012). The expression of 
TRPV4 has been shown to be significantly reduced in the retinal microvascular endothelium 
(Monaghan et al., 2015). Apigenin inhibits lipopolysaccharide-associated inflammatory complications 
in mice by down-regulating increased mRNA expression of IL-6 and IL-1β via hindering actions of 
extracellular-signal-regulated kinases 1/2 (Zhang et al., 2014). Moreover, this flavone has recently 
been shown to combat diabetes-associated cognitive decline in rats by inhibiting oxidative stress and 
apoptosis in rats (Mao et al, 2015); and attenuates 2-deoxy-D-ribose-induced oxidative cell damage in 
pancreatic β-cells (Suh et al., 2012). Its hypoglycaemia-associated effect is linked with its capacity to 
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inhibit α-glucosidase activity and mediate glucose and lipid homeostasis when tested in vitro and 
diabetic animals (Panda and Kar, 2007; Cazarolli et al., 2012; Ohno et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The chemical structure of major flavones present in Aspalathus linearis (rooibos). The group of 
flavones present in rooibos includes orientin, isoorientin and apigenin, which are classified by a basic chemical 
structure consisting of a chromone (1,4-benzopyrone) moiety connected to a phenyl ring in position 2-(2′-
phenyl)-chromen-4-one or 2-phenyl-1,4-benzopyrone) . 
 
1.10.4. Cardioprotective potential of flavonols present in rooibos 
Quercetin and its glycoside, rutin are classified by a distinct 3-hydroxyflavone backbone and are the 
most explored group of flavonols in rooibos (Fig. 9.). Quercetin exhibits a broad range of 
pharmacological activities with the myocardium. It protects against atherosclerosis by inhibiting 
lipoxygenase-induced lipoprotein oxidation in endothelial cells and high fat-induced obese 
apolipoprotein E knockout mice (Reiterer et al., 2004; Russo et al., 2012; Shen et al., 2013). Its 
experimental use at a dose of 10 mg/kg body weight for 28 days protects against autoimmune 
myocarditis by suppressing oxidative stress in rats (Arumugam et al., 2012). Quercetin is thought to 
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exert its cardiac protection through quenching lipid peroxidation, as it is a known scavenger of peroxyl 
radicals (Terao et al., 1994; Da Silva et al., 1998). 
 
 
 
 
 
 
 
 
Figure 9. The chemical structure of major flavonols present in Aspalathus linearis (rooibos). Quercetin 
and its glycoside, rutin are classified by a distinct 3-hydroxyflavone backbone chemical structure. 
 
Quercetin ameliorates hyperglycemia and dyslipidemia by improving the antioxidant status and 
inflammatory response in diabetic mice and rats (Cho et al., 2003; Oršolić et al., 2011; Maciel et al., 
2013; Alam et al., 2014). In a double-blind randomized clinical trial done on women (n=72), quercetin 
supplementation (500 mg capsule daily) significantly reduced systolic blood pressure (Zahedi et al., 
2013). In combination with rutin, it enhances glucose uptake in muscle cells subjected to oxidative 
stress (Dhanya et al., 2014). It also attenuates STZ-induced hepatocellular damage and kidney 
muscle dysregulations such as intracytoplasmic vacuolization and brush border loss (Elbe et al., 2015; 
Gomes et al., 2014). Quercetin has a high affinity to inhibit AGEs such as methylglyoxal and glyoxal in 
the bovine serum albumin system (Li et al., 2014). Its proposed potential mechanism against high 
glucose-induced damage is associated with the modulation of sirtuin-1-dependent endothelial nitric 
oxide synthase upregulation in endothelial progenitor cells (de Boer et al., 2006; Allard et al., 2009). It 
may also act by activating AMPK, causing increased GLUT-4 translocation associated with enhanced 
glucose uptake in rat muscle and liver cells (Eid et al., 2015). Likewise, rutin has been shown to 
display strong properties halt myocardial damage in a diabetic state decreasing postprandial 
hyperglycemia and slowing down formation of AGEs in various experimental models (Odetti et al., 
1990; Stanley and Kamalakkannan, 2006; Fernandes et al., 2010; Wang et al., 2015).  
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1.10.5. The phenyl-propenoic acid glucoside present in rooibos 
The occurrence of PPAG in rooibos was described for the first time about a decade ago (Fig. 10) 
(Marais et al., 1996). Phenylpyruvic acids apparently play a key role in the biosynthesis of a number of 
secondary metabolites, including PPAG (Joubert et al., 2013). Likewise, the biological activity of 
polyphenolic compounds with similar structures to PPAG such as 3-phenylpyruvate and β-
phenylpyruvate have long been reported to display antidiabetic properties (Malaisse et al., 1983; Ben-
Abraham et al., 2003). A fermented rooibos extract has been shown to contain abundant levels of 
PPAG compared to its unfermented form (Joubert et al., 2013). Exposure of cardiomyocytes isolated 
from diabetic rats to a low concentration of fermented rooibos that contains high levels of PPAG 
prevents oxidative stress and apoptosis (Dludla et al., 2014). Recent findings, studying PPAG have 
shown that this compound attenuates insulin resistance and protect beta cells from obese mice 
against endoplasmic reticulum stress-induced apoptosis by improving glucose tolerance (Muller et al., 
2013; Mathijs et al., 2014; Himpe et al., 2016). Although an in vitro study on H9c2 cardiomyocytes 
recently showed that PPAG abolishes high glucose-induced altered myocardial substrate metabolism 
and apoptosis by increasing Bcl2/Bax ratio and reducing caspase 3/7 activity (Dludla et al., 2016), 
very limited data is available on the cardioprotective properties of PPAG.  
 
 
 
 
 
 
 
 
Figure 10. The chemical structure of a phenylpropenoic acid-2-O-β-D-glucoside (PPAG) present in 
Aspalathus linearis (rooibos).  
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 27 
1.11. Problem statement 
The World Health Organization is constantly reporting on the rise in the burden of non-communicable 
diseases. The increased percentage (up to 80%) in premature deaths resulting from non-
communicable diseases in low and middle countries places a growing burden on healthcare resources 
in managing this worldwide epidemic. The largest proportion of non-communicable diseases are 
caused by complications associated with CVDs and DM. Furthermore, blood glucose lowering 
therapies such as insulin and metformin have played a major role in prolonging lives of diabetic 
patients. However, tight control of blood glucose still remains a challenge in such patients. By contrast, 
ameliorative therapies for oxidative stress, including polyphenols as an adjunct to current blood 
lowering drugs, show promise in protecting diabetic hearts in experimental models. In recent years 
rooibos has gained popularity due to its potential use as a dietary supplement that is rich in 
polyphenols. An increasing number of rooibos polyphenols present robust antioxidant properties that 
are associated with ameliorative effects on inflammation and apoptosis, leading to improved cardiac 
function in different animal models. However, the mechanisms by which rooibos and its polyphenolic 
compounds modulate hyperglycemia-induced oxidative stress are not fully elucidated, and the present 
dissertation aimed to improve on this understanding. 
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Abstract 
 
Chronic hyperglycemia is closely associated with impaired substrate metabolism, dysregulated 
mitochondrial membrane potential and apoptosis in the diabetic heart. As adult cardiomyocytes 
display limited capacity to regenerate following an insult, it is essential to protect the myocardium 
against the detrimental effects of chronic hyperglycemia. This study therefore investigated whether 
phenylpyruvic acid-2-O-β-D-glucoside (PPAG), present in Aspalathus linearis (rooibos), is able to 
attenuate hyperglycemia-induced damage in H9c2 cardiomyocytes. H9c2 cardiomyocytes were 
exposed to a high glucose concentration (33 mM) prior to treatment with PPAG (1 µM), metformin (1 
µM), or a combination of PPAG and metformin (both at 1 µM). Our data revealed that high glucose 
exposure increased cardiac free fatty acid uptake and oxidation, mitochondrial membrane potential 
and apoptosis (caspase 3/7 activity and TUNEL) and decreased the Bcl2/Bax protein expression ratio. 
PPAG treatment, alone or in combination with metformin, attenuated these glucose-induced 
perturbations, confirming its protective effect in H9c2 cardiomyocytes exposed to chronic 
hyperglycemia. 
 
Key words: Phenylpyruvic acid-2-O-β-D-glucoside, hyperglycemia, fatty acid uptake and oxidation, 
myocardial apoptosis. 
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Introduction 
Cardiovascular diseases (CVD) are a leading cause of death worldwide [1]. Moreover, the continuous 
rise in non-communicable diseases such as diabetes mellitus (DM) and obesity remains a major 
burden contributing to increased CVD onset [1]. There are currently ~415 million individuals burdened 
with DM and this is estimated to reach ~642 million by the year 2040 [2]. Patients with DM are at 
increased risk of developing CVD [2, 3]. In addition, the chronic hyperglycemia of DM contributes to 
the development of diabetic cardiomyopathy [4, 5]. Cardiomyopathies are a class of heart diseases 
that distinctly affect the structure of the heart muscle independently of coronary artery disease and 
hypertension [4, 5]. Although mainly non-ischemic of nature, cardiomyopathies play a predominant 
role to induce heart failure and are one of the major causes of death in southern Africa [5, 6].  
The mechanisms by which chronic hyperglycemia induces myocardial injury are varied and have not 
been fully elucidated [7]; however, enhanced intracellular flux of free fatty acids (FFAs) is implicated 
as it can result in mitochondrial deficiencies and subsequently trigger myocardial apoptosis [8-10]. 
FFAs are the preferred substrate for energy generation within the normal mammalian heart, while 
glucose provides the majority of the remaining proportion [11]. The diabetic heart utilizes a high 
proportion of FFAs as an energy source that can elicit detrimental effects, e.g. the deterioration of 
heart function and a state of energy deficiency [11-13]. Furthermore, increased FFA uptake within 
cardiomyocytes subjected to elevated concentrations of glucose is accompanied by aberrant 
mitochondrial membrane potential, preceding myocardial apoptosis [14, 15]. 
 
 
Figure 1. The chemical structure of phenylpyruvic acid-2-O-β-D-glucoside (PPAG). 
 
Phytochemicals, especially those present in plant foods, are gaining increasing popularity due to 
potential health-promoting properties. Such compounds are therefore actively screened for novel 
antidiabetic and cardioprotective properties [16-19]. For example, Aspalathus linearis (Brum.f) Dahlg. 
(Fabaceae) used to brew a popular herbal tea known as rooibos, contains polyphenols such as the 
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novel dihydrochalcone, aspalathin, with robust antioxidant properties [17]. A precursor in the flavonoid 
biosynthesis pathway and a non-phenolic compound, phenylpyruvic acid-2-O-β-D-glucoside (PPAG) 
(Fig. 1) [20], is not unique to rooibos, but it occurs rarely in nature and only few studies have reported 
on its presence in plants [21]. Of note, in vitro and in vivo models of diabetes previously demonstrated 
that PPAG improved metabolic parameters such as glucose intolerance and it also protected 
pancreatic β-cells against endoplasmic reticulum stress and palmitate-induced apoptosis [19, 22]. 
However, as its effects within the mammalian heart are unknown, this study aimed to establish 
whether PPAG can protect heart cells exposed to chronic hyperglycemia. 
 
Results 
Compared to the experimental control (cells exposed to media only) (100.0 ± 8.2%), PPAG induced a 
concentration-dependent response with the highest ATP concentrations at 1 µM (119.4 ± 0.5%, p = 
0.0001) (Fig. 2). We therefore employed this dosage for the remainder of experiments conducted in 
this study.  
 
 
 
 
 
 
 
 
 
Figure 2. Determination of optimal PPAG treatment dose. H9c2 cardiomyocytes were treated for 12 hours with 
various concentrations of PPAG (0.01 to 1000 µM) to determine ATP content as a measurement of metabolic 
activity. Results are the mean ± SD of 3 independent biological experiments, each done in triplicate. *p ≤ 0.05, 
**p < 0.01, ***p < 0.001 compared to experimental control (EC; untreated cells). 
 
High glucose (33 mM) induced a robust increase in fatty acid uptake (FAU) (135.2 ± 4.9%, p = 0.0001) 
and fatty acid oxidation (FAO) (140.0 ± 7.0%, p = 0.0002) in H9c2 cardiomyocytes when compared to 
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the normal glucose control (100.0 ± 3.9% and 100.0 ± 4.2%, respectively) (Fig. 3A, B). Post-treatment 
with metformin (123.2 ± 6.1%, p = 0.05 and 120.1 ± 8.2%, p = 0.05), PPAG (115.0 ± 4.7%, p = 0.001 
and 112.1 ± 3.2%, p = 0.001), as well as a combination of metformin + PPAG (114.0 ± 2.4%, p = 
0.001 and 113.2 ± 3.9%, p = 0.001) significantly reduced FAU and FAO, respectively (Fig. 3A, B).  
 
 
 
 
 
 
 
 
 
Figure 3. Effect of PPAG, metformin (MET) and MET + PPAG on high glucose-induced alteration of fatty acid 
uptake and oxidation in H9c2 cardiomyocytes. (A) Rate of fatty acid uptake (FAU) and (B) fatty acid oxidation 
(FAO). Mannitol (MAN) did not have an effect on either FAU or FAO and was comparable to the normal glucose 
(NG) control. Results are the mean ± SEM of 3 independent biological experiments relative to the NG control, 
each done in triplicate. ***p < 0.0001 versus NG; #p < 0.05, ##p < 0.001, ###p < 0.0001 versus high glucose (HG). 
Ψp < 0.05 versus MET. 
 
2', 7’-dichlorfluorescein diacetate (DCFH-DA) fluorescence intensity as a representative of reactive 
oxygen species (ROS) formation was significantly increased (141.3 ± 4.9%, p = 0.0001) after 
chronically exposing H9c2 cells to 33mM glucose when compared to the normal glucose control 
(100.1 ± 3.1%) (Fig. 4A). Enhanced ROS in high glucose exposed cells occurred concomitant to the 
reduction of glutathione (GSH) content (CellTracker fluorescent intensity) (62.4 ± 1.6%, p = 0.0001) 
and superoxide dismutase (SOD) activity (59.4 ± 3.9%, p = 0.0001) (Fig. 4AB). Although PPAG was 
able to reduce enhanced ROS production (127.3 ± 5.0%, p = 0.05), it failed to improve decreased 
GSH content (68.4 ± 4.0%) and SOD activity (61.4 ± 4.8%). Interestingly, metformin and its 
combination with PPAG showed more potency in ameliorating ROS generation (123.4 ± 2.9%, p = 
0.001 and 110.4 ± 5.0%, p = 0.0001) and improving GSH content (81.2 ± 4.2%, p = 0.0001 and 88.4 ± 
4.4%, p = 0.0001) and SOD activity (86.0 ± 4.5%, p = 0.0001 and 75.2 ± 4.9%, p = 0.001) when 
compared to PPAG monotherapy (Fig. 4ABC). 
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Figure 4. Effect of PPAG, metformin (MET) and MET + PPAG on oxidative stress markers. (A) Formation of 
reactive oxygen species (ROS), (B) glutathione (GSH) content and (C) superoxide dismutase (SOD) activity. 
Dichlorofluorescein diacetate (DCF-DA) fluorescent stain was used to detect the generation of ROS while 
CellTracker Blue CMAC fluorescent stain was used to detect the amount of GSH. Mannitol (MAN) did not have 
an effect on oxidative stress markers and was comparable to the normal glucose (NG) control. Results are the 
mean ± SEM of 3 independent biological experiments relative to the NG control, each done in triplicate. *p < 
0.05, **p < 0.001, ***p < 0.0001 versus NG; #p < 0.05, ##p < 0.001, ###p < 0.0001 versus high glucose (HG). 
 
Exposure of H9c2 cardiomyocytes to high glucose increased mitochondrial membrane potential in 
cells stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) 
fluorescence stain (Figure 5A). Treatment with metformin, PPAG or metformin + PPAG ameliorated 
this effect (Figure 5A). Quantitative fluorescent analysis revealed that high glucose increased 
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mitochondrial membrane potential by 138.0 ± 4.1% (p = 0.0001) when compared to the normal 
glucose exposed cells (100.0 ± 3.6%) (Fig. 5B). PPAG, metformin and metformin + PPAG treatment 
attenuated this effect (110.4 ± 5.3%, p = 0.0001; 121.2 ± 4.1%, p = 0.006; and 115.3 ± 7.3%, p = 0.05, 
respectively) (Fig. 5A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of PPAG, metformin (MET) and MET + PPAG on mitochondrial transmembrane potential (ΔΨm) 
measured by JC-1 stain. (A) Representative images of H9c2 cardiomyocytes exposed to 33 mM glucose for 48 h 
before treatment with either PPAG, MET or MET + PPAG; cells with non-depolarized mitochondria exhibited an 
orange fluorescence while depolarized cell mitochondria displayed green fluorescence. Mannitol (MAN) did not 
have an effect on mitochondrial membrane potential and was comparable to the normal glucose (NG) control. 
(B) Quantitative analysis of JC-1 fluorescence staining. Results are the mean ± SEM of 3 independent biological 
experiments relative to the NG control, each done in triplicate. ***p < 0.0001 versus NG; #p < 0.05, ##p < 0.001, 
###p < 0.0001 versus high glucose (HG). 
 
High glucose-induced cells displayed increased levels of fluorescence intensity associated with late 
apoptosis (propidium iodide and TUNEL staining) when compared to the normal glucose controls (Fig. 
6A). In support, H9c2 cardiomyocytes exposed to high glucose exhibited increased caspase 3/7 
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activity (132.2 ± 6.1%, p = 0.05), with a concomitant upregulation in TUNEL positive cells (8.4 ± 1.1, p 
= 0.001) when compared to normal glucose treated cells (101.0 ± 8.7% and 2.6 ± 0.7, respectively) 
(Fig. 6B, C). Treatment with PPAG and metformin + PPAG decreased both the activity of caspase 3/7 
(109.3 ± 5.3%, p = 0.05 and 4.6 ± 0.4, p = 0.05), and TUNEL positive cells (108.2 ± 3.7%, p = 0.001 
and 4.1 ± 1.0, p = 0.05) (Fig. 6A, B, C). 
A 
 
 
B       C 
 
 
 
 
 
 
 
Figure 6. Effect of PPAG, metformin (MET) and MET + PPAG on high glucose-induced cell apoptosis in H9c2 
cardiomyocytes. (A) Representative images of H9c2 cardiomyocytes exposed to 33 mM glucose for 48 h before 
treatment with either PPAG, MET or MET + PPAG; cells positive for propidium iodide nuclear stain exhibited red 
fluorescence, while those positive for TUNEL, displayed green fluorescence. (B) The anti-apoptotic potential of 
PPAG to reduce caspase 3/7 activity, (C) and TUNEL fluorescent staining was comparable to an additive effect 
of MET and PPAG. Results are the mean ± SEM of 3 independent biological experiments, each done in 
triplicate. *p < 0.05, **p < 0.001 versus normal glucose (NG); #p < 0.05, ##p < 0.001 versus high glucose (HG). 
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Bcl2/Bax protein expression ratio was robustly diminished in H9c2 cells exposed to high glucose (80.1 
± 8.8%, p = 0.03) when compared to normal glucose treated cells (100.0 ± 1.7%) (Fig. 7). Treatment 
with PPAG (107.4 ± 4.8%, p = 0.009) and metformin (104.4 ± 3.6%, p = 0.01) was able to ameliorate 
this effect (Fig. 7). However, treatment with metformin + PPAG (95.2 ± 2.5%) was ineffective (Fig. 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of PPAG, metformin (MET) and MET + PPAG on Bcl2 and Bax protein expression. While high 
glucose (HG) reduced Bcl2/Bax expression ratio, treatment with PPAG was able to improve the survival ratio 
when compared to MET alone or in combination with PPAG. Results are the mean ± SEM of 3 independent 
biological experiments relative to the normal glucose (NG) control, each done in triplicate. *p < 0.05 versus NG; 
#p < 0.05, ##p < 0.001 versus HG.  
 
Discussion 
Previous studies found that rooibos can trigger a peripheral hypoglycemic effect, improve glucose 
uptake and relieve endoplasmic reticulum stress-induced cell apoptosis in muscle, liver and pancreatic 
β-cells of diabetic animals [19, 22]. Focusing on the heart, selective rooibos compounds can attenuate 
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myocardial dysfunction by improving endothelial function and limiting ischemia/reperfusion injury [23, 
24]. However, it remains unknown whether PPAG is able to protect the myocardium against 
hyperglycemia-mediated apoptosis. The current study therefore focussed specifically on this 
phenylpropenoic acid glucoside, present in rooibos, by employing an in vitro cardiac model of chronic 
hyperglycemia. Our findings demonstrate that relatively low PPAG doses attenuated high glucose-
induced apoptosis in H9c2 cardiomyocytes, thus offering early promise as a novel cardioprotective 
agent. 
The initial experiments revealed that low PPAG doses increased metabolic activity of H9c2 
cardiomyocytes. However, higher PPAG concentrations significantly reduced cell viability. These data 
are in agreement with earlier work demonstrating that a lower PPAG dose stimulated glucose uptake 
in Chang cells [19], unlike the high dose that resulted in reduced uptake.  
Chronic hyperglycemia can result in a number of pathophysiologic disturbances that contribute to 
myocardial injury [7, 9]. Such perturbations include derangements in both glucose and fatty acid 
metabolic pathways, with increased ROS generation emerging as a central, damaging outcome in this 
process. This study found that high glucose availability resulted in altered cardiac FAU and FAO 
concomitant to increased ROS and reduced intracellular antioxidant capacity of the cells. In parallel, 
mitochondrial membrane potential was higher together with increased myocardial apoptosis. This is 
consistent with the findings of others [15, 25], where high glucose exposure induced mitochondrial 
membrane hyperpolarization and apoptosis in undifferentiated H9c2 cells compared to controls. It is 
likely that in our model elevated fuel substrate availability (e.g. fatty acids) results in increased flux 
through the mitochondrial electron transport chain leading to enhanced proton extrusion into the inter-
mitochondrial membrane space [11, 12, 14]. Higher intracellular glucose levels will also lead to 
increased mitochondrial membrane potential due to greater availability of reducing equivalents for the 
mitochondrial electron transport chain [7]. Subsequently, this will generate increased mitochondrial 
ROS levels (due to impaired electron flow at electron transport complexes) and contribute to 
myocardial apoptosis [15, 26]. For example, others found that chronic hyperglycemia and associated 
mitochondrial deficiency are key factors that trigger myocardial apoptosis in a diabetic state [10, 11]. 
Increased mitochondrial membrane potential can also cause the release of pro-apoptotic proteins into 
the cytosol [27]. In agreement, our data show lower Bcl2/Bax protein expression together with 
increased caspase activity and higher propidium iodide and TUNEL staining. These observations are 
consistent with enhanced propidium iodide and TUNEL staining found in isolated heart cells of diabetic 
mice [28, 29]. Higher intracellular glucose and fatty acid levels can also trigger multiple, non-
mitochondrial effects that can also contribute to the onset of myocardial cell death [30, 31].  
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Our data revealed that 1 μM PPAG treatment for 12 h attenuated several of the high glucose-induced 
perturbations earlier discussed. For example, PPAG treatment limited cardiac FAU and FAO, 
decreased mitochondrial membrane potential and lowered cardiac apoptosis. These findings are in 
agreement with the other results showing that PPAG ameliorated apoptosis by increasing Bcl2 
expression and inhibiting Bax translocation to the mitochondrion. Similar findings were also reported in 
pancreatic β-cells of mice fed a high-fat diet [22]. In agreement with this, fermented rooibos extract 
with abundant levels of PPAG protected primary rat cardiomyocytes against oxidative stress-induced 
myocardial injury [16]. We have previously demonstrated that aspalathin, the major phenolic 
compound in rooibos protected against shifts in substrate preference in H9c2 cardiomyocytes exposed 
to high glucose concentrations and that this protective effect was enhanced if aspalathin was 
combined with metformin [32]. PPAG also decreased ROS production; interestingly, this effect was 
enhanced by metformin.  
The potential mechanism by which PPAG inhibits hyperglycemia induced myocardial injury remains to 
be fully elucidated. However, recent research is highlighting a strong connection between activation of 
tumor protein p53 (p53) and increased expression of Bax or inhibition of Bcl2 in various disease 
models [33-35]. In hearts of diabetic mice, upregulated expression of p53 is associated with enhanced 
lipid accumulation and mitochondrial generated ROS, leading to apoptosis [35]. Thus, we propose that 
PPAG prevents hyperglycemic induced cardiac apoptosis through modulating increased FFA 
substrate flux into mitochondrial respiration complexes with a concomitant amelioration of the 
Bcl2/Bax ratio. However, further studies are required to assess the involvement of the p53 tumor 
suppressor gene in our model. 
In summary, this study reveals the cardioprotective potential of PPAG against hyperglycemia-induced 
cell injury and provides impetus for future investigations into its long-term effects on CVD in diabetic 
individuals. 
 
Materials and Methods 
Materials 
The ViaLight plus ATP kit, cell culture tested water, Dulbecco’s modified Eagle’s medium, Hank’s 
balanced salt solution and Dulbecco's phosphate-buffered saline (DPBS) were obtained from Lonza; 
14C-palmitate from American Radiolabelled Chemicals; fetal bovine serum and horse serum from 
Biochrom; Bcl2 antibody from Cell Signaling Technology; secondary antibodies, Bax and β-actin from 
Santa Cruz Biotechnology; and the Caspase-Glo 3/7 kit from Promega. PPAG (99% purity; batch: 
MC1(2)-248-91D) was synthesized by High Force Research. H9c2 rat derived cardiomyoblasts 
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(ECACC No. 8809294) were purchased from European Collection of Cell Cultures. All consumables 
and reagents, including metformin (99% purity) and mannitol (99% purity) were purchased from 
Sigma-Aldrich Corp., unless otherwise specified. 
 
Preparation of PPAG solution 
PPAG (MW: 326) at 10 mg was dissolved in 1 mL cell culture-tested water to give a final concentration 
of 30.67 mM stock solution which was stored at –80°C. Working solutions of 1 mM were made up from 
the initial stock using Dulbecco’s modified Eagle’s medium to give dilutions ranging from 0.01 to 1000 
µM.  
 
H9c2 cell culture and treatment with PPAG 
Embryonic heart-derived H9c2 cardiomyoblasts were cultured in supplemented Dulbecco’s modified 
Eagle’s medium (10% fetal bovine serum) for 48 h under standard tissue culture conditions (37°C in 
humidified air and 5% CO2). Depending on the assay performed, 60-80% confluent cells were seeded 
at a density of 2 x 104 or 0.8 x 104 cells /mL in 6-well or 96-well multi-plates, respectively. After 48 h of 
culture, H9c2 cardiomyoblasts were differentiated into cardiomyocytes by substituting growth media 
with differentiation media consisting of Dulbecco’s modified Eagle’s medium supplemented with 1% 
horse serum and 10 nM all-trans-retinoic acid for 6 days [36]. All experiments were initiated on day 7. 
H9c2 cells were exposed to a range of PPAG log concentrations (0.01 to 1000 µM) for 3, 6, 12, 24 and 
48 h, respectively. Thereafter, the effect of PPAG on hyperglycemia-induced cell apoptosis was 
tested. Here H9c2 cells were exposed to 33 mM glucose for 48 h prior to treatment with either PPAG 
(1 µM), metformin (1 µM) or metformin + PPAG (both at 1 µM) for an additional 12 h. Cells exposed to 
either 5.5 mM glucose, 33 mM glucose or 33 mM mannitol served as controls for normal glucose, high 
glucose and osmotic stress, respectively [25]. 
 
Measurement of metabolic activity 
ATP production as a measurement of metabolic activity in H9c2 cells was determined using the 
ViaLight plus ATP kit, according to the manufacturer’s instructions. Briefly, treated cells were lysed 
and incubated for 10 min at room temperature. Thereafter, ATP monitoring reagent was added and 
the luminescence determined after 2 min, using a BioTek FLx800 plate reader with data acquisition 
using Gen 5 software (Bio-Tek Instruments, Inc.). 
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Fatty acid uptake and oxidation 
FAU and FAO were determined as previously described [32, 37]. Following treatment, H9c2 cells were 
washed twice with warm DPBS and re-cultured in high glucose Dulbecco’s modified Eagle’s medium 
(without phenol red) containing 0.5 µCi/mL final concentration of palmitate-D-[14C (U)] in clear 6-well 
multi-plates. Each well was covered with filter paper wetted with 0.1 M NaOH for collection of 14CO2 
released from 14C-palmitate. The filter paper was replaced every 3 h and at the end of the experiment, 
14C activity was measured by liquid scintillation (2220 CA, Packard Tri-Carb series, PerkinElmer) to 
calculate FAO. The remaining cells were rinsed in ice cold DPBS to stop metabolism, then lysed with 
0.3 M NaOH + 1% sodium dodecyl sulfate buffer. The cell lysate was used to assess 14C-palmitate by 
liquid scintillation, as well as protein content using the Bradford’s protein assay [38]. The counts per 
minute (CPM) over specific activity (pre-determined using GraphPad radioactivity calculator: 
http://www.graphpad.com/quickcalcs/radcalcform.cfm) was used to determine fmol/mg protein.  
 
Measurement of oxidative stress markers 
Intracellular production of ROS was detected using DCFH-DA fluorescent dye (Cell Biolabs Inc.) as 
previously described [32]. Briefly, 100 µL of a 1 µM DCFH-DA final solution prepared in Hank’s 
balanced salt solution was added to H9c2 cells in a multi well plate and incubated at 37°C for 30 min 
in humidified air with 5% CO2. After 30 min, the dye was aspirated and cells rinsed in Hank’s balanced 
salt solution. DCFH-DA fluorescent intensity (Ex 485 ± 20 nm; Em 528 ± 20 nm) was measured using 
a BioTek FLx800 plate reader. 
GSH content was determined using 7-amino-4chloromethylcoumarin (CellTracker Blue CMAC) 
(Invitrogen). Briefly, 100 µL of 2.5 μM CellTracker solution was added to H9c2 cells and incubated at 
37ºC for 30 min. Thereafter, media containing CellTracker solution was removed and cells rinsed in 
DPBS before fluorescence intensity (Ex 360 ± 20 nm; Em 460 ± 40 nm) was measured using a BioTek 
FLx800 plate reader. 
SOD activity was quantified using a Biovision kit. Briefly, following treatment, H9c2 cells were lysed by 
the addition of 100 µL lysis buffer. Ten-microliter cell lysate was then transferred to a new 96 well plate 
to which 200 µL tetrazolium working solution was added. SOD activity was measured at an 
absorbance of 450 nm using a BioTek ELx800 plate reader. 
 
Stellenbosch University  https://scholar.sun.ac.za
 64 
Determination of mitochondrial membrane potential (ΔΨm) 
Membrane depolarization was assessed by staining H9c2 cardiomyocytes with JC-1 according to a 
previously described method [15]. Briefly, treated H9c2 cells were washed twice with warm DPBS, 100 
µL of 2 µM JC-1 solution (made up in Dulbecco’s modified Eagle’s medium without phenol red) was 
added and the cells then incubated at 37°C in humidified air and 5% CO2 for 30 min the dark. After 
JC-1 exposure, cells were rinsed in DPBS before fluorescence (Ex 485 ± 20 nm; Em 530 ± 25 nm and 
590 ± 35 nm) was measured using a BioTek FLx800 plate reader and Gen 5 software. In addition, 
fluorescent photomicrographs were taken at 10x magnification using a Nikon Eclipse Ti inverted 
microscope and NIS-Elements imaging software. 
 
Propidium iodide fluorescent stain 
Propidium iodide staining assay was performed following a published protocol [39]. Briefly, treated 
cells were exposed to 1 μg/mL propidium iodide solution for 30 min at 37°C in humidified air with 5% 
CO2. After 30 min, cells were rinsed in DPBS and analyzed as described for determination of 
membrane depolarization. Fluorescent photomicrographs were taken at 10x magnification using a 
Nikon Eclipse Ti inverted microscope and NIS-Elements imaging software. 
 
Caspase 3/7 activity assay 
In this assay, Caspase-Glo 3/7 reagent is cleaved by caspases producing a luminescent signal 
proportional to caspase activity. Briefly, treated cells were washed twice with warm DPBS before 
being lysed. Caspase-3/7 Glo reagent was mixed with cell lysates and the mixture was incubated in 
the dark at 37°C in humidified air with 5% CO2 for 30 min. Luminescence was measured using an 
integration time of 1 s and equipment described for measurement of metabolic activity. Results were 
normalized to the protein content determined according to the method of Bradford [38].  
 
TUNEL assay 
DNA fragmentation, as a measure of apoptosis in H9c2 cells, was detected using a DeadEnd 
Fluorometric TUNEL kit, according to the manufacturer’s instructions. Briefly, treated cells were 
washed twice in DPBS and permeabilized with 0.2% Triton X-100. Thereafter, the equilibration buffer 
and TdT reaction mix (supplied with the kit) were added before incubation at 37°C in humidified air 
with 5% CO2 incubator for 60 min. The apoptotic rate was calculated as the average number of 
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condensed TUNEL-positive cells in non-overlapping fields of 1 mm2 under 10x magnification field 
(average of at least 5 fields per well) using a Nikon Eclipse Ti inverted fluorescent microscope and NIS 
Elements imaging software.  
 
Western blot analysis 
Protein extracts were isolated from different treatment groups and Western blot analysis performed 
according to an already described method [40]. Membranes were immunoblotted for 16 h at 4°C with 
the following primary antibodies: anti-Bax (1:250 dilution), anti-Bcl2 (1:1,000 dilution) and anti-β-actin 
(1:1,000 dilution) antibody, included as a loading control. The relevant horseradish peroxidase 
conjugated secondary antibodies were applied the following day for 90 min at room temperature. The 
protein signal was detected using a chemiluminescence solution and quantified using a Chemidoc-
XRS imager (Bio-Rad). 
 
Statistical analysis 
Results were expressed as the mean ± SEM of 3 independent biological experiments. Statistical 
analysis was performed using GraphPad Prism software (GraphPad Software, Inc.). Comparisons 
between treatment groups were performed using a one way ANOVA followed by a Tukey post hoc test 
or unpaired Student t-test where appropriate. P-value of ≤ 0.05 was deemed as statistically significant. 
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Abstract 
 
Scope: Energy deprivation in the myocardium is associated with impaired heart function. This study 
aims to investigate if aspalathin (ASP) can ameliorate hyperglycemic-induced shift in substrate 
preference and protect the myocardium against cell apoptosis. 
Methods and results: H9c2 cells were exposed to, either normal (5.5 mM) or high (33 mM) glucose 
concentrations for 48 hours. Thereafter, cells exposed to 33 mM glucose were treated with metformin 
(1 µM) or ASP (1 µM), as well as a combination of metformin and ASP for 6 hours. In vitro studies 
revealed that ASP improved glucose metabolism by decreasing fatty acid uptake and subsequent β-
oxidation through the decreased expression of adenosine monophosphate-activated protein kinase 
threonine 172 (pAMPK (Thr172)) and carnitine palmitoyltransferase 1 (Cpt1), while increasing acetyl-
CoA carboxylase (ACC) and glucose transporter 4 (Glut4) expression. ASP inhibited high glucose-
induced loss of membrane potential in H9c2 cells as observed by an increase in 5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) ratio (orange\red fluorescence) and 
decreased apoptosis by reducing intracellular reactive oxygen species and DNA nick formation, while 
increasing glutathione, superoxide dismutase, uncoupling protein 2 (UCP2) and Bcl-2\Bax ratio.  
Conclusion: Our study provides evidence that ASP increases glucose oxidation and modulates fatty 
acid utilization producing a favorable substrate shift in H9c2 cardiomyocytes exposed to high glucose. 
Such a favorable shift will be of importance in the protection of cardiomyocytes in the diabetic heart.  
 
Keywords 
Apoptosis; diabetes; cardiomyopathy; fatty acid oxidation. 
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1. Introduction 
In the last two decades, the incidence of diabetes mellitus (DM) has increased worldwide with a 
concomitant increase in cardiovascular complications [1]. This is not surprising as diabetes is a known 
contributor to the development of cardiovascular disease (CVD), with diabetic individuals having a 2-3 
times higher risk of developing cardiovascular complications compared to the non-diabetic population 
[2]. This makes CVD the most common cause of mortality and morbidity in the diabetic population [2, 
3]. However, the underlying pathogenesis of diabetic-induced cardiomyopathy (DICM) is still unclear. 
Current consensus is that exposure to chronic hyperglycemia enhances the production of reactive 
oxygen species (ROS) which may contribute to the development of DICM [4-6].  
Hyperglycemia, dyslipidemia, and inflammation increase the generation of ROS or nitrogen species 
(RNS), key factors associated with the pathogenesis of DICM. The diabetic heart is particularly 
vulnerable to increased oxidative stress due to a deficient endogenous antioxidant defense 
mechanism [5, 7-9]. This impaired equilibrium between production and elimination of reactive species 
associated with the diabetic state results in structural remodeling of the myocardia and left ventricular 
dysfunction, which is the hallmark of DICM [3, 4, 10]. 
The mitochondria can be described as “the power house of the cell” and apart from increased ROS 
production, mitochondrial dysfunction and impaired energy metabolism have been associated with 
many forms of heart disease including DICM [11]. An increased shift in fatty acid β-oxidation (FAO) 
relative to carbohydrate oxidation has the potential to decrease cardiac efficiency and increase 
contractile dysfunction as observed in DICM. Increasing evidence suggests that therapies aimed at 
decreasing FAO, or directly stimulating glucose oxidation would be of benefit to the diabetic heart 
during and following myocardial ischemia [12, 13]. 
Metformin is a first-line antidiabetic drug known to reduce the risks of heart disease in people with 
diabetes. To date, several studies have shown that metformin is able to preserve left ventricular 
function by reducing endogenous glucose production and hepatic gluconeogenesis through the 
stimulation of AMP-activated protein kinase activity [14]. However, the efficacy of metformin to protect 
the diabetic heart at risk from increased chronic hyperglycemia decreases over time [15].  
The antioxidant efficacy of dietary flavonoids and their beneficial effect on health have been reported 
on previously [16-18]. The use of plant-based products as a means to increase the antioxidant 
defense in the body is gaining popularity. The balance between oxidation and the body’s antioxidant 
system is critical in maintaining optimal cellular function. Flavonoids as antioxidants have the ability to 
scavenge and reduce free radical formation [19]. In the human body, flavonoids function as 
antioxidants and exert their protective effect through their ability to increase levels of endogenous 
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antioxidant defenses such as superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx) 
and glutathione (GSH) which allow for the elimination of excessive ROS in the body [20, 21]. 
Therefore, preventing redox disequilibrium caused by increased oxidative stress.  
Aspalathin (ASP) a dietary flavonoid present in Aspalathus linearis (rooibos) has known antioxidant 
and antidiabetic properties. Muller et al (2012) reported that ASP has a sustained glucose lowering 
effect comparable to metformin in STZ-induced diabetic rats [22]. Furthermore, ASP was shown to 
suppress ROS induced by advanced glycation end products (AGEs) in vivo [23]. Therefore, ASP, as a 
dietary supplement, through its beneficial effect on glycemia and associated oxidative stress may 
protect the diabetic heart. A systematic review of literature led us to believe that a combination of ASP 
with metformin may have an additive effect on glycemia, reduce oxidative stress and lower the risk for 
DICM [22-28]. The aim of our study was to investigate the ameliorative effect of ASP as a 
monotherapy or in combination with metformin on oxidative stress and FAO in H9c2 cardiac muscle 
cells exposed to a high glucose (HG) concentration. 
 
2. Materials and Methods 
2.1. Reagents list 
Dulbecco's Modified Eagle's Medium (DMEM), Dulbecco`s phosphate buffered saline (DPBS) and 
penicillin/streptomycin were from Lonza BioWhittaker (Verviers, Belgium). All other cell culture 
reagents were obtained from Sigma-Aldrich (Saint Louis, Missouri, MO, USA). Protease and 
phosphatase inhibitor tablets were purchased from Roche Diagnostics (Mannheim, Germany). Radio-
immunoprecipitation assay (RIPA) buffer and all primary antibodies were purchased from Cell 
Signaling Technologies (Beverly, MA, USA). Secondary antibodies and β-actin were obtained from 
Santa Cruz Biotechnology (Dallas, TX, USA). Fetal bovine serum (FBS) and horse serum (HS) were 
from Biochrom (Berlin, Germany). Aspalathin (ca. 98%, batch SZI-356-54) was synthesized according 
to the method of Han et al (2014) [29] by High Force Research LTD (Durham, UK). Two-deoxy-[3H]-D-
glucose and 14C palmitate were obtained from American Radiolabeled Chemicals (St Louis, MO, 
USA). Palmitic acid (C18:O) and all other chemicals (analytical grade) were obtained from Sigma-
Aldrich (Saint Louis, MO, USA). 
 
2.2. In vitro culturing of embryonic ventricular rat heart derived cells (H9c2) 
Embryonic rat heart-derived cardiac myoblasts H9c2 (ATCC, CRL-1446) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (supplemented with 10% (v/v) FBS, 100 U/ml of penicillin and 100 
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mg/ml of streptomycin) under standard tissue culture conditions (37°C in a water-saturated 
atmosphere of 5% CO2) in 75 cm2 culture flasks at a seeding density of 1 x 106. After 48 hours, sub-
confluent (60%) cells were split and plated in either 6-, 24- or 96-well plates in DMEM (containing 10% 
FBS) at seeding densities of 2 x 104, 1 x 104 or 0.8 x 104, respectively for 48 hours. Thereafter, cells 
were differentiated for 6 days in DMEM supplemented with 1% horse serum and 10 nM retinoic acid 
(RA). The culture medium was replaced daily and experiments were initiated on day 7. To assess the 
effect of normal glucose (NG; 5.5 mM) compared to HG (HG; 33 mM), H9c2 cells were first washed in 
glucose free DMEM before exposure to DMEM containing 5.5 mM or 33 mM glucose for 24 and 48 
hours, respectively. Control cells were treated with 33 mM mannitol to rule out the effect of osmolarity.  
 
2.3. Effect of aspalathin on H9c2 treatment 
A stock solution of ASP was prepared according to Muller et al (2012) [22]. Following pre-treatment of 
cardiomyocytes, with either 5.5 mM or 33 mM glucose for 48 hours, H9c2 cells were treated with or 
without either ASP (1 μM), metformin (MET) (1 µM) or a combination of ASP and MET (both at 1 µM). 
Experimental groups consisted of (1) NG control (5.5 mM); (2) HG control (33 mM); (3) HG + MET (1 
µM); (4) HG + ASP (1 µM) and (5) HG + MET+ ASP (both at 1 μM).  
 
2.4. ATP assay 
Cellular ATP content used as a measure of metabolic activity was performed using a ViaLight™ plus 
ATP kit (Lonza, Basel, Switzerland), following the manufacturer’s instructions. Luminescence was 
quantified using a BioTek® FLx800 plate reader and Gen 5® software (BioTek Instruments Inc., 
Winooski, VT, USA). 
 
2.5. Fatty acid uptake and oxidation 
Fatty acid uptake (FAU) and FAO were determined using a modified method of Nugent (2001) [30]. 
Briefly, ASP treated cells were cultured in DMEM (without phenol red) containing a final 0.5 µCi/mL of 
palmitate-D-[14C (U)] for 6 hours in 6-well tissue culture plates, overlaid with filter paper moistened with 
0.1 M NaOH. After 6 hours, the filter paper was removed and the absorbed 14CO2 as a product of 
palmitate-D-[14C (U)] was detected by liquid scintillation. Thereafter, medium was removed and cells 
washed with 1 mL DPBS. Cells were then lysed with 0.3 M NaOH, and FAU of palmitate-D-[14C (U)] 
was assessed in the lysate by liquid scintillation (2220 CA, Packard Tri-Carb series, PerkinElmer, 
Downers Crove, IL, USA. Results were calculated as fmol/mg. Counts per minute (CPM) divided by 
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specific activity (calculated by Graphpad radioactivity calculator 
(http://www.graphpad.com/quickcalcs/radcalcform.cfm)), normalized to protein content was used to 
estimate fmol/mg. Data are expressed in relative to the control in arbitrary units. 
 
2.5.1. 2-Deoxy-[3H]-D-glucose uptake 
2-Deoxy-[3H]-D-glucose uptake (GU) was measured using the method described by Muller et al 
(2012). Briefly, after 6-hours of incubation with the relevant treatments or controls, in 24 well plates, 
the cells were incubated with a final concentration of 0.5 μCi/mL 2-deoxy-[3H]-D-glucose for 15 
minutes at 37 °C in 5% CO2 and humidified air. 2-Deoxy-[3H]-D-glucose uptake was assessed by 
liquid scintillation [22]. Results were calculated as fmol/mg as described in subsection 2.5. Data are 
expressed relative to the control in arbitrary units. 
 
2.5.2. Glucose oxidation  
Glucose oxidation (GO) was determined as described by Mazibuko et al (2013) [31]. Briefly, following 
6 hour treatment, cells were cultured in DMEM containing 0.5 µCi/mL glucose D-[14C (U)] and CO2 
released from the culture media was trapped with filter paper moistened with 0.1 M NaOH. After 6 
hours, the filter paper was removed and placed in scintillation vials for quantification of GO by liquid 
scintillation. Data are expressed relative to the control in arbitrary units. 
 
2.6. Measurement of pro-oxidant and antioxidant activity  
Intracellular production of ROS was detected using 2', 7’-dichlorfluoresceindiacetate (DCFH-DA) 
fluorescent dye (Cell Biolabs Inc., San Diego, CA, USA). Briefly, 100 µL of a 1 µM DCFH-DA final 
solution prepared in Hank’s balanced salt solution (HBSS) was added to H9c2 cells in a multi well 
plate and incubated at 37 °C for 30 minutes in humidified air with 5% CO2. After 30 minutes, the dye 
aspirated, the cells rinsed in HBSS and DCFH-DA fluorescent intensity measured using a BioTek® 
FLx800 plate reader. GSH content was determined using 7-amino-4chloromethylcoumarin 
(CellTracker™ Blue CMAC) (Invitrogen Corporation, Carlsbad, CA, USA). Briefly, 100 µL of 2.5 μM 
CellTracker solution was added to H9c2 cells and incubated at 37ºC for 30 minutes. Thereafter, media 
containing CellTracker solution was removed and cells rinsed in DPBS before fluorescence intensity 
was measured using a BioTek® FLx800 plate reader. SOD activity was quantified using a Biovision kit 
(Mountain View, CA, USA). Briefly, following treatment, H9c2 cells were lysed by the addition of 100 
µL lysis buffer. Ten-microliter cell lysate was then transferred to a new 96 well plate to which 200 µL 
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tetrazolium working solution was added. SOD activity was measured using a BioTek® ELx800 plate 
reader.  
 
2.7. Determination of mitochondrial membrane potential  
Mitochondrial membrane potential was assessed using the cationic dye 5,5',6,6'-tetrachloro-1,1',3,3-
tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) (Sigma-Aldrich, St Louis, MO, USA). In healthy 
cells with normal mitochondrial membrane potential, JC-1 forms complexes known as J-aggregates 
producing an orange/red fluorescence. In cells with mitochondrial dysfunction, JC-1 remains in the 
monomeric form and exhibits a green fluorescence. To assess mitochondrial membrane potential, 
H9c2 cells were washed with DPBS, 2 µM of JC-1 solution was added to the cell mixture and 
incubated in the dark at 37°C for 30 minutes. JC-1 fluorescent intensity was measured using a 
BioTek® FLx 800 plate reader (Ex 485 nm, Em 530±25 nm and 590±35). In addition fluorescent 
photomicrographs were captured at 10x magnification using NIS elements software, with a Nikon 
Eclipse Ti inverted microscope. 
 
2.8. TUNEL assay 
DNA nicks were detected by DeadEnd™ Fluorometric TUNEL assay according to manufacturer’s 
instructions (Promega Corporation, Madison, USA). Briefly, TdT solution was added to the treated 
cells and incubated at 37°C for 60 minutes. After incubation, cells were rinsed twice in SSC buffer for 
15 minutes each. TUNEL-positive cells were detected by direct visualization of fluorescent staining. 
The apoptotic rate was calculated as the average number of condensed TUNEL-positive cells of non-
overlapping fields of 1 mm2 under x 100 magnification (average of at least 5 fields per well). 
 
2.8. Caspase-3/7 activity 
Caspase-3 and caspase-7 activities of H9c2 cells exposed to HG concentration were measured using 
a Caspase-Glo® 3/7 luminescent kit (Promega Corporation, Madison, USA), following manufacturer’s 
instructions. Briefly, following treatment, cells were lysed and 20 µl of the cell lysate transferred to a 
white 96-well plate. An equal amount of Caspase-3/7 Glo reagent was added to each well; and 
incubated for 30 minutes. Luminescence was measured in a BioTek® FLx 800 plate reader. Results 
were normalized to pre-determined protein content determined using Bradford assay. 
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2.9. mRNA expression analysis 
Total RNA was extracted from H9c2 cells using Trizol reagent. Briefly, H9c2 cells were homogenized 
using a TissueLyser (Qiagen, Hilden, Germany) at 25 Hz for 2 minutes according to the 
manufacturer’s instructions. RNA was purified using an RNeasy Mini kit (Qiagen, Germantown, MD, 
USA) and genomic DNA was removed using the Ambion Turbo DNase kit (Applied Biosystems, 
Austin, Texas, USA) according to the manufacturer’s instructions. RNA samples were converted to 
cDNA using the High Capacity Reverse Transcription kit (Applied Biosystems, Austin, Texas, USA) as 
recommended by the manufacturers. Quantitative RT-PCR was performed on an ABI 7500 Instrument 
(Applied Biosystems, Austin, Texas, USA). The reaction mix was prepared by adding 12.5 µL Taqman 
universal PCR master mix, 1.25 µL Taqman Gene Expression Assay (for Glut4, ACC and UCP2), 25 
ng of cDNA, and RNAse free water to a final volume of 25 µL. The quantitative RT-PCR protocol was 
conducted as follows: 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute. Gene expression data were normalized to hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). 
 
2.10. Western blot analysis 
H9c2 cells were lysed in ice-cold RIPA buffer (Pierce Biotechnologies, Rockford, CA, USA). The 
lysates were centrifuged and the supernatant collected. Twenty micrograms of cell lysate were 
denatured and loaded onto a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride 
(PVDF) membrane. Nonspecific binding on the membranes were blocked, using 5% (w/v) low-fat milk 
in Tris-buffered saline with Tween-20 (TBS-T; 10 mmol/L Tris-HCl, pH 7.5, 200 mmol/L NaCl, 0.05% 
Tween-20) at room temperature for 2 hours. Subsequently, the membrane was incubated overnight at 
4ºC with the following primary antibodies: anti-Bcl-2 (1:1 000 dilution), anti-Bax (1:1000), pAMPK 
(Thr172) (1:1000) and CPT1 (1:1000) with the relevant horseradish peroxidase (HRP) conjugated 
secondary antibodies applied the following day for 90 minutes at room temperature. β-Actin (1:4000) 
antibody was added as a loading control. Proteins were detected and quantified using a Chemidoc-
XRS imager and Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). 
 
2.11. Statistical analysis 
Data were expressed as the mean ± SEM of three independent biological experiments with each 
experiment containing at least 3 technical replicates. GraphPad Prism software (GraphPad Software 
Inc. La Jolla, CA, USA) was used for calculation of one-way multivariate ANOVA, followed by a Tukey 
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post hoc test or student t-test where appropriate. A p value of ≤ 0.05 was deemed as statistically 
significant. 
 
3. Results 
3.1. Effect of high glucose concentration on cardiac muscle cells  
The effect of HG on metabolic activity was determined by exposing H9c2 cells to NG (5.5 mM) and 
HG (33 mM) over a 24 and 48-hour period, respectively. Culturing cells exposed to 33 mM glucose for 
24 hours did not show a significant difference in metabolic activity when compared to the control. 
However, chronic exposure of cardiomyocytes to HG for 48 hours resulted in a decrease in metabolic 
activity when compared to the NG control (Figure 1). ASP does not have an effect on H9c2 cells 
treated with 5.5 mM glucose (unpublished data). 
 
Figure 1. Effect of 33 mM glucose on metabolic activity. H9c2 cells treated with 5.5 mM glucose (normal 
glucose, NG) and 33 mM glucose (high glucose, HG) for (A) 24 and (B) 48 hours. Results are expressed as the 
mean ± SEM of three independent experiments. ATP luminescence results are presented in arbitrary units (AU). 
***p < 0.0001 versus NG. 
 
3.2. Energy metabolism in the diabetic heart 
H9c2 cells exposed to HG showed a significant increase in FAU while GU was significantly decreased 
(1.5 ± 0.09; p < 0.0001 and 0.6 ± 0.04; p < 0.001). Treatment with MET resulted in a decrease in FAU 
with a concomitant increase in GU (1.2 ± 0.04; p < 0.01 and 0.9 ± 0.05). Similarly, ASP (1.2 ± 0.07; p 
< 0.0001 and 0.9 ± 0.07; p < 0.001) and a combination of MET and ASP (1.1 ± 0.04; p < 0.0001 and 
0.9 ± 0.09; p < 0.001) were effective in decreasing FAU while increasing GU (Figure 2A and B).  
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Results obtained also showed that HG elicited a significant increase in FAO with a concomitant 
decrease in GO (0.84; p < 0.0001 and 0.22; p < 0.001) (Figure 2C). Treatment with MET decreased 
FAO by 16% (p < 0.01) while GO was increased by 16% (p < 0.01). Treatment of H9c2 cells with 
either ASP or a combination of MET and ASP decreased FAO by 18% (p < 0.01) and 23% (p < 0.001) 
and increased GO by 18% and 23% (p < 0.01 and p < 0.0001), respectively (Figure 2C). 
 
     A                                                                            B 
 
 
 
 
 
 
 
                                     C 
 
 
 
 
 
 
 
Figure 2. Effect of ASP on shift in substrate preference. Fatty acid uptake (A), glucose uptake (B) and fatty acid 
and glucose oxidation combination stacked bar graph (C) of H9c2 cells treated with 33 mM glucose (high 
glucose, HG) for 48 hours and post treated with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the 
combination of MET and ASP (1 μM each) for 6 hours. Mannitol (MAN) at a concentration of 33 mM was used to 
rule out the effect of osmolarity. Glucose uptake and palmitate uptake are expressed in arbitrary units (AU) for 2-
Deoxy-[3H]-D-glucose and palmitate-D-[14C (U)], respectively. Results are expressed as the mean of three 
independent experiments relative to the normal glucose (NG) control (5.5 mM). **p < 0.001 and ***p < 0.0001 
versus NG control. #p < 0.01, ##p < 0.001 and ###p < 0.0001 versus HG control. 
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3.3. Increased ROS production 
A 41% increase in ROS production was observed in H9c2 cells exposed to HG (141 ± 2.3%; p < 
0.0001) (Figure 3). Treatment of cells with MET decreased ROS production by 20% (121 ± 2.2%; p< 
0.0001), while ASP (121 ± 2.1%; p < 0.0001) and the combination of MET and ASP (115 ± 2.6%; p< 
0.0001) subdued the HG-induced increase of intracellular ROS by 20% and 26% respectively.   
 
 
 
 
 
 
 
 
Figure 3. Effect of ASP on intracellular ROS formation. DCFH-DA fluorescence intensity of intracellular ROS 
formation of H9c2 cells treated with 33 mM glucose (HG) for 48 hours and post treated with metformin (MET; 1 
μM), aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM each) for 6 hours. Mannitol (MAN) at a 
concentration of 33 mM was used to rule out the effect of osmolarity. Results are expressed as the mean of 
three independent experiments relative to the normal glucose (NG) control (5.5 mM) at 100% ± SEM. ***p < 
0.0001 versus NG control  ###p < 0.0001 versus HG control. 
 
3.4. Mitochondrial transmembrane potential (ΔΨm) 
Pre-treatment of cells with HG resulted in an increase in green fluorescence after H9c2 cells were 
stained with JC-1 (Figure 4A and B), indicating a reduction in mitochondrial transmembrane potential 
(ΔΨm). The HG concentration significantly increased mitochondrial depolarization by a ratio of 0.46 
(from 1 ± 0.05 to 1.46 ± 0.1; p < 0.0001). Both MET (1.16 ± 0.044; p < 0.01) and ASP (1.13 ± 0.07; p < 
0.01) were able to ameliorate this effect. An enhanced effect was observed when H9c2 cells, exposed 
to glucose, were treated with the MET and ASP combination (1.02 ± 0.07; p < 0.0001). The observed 
effect was similar to that of the normal control and slightly better than either MET or ASP alone. 
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Figure 4. Effect of ASP on mitochondrial membrane potential. Fluorescent photomicrographs of JC-1 fluorescent 
mitochondrial depolarization of H9c2 cells treated with 33 mM glucose (high glucose, HG) for 48 hours and post 
treated with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM each) 
for 6 hours. Mannitol (MAN) at a concentration of 33 mM was used to rule out the effect of osmolarity. Results 
are expressed as the mean of three independent experiments relative to the normal glucose (NG) control (5.5 
mM). ***p < 0.0001 versus NG control. #p < 0.01 and ###p < 0.0001 versus HG control. 
 
3.5. GSH content and SOD activity 
Chronically exposing H9c2 cells to HG decreased SOD activity to 47% (47 ± 9%; p < 0.0001). MET 
increased SOD activity by 57% (104 ± 5.3%; p < 0.0001) while both ASP (118 ± 4.9%; p < 0.0001) 
and the combination of MET and ASP (118 ± 5.2%; p < 0.0001) increased de-novo SOD synthesis by 
87% (Figure 5A). The effect of ASP was marginally better than that of MET alone, although non-
significant. HG also reduced the GSH content of H9c2 cells (0.59 ± 0.03; p < 0.0001), while treatment 
with MET (0.82 ± 0.03; p < 0.0001), ASP (0.89 ± 0.03; p < 0.0001) or the combination of MET and 
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ASP (0.94 ± 0.02; p < 0.0001) increased GSH content under HG conditions (Figure 5B). The observed 
effect was comparable to that of the NG control (1 ± 0.02; p = NS). 
 
      A                                                                          B 
 
 
 
 
 
 
 
Figure 5. Effect of ASP on SOD activity and GSH fluorescence. Superoxide dismutase (SOD) activity (A) and 
CellTrackerTM Blue CMAC fluorescence as a measure of glutathione (GSH) content (B) was assessed in H9c2 
cells treated with 33 mM glucose (high glucose, HG) for 48 hours and post treated with metformin (MET; 1 μM), 
aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM) for 6 hours. Mannitol (MAN) at a 
concentration of 33 mM was used to rule out the effect of osmolarity. Results are expressed as the mean ± SEM 
of three independent experiments relative to the normal glucose (NG) control (5.5 mM). ***p < 0.0001 versus NG 
control. ###p < 0.0001 versus HG control. 
 
3.6. H9c2 cell apoptosis 
HG significantly increased Caspase-3/7 activity in H9c2 cell (139 ± 6.9%; p < 0.0001), while treatment 
with ASP (116 ± 5.3%; p < 0.01) or the combination of MET and ASP (116 ± 3.8%; p < 0.01) 
decreased HG-induced apoptosis (Figure 6). Increased numbers of TUNEL-positive cells were 
observed in H9c2 cells exposed to HG compared to that of the NG control (7.7 ± 0.5 compared to 1.2 
± 0.2; p < 0.0001). Treatment with ASP and the combination of MET and ASP significantly decreased 
the amount of TUNEL positive cells (3.6 ± 0.12; p < 0.001 and 4.4 ± 0.6; p < 0.01). However, no 
significance was observed with MET treatment (5.2 ± 0.48) (Figure 7). 
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Figure 6. Effect of ASP on cell apoptosis. Caspase-3/7 activity of H9c2 cells treated with 33 mM glucose (high 
glucose, HG) for 48 hours and post treated with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the 
combination of MET and ASP (1 μM) for 6 hours. Results are expressed as the mean of three independent 
experiments relative to the normal glucose (NG) control (5.5 mM) at 100% ± SEM. ***p < 0.001 versus NG 
control. #p < 0.01 versus HG control. 
 
3.7. Western blot analysis 
3.7.1. Bcl-2\Bax ratio  
A significant decrease in the Bcl-2\Bax ratio was observed when cells were exposed to HG (71 ± 
2.2%; p < 0.01). Treatment with MET (106 ± 6.1%; p < 0.001), ASP (111 ± 6.5%; p < 0.001) and a 
combination of MET and ASP (115 ± 10.7%; p < 0.0001) was able to ameliorate this effect significantly 
(Figure 8). 
 
3.7.2. β-Oxidation  
Exposure of H9c2 cells to a HG concentration increased pAMPK (Thr172)  and CPT1 expression by 5.9 
fold (p < 0.001) and 1.4 fold (p < 0.01), respectively. Treatment with ASP and the combination of MET 
and ASP decreased the expression of pAMPK (Thr172) by 1.96 fold (p < 0.01) and 1.84 fold (p < 0.01), 
respectively. MET had no effect. Treatment with ASP, MET and combination of MET and ASP 
decreased CPT1 expression by 1.4 fold (p < 0.0001), 2.1 (p < 0.0001) and 1.3 fold (p < 0.0001), 
respectively, when compared to the HG control (Figure 9A and B). 
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Figure 7. Effect of ASP on diminishing DNA fragmentation of apoptotic cells. Fluorescent photomicrographs of 
TUNEL positive H9c2 cells and B) treated with 33 mM glucose (high glucose, HG) for 48 hours and post treated 
with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM each) for 6 
hours. White arrows illustrate apoptotic TUNEL positive cells. Mannitol (MAN) at a concentration of 33 mM was 
used to rule out the effect of osmolarity. Results are expressed as the mean of three independent experiments 
relative to the normal glucose (NG) control (5.5 mM) at 100% ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001 
versus NG control. #p < 0.01 and ##p < 0.001 versus HG control. 
 
3.8. mRNA expression analysis 
Exposure of H9c2 cells to a HG concentration decreased the expression of GLUT4 by 2.2 fold (p < 
0.01) and ACC by 2.5 fold (p < 0.001), respectively when compared to that of the NG control. MET, 
ASP and the combination of MET and ASP significantly increased mRNA expression of GLUT4 by 1.1 
fold (NS), 2.3 fold (p< 0.01) and 2.8 fold (p < 0.01) and that of ACC by 1.9 fold (p < 0.0001), 3.3 fold (p 
< 0.0001) and 4.7 fold (p < 0.0001) when compared to that of the HG control (Figure 10A and B). HG 
also decreased the expression of UCP2 by 2.2 fold (p < 0.01) in H9c2 cells (Figure 10C). Aspalathin 
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and the combination of MET and ASP reversed this effect by 2.6 fold (p < 0.001) and 2.3 fold (p < 
0.001), respectively. MET monotherapy was less effective.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of ASP On Bcl-2 and Bax protein expression. H9c2 cells treated with 33 mM glucose (HG) for 
48 hours and post treated with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the combination of MET and 
ASP (1 μM each) for 6 hours. Results are expressed as the mean of three independent experiments relative to 
the normal glucose (NG) control (5.5 mM) at 100% ± SEM. *p < 0.01 versus NG control. ##p < 0.001 and ###p < 
0.0001 versus HG control. 
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Figure 9. Effect of ASP on pAMPK and CPT1 protein expression. pAMPK(Thr172) (A) and CPT1 (B) protein 
expression of H9c2 cells treated with 33 mM glucose (high glucose, HG) for 48 hours and post treated with 
metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM each) for 6 hours. 
Results are expressed as the mean of three independent experiments relative to the normal glucose (NG) 
control (5.5 mM) at 100% ± SEM. *p < 0.01 versus NG control. #p < 0.01, ##p < 0.001 and ###p < 0.0001 versus 
HG control. 
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Figure 10. Effect of ASP on GLUT4, ACC and UCP2 mRNA expression. GLUT4 (A), ACC (B) and UCP2 (C) 
mRNA expression in H9c2 cells treated with 33 mM glucose (high glucose, HG) for 48 hours and post treated 
with metformin (MET; 1 μM), aspalathin (ASP; 1 μM) and the combination of MET and ASP (1 μM each) for 6 
hours. Results are expressed as the mean of three independent experiments relative to the normal glucose (NG) 
control (5.5 mM) at 100% ± SEM. *p < 0.01, **p < 0.001 and ***p < 0.0001 versus NG control. #p < 0.01, ##p < 
0.001 and ###p < 0.0001 versus HG control. 
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4. Discussion  
In normal cardiomyocytes FAO contributes to approximately 70% and GO to the remaining 30% of 
energy production. This balance in energy production is crucial for optimal contractile function of the 
heart. In the diabetic heart, there is a shift in mitochondrial substrate preference from glucose towards 
an almost complete reliance on FAO (80-90%) as the preferred energy source [10]. This 
compensatory shift in energy substrate is believed to be involved in impaired cardiac function of the 
failing heart [32]. Studies done in T2DM rodent models with associated HF, showed a dramatic 
increase in lipid accumulation and FAO with a concomitant decrease in GO [33, 34]. Similar findings 
were also reported for studies of the hearts of human patients with T2DM [35]. In this study, a shift in 
substrate preference with an associated decreased metabolic activity was observed when H9c2 cells 
were chronically exposed to a HG concentration of 33 mM. ASP, as well as the combination of MET 
and ASP, was able to reverse this effect. These findings can indirectly improve heart contractile 
function as energy metabolism is closely linked to cardiac function [36]. Our findings are supported by 
a study conducted by Kantor et al (2000) demonstrating that trimetazidine, an anti-anginal agent and 
FA inhibitor, was able to protect the diabetic heart by decreasing FAO and increasing GO in the hearts 
of Zucker rats [36]. 
This shift in substrate preference and the ability of cells to survive metabolic dysfunction relies, in part, 
on the response of intracellular kinases [37]. A change in contractile activity of diabetic 
cardiomyocytes results in a temporal increase in the adenosine monophosphate/triphosphate 
(AMP/ATP) ratio, which induces a conformational change within AMPK, making it accessible for 
phosphorylation (pAMPK). Increased pAMPK suppresses acetyl-CoA carboxylase (ACC) activity, 
decreases malonyl-CoA levels and subsequently the inhibitory effect of malonyl-CoA on CPT1 is 
lessened with a resultant increase in FAO. Our findings support such a hypothesis whereby exposure 
of the cells to a HG concentration decreased ATP and increased pAMPK expression. This brought 
about a decrease in ACC and increased CPT1 with a subsequent increase in FAU and FAO. ASP and 
the combination of MET and ASP was able to reduce FAU and FAO while increasing glucose uptake 
as observed by decreased fatty acid translocase (FAT/CD36) (supplementary data) and increased 
GLUT4 mRNA expression. This infers that ASP can improve myocardial energy balance by switching 
energy preference from FAO to GO and thus protecting the diabetic heart against contractile 
dysfunction. This is an important finding, as both FAT/CD36 and GLUT4 are major transporter proteins 
with fundamental roles in fatty acid and glucose uptake respectively. In T2DM FAT/CD36 remains 
localized at the sarcolemma whereas GLUT4 internalizes, resulting in a shift in substrate preference 
[38]. This shift in substrate utilization results in increased FAU, at the expense of glucose as observed 
in this study. The effect of ASP on GLUT4 gene expression with concomitant increased GU results in 
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an improved glucose to fatty acid utilization ratio. In addition, we showed that ASP has a modulating 
effect on FAT/CD36 that could culminate in an improved substrate utilization in the diabetic heart. 
Chronic hyperglycemia is also known to be responsible for cardiac dysfunction through the generation 
of increased oxidative stress [4, 6]. Oxidative stress is defined as the imbalance between the 
production and elimination of ROS, which plays a critical role in left ventricular remodeling and HF 
[39]. The cardiomyocytes have a very low antioxidant capacity and a shift in mitochondrial substrate 
preference can result in increased ROS production. Uncoupling protein 2 (UCP2) is a negative 
regulator of mitochondrial derived ROS and plays an important role in mitochondrial cellular redox 
homeostasis. Augmentation of UCP2 expression could result in decreased ROS production and 
protect the cell against oxidative damage [40, 41]. Data from this study showed that chronic exposure 
of H9c2 cells to 33 mM glucose triggered increased ROS production. This increase in ROS was 
associated with decreased UCP2 mRNA expression. Both ASP alone and the combination of MET 
and ASP were able to attenuate intracellular ROS through up regulation of UCP2. Furthermore, 
excessive ROS production can induce intracellular mitochondrial damage including opening of the 
mitochondria permeability transition (MPT), leading to mitochondrial depolarization. This results in the 
expression and leakage of various proteins including endogenous antioxidant enzymes, GSH and 
SOD, as observed in this study. Treatment with ASP enhanced the endogenous antioxidant capacity 
of the cell and potentially could protect the myocardium against HG-induced oxidative stress and 
subsequent mitochondrial depolarization.  
Furthermore, the mitochondrial apoptotic pathway is largely mediated through Bcl-2 family proteins. 
Bcl-2, a human proto-oncogene, protects against mitochondrial permeability and subsequent 
programmed cell death [39, 42]. Bax, a pro-apoptotic member of the Bcl-2 family, initiates apoptosis 
by inserting its C-terminal end into the mitochondrial outer membranes upon induction of cell death. A 
shift in the Bcl-2\Bax ratio can therefore result in increased mitochondrial depolarization and 
cytochrome-c release, a crucial molecule in the induction of apoptosis. In this study, the 33 mM 
glucose (HG) treatment resulted in a significant decrease in the Bcl-2\Bax ratio and a subsequent 
increase in cell apoptosis. ASP, MET or the combination of ASP and MET were able to reverse HG-
induced apoptosis by increasing the Bcl-2\Bax ratio, decreasing mitochondrial membrane 
depolarization, caspase-3/7 activity and reducing tunnel positive cells. However, in terms of efficacy 
no differences were found between the treatments, suggesting that there was no additive effect 
between MET and ASP.  
The mechanism by which ASP modulates cellular antioxidant defenses and function of 
cardiomyocytes remains to be fully elucidated. However, unpublished data from our group suggest 
that ASP is able to activate the redox-sensitive transcription factor, nuclear factor erythroid 2-related 
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factor (Nrf2). Nrf2 is a transcriptional regulator that plays a key role in regulating phase II detoxifying 
and antioxidant enzymes in response to stressful conditions. Niture and Jaiswel (2012) demonstrated 
that Nrf2 regulates Bcl-2 gene expression and prevents apoptosis in human lung cancer cells [42]. 
Based on their findings and evidence obtained from the current study, we proposed that ASP also 
activates Nrf2 during chronic hyperglycemia. Activation of Nrf2 upregulates various antioxidant genes 
including GSH and SOD [43]. Furthermore, this increase in hyperglycemic-induced oxidative stress 
activates AMPK, a kinase like Nrf2 that controls the redox-status of the cell. AICAR, an AMPK 
activator, induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells [44]. 
Thus, we proposed that although both AMPK and Nrf2 maintain cellular homeostasis, they act 
independently of each other. AMPK increases cell survival by regulating FAT/CD36 expression and β-
oxidation while Nrf2 increase cell survival by decreasing oxidative stress and increasing the 
antioxidant capacity. 
In conclusion, our study provides evidence that ASP is able to protect H9c2 cardiomyocytes against 
HG-induced shifts in substrate preference by decreasing FAU and FAO, inferring that ASP might act 
as a FAO modulator in the heart of the diabetic individuals. Furthermore, results obtained from this 
study showed that ASP was as effective as metformin to inhibit glucose-induced increased fatty acid 
β-oxidation and subsequent increased oxidative stress. Additional evidence produced, demonstrated 
that ASP enhances endogenous antioxidant defenses and protects against HG-induced membrane 
depolarization and subsequent apoptotic cell death of vulnerable cardiomyocytes under hyperglycemic 
conditions. Interestingly, the effect of ASP or the combined effect of ASP and MET was more effective 
than MET alone. 
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Supplementary 
mRNA expression analysis 
Total RNA was extracted from H9c2 cells using Trizol reagent. Briefly, H9c2 cells were homogenized 
using a TissueLyser (Qiagen, Hilden, Germany) at 25 Hz for 2 minutes according to the 
manufacturer’s instructions. RNA was purified using an RNeasy Mini kit (Qiagen, Germantown, MD, 
USA) and genomic DNA was removed using the Ambion Turbo DNase kit (Applied Biosystems, 
Austin, Texas, USA) according to the manufacturer’s instructions.  
 
RT2-PCR arrays 
Quantitative reverse transcription real-time PCR (qRT-PCR) was used to quantify the amounts of 
mRNA in the H9c2 cells using a Rat Insulin resistant RT2 Profiler PCR Arrays (PARN -145Z) ( 
Qiagen/SA Biosciences). The arrays included 84 assay genes, 5 housekeeping genes, and reverse 
transcription efficiency and DNA contamination controls. cDNA was synthesized from 2 µg of RNA 
using RT2 PCR Array First Strand Kit (Qiagen/SA Biosciences) and the arrays were performed 
according to the manufacturer instructions using Qiagen/SA Biosciences Master Mix. Each experiment 
was performed on RNA pooled samples from 3 biological replicates and repeated only once for each 
condition. 
 
Results 
Fatty acid oxidation is the source of energy for cardiac myocytes and changes in fatty acid metabolism 
have been implicated in the diabetic-induced cardiac disease state. To give insight into the 
intracellular transportation of fatty acids, we investigated the expression of fatty acid translocase 
(FAT/CD36) using an Insulin resistant RT2-PCR array. The result obtained confirmed an increased in 
CD36 (3.7 fold) mRNA expression after 33mM glucose treatment, however treatment with ASP and 
MET + ASP decreased this effect (1.27 and -1.37 fold, respectively). 
 
Table1. Summary of CD36 gene expression in H9c2 cells treated with ASP 
Symbol Description Name RT2 Catalog HG ASP MET+ASP 
Cd36 CD36 FAT/CD36 PPM03796D 3.75  1.27  -1.37  
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Abstract 
Background and aim: Aspalathin, a C-glucosyl dihydrochalcone, can protect H9c2 cardiomyocytes 
against high glucose (HG)-induced shifts in myocardial substrate preference, oxidative stress and 
apoptosis. While the protective mechanism of aspalathin remains unknown, nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) has emerged as a crucial factor for intracellular responses against oxidative 
stress. Therefore, we hypothesized that aspalathin protects the myocardium against hyperglycemia-
induced oxidative damage by up-regulating Nrf2 expression in H9c2 cardiomyocytes and diabetic 
(db/db) mice. 
Methods: H9c2 cardiomyocytes exposed to HG for 48 hours were treated with aspalathin (1 µM) for 6 
hours. RT2 Profiler PCR array was used to measure differential expression of genes associated with 
oxidative damage. Nrf2 siRNA was employed to further evaluate our hypothesis and to gain novel 
mechanistic insights. We also evaluated our hypothesis in an in vivo context and here db/db mice and 
their non-diabetic (db/+) littermate controls were treated daily for 6 weeks with either a low (13 mg/kg) 
or high (130 mg/kg) aspalathin dose versus metformin (150 mg/kg dosage), a known antidiabetic 
agent. Cardiac fibrosis was assessed by histopathological examination and the degree of oxidative 
stress determined by qRT-PCR. 
Results and discussion: Aspalathin protected H9c2 cardiomyocytes against HG-induced oxidative 
stress. However, Nrf2 silencing abolished this protective response and exacerbated cardiomyocyte 
apoptosis. In parallel, daily aspalathin treatment of db/db mice (130 mg/kg dose for 6 weeks) reversed 
cardiac fibrosis and oxidative stress versus untreated, control hearts. The higher aspalathin dosage 
also resulted in the most effective response when compared to the lower aspalathin dosage and 
metformin. In addition, the higher aspalathin dose elicited enhanced cardiac Nrf2 expression and its 
downstream antioxidant genes such as glutathione peroxidase 2, glutathione synthetase and 
Parkinson protein 7.  
Conclusion: These results indicate that aspalathin maintains cellular homeostasis and protects the 
myocardium against hyperglycemia-induced stress through activation of Nrf2 and its downstream 
target genes. 
 
Keywords 
Diabetes mellitus; cardiomyopathy; hyperglycemia; oxidative stress; antioxidants, aspalathin. 
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Introduction 
The International Diabetes Federation (IDF) recently reported a rapid rise in cases of diabetes mellitus 
(DM) worldwide (IDF, 2015). The current number of individuals living with DM is estimated to be 415 
million and this figure is expected to reach 642 million by the year 2040 (IDF, 2015). Diabetes is a 
major risk factor for the development of cardiovascular complications. Hyperglycemia, a hallmark of 
DM, is associated with rising cardiovascular deaths in the diabetic population (Inzucchi et al., 2015). 
Coronary artery disease (CAD) remains the causal factor linked to the increase of cardiovascular-
related deaths in diabetic persons (Inzucchi et al., 2015). However, diabetic cardiomyopathy (DCM) is 
a frequent but commonly unrecognized pathology that exists in the absence of CAD or hypertension 
(Rubler et al., 1972). DCM is characterized by left ventricular (LV) dysfunction leading to decreased 
cardiac efficiency in diabetic individuals (Fonarow, 2005). Alterations in myocardial substrate 
preference and mitochondrial dysfunction are some of the metabolic perturbations implicated in the 
onset of LV dysfunction (Bayeva et al., 2013). Oxidative stress is another factor linked with cardiac 
structural and functional modifications observed in a diabetic heart (Thandavarayan et al., 2011). The 
mechanisms related to the development of oxidative injury are often multifactorial and may involve a 
cascade of events associated with various cell signaling pathways. 
Humans are equipped with a defense system that controls free radical species and reduces oxidative 
stress. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is an emerging regulator of cellular 
resistance to oxidants. Nrf2 plays a crucial role in controlling basal and induced expression of an array 
of cytoprotective and antioxidant defense genes important for the regulation of physiological and 
pathophysiological outcomes in response to oxidative exposure (He et al., 2009). In cultured 
cardiomyocytes and endothelial cells, suppression of Nrf2 expression results in oxidative stress-
induced insulin resistance (Tan et al., 2011), while heart tissues isolated from Nrf2 knockout mice 
display a marked increase in the production of reactive oxygen species (ROS) compared to wild type 
mice (He et al., 2009). Nrf2 preserves intracellular redox homeostasis by increasing the expression of 
antioxidant and detoxifying genes such as glutathione peroxidase 2 (Gpx2), superoxide dismutase 
(SOD) and NAD(P)H dehydrogenase [quinone] 1 (Nqo1) (Chen et al., 2013). Under conditions of 
oxidative stress, Nrf2 is activated by disassociating from its negative regulator Kelch-like ECH-
associated protein 1 (KEAP1) and translocating to the nucleus, where it binds to the antioxidant 
response element (ARE), activating detoxifying enzymes and genes to inactivate the stressors and 
restore homeostasis (Bai et al., 2013).  
Various phytochemicals from food substances, such as sulforaphane, derived from a major 
glucoslinolate of broccoli and quercetin, an aglycone, derived from flavonol glycosides, common to 
plant foods, can prevent oxidative injury by up-regulating Nrf2 expression (Bai et al., 2013 and 
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Granado-Serrano et al., 2012). Several studies carried out in our laboratory demonstrated the 
beneficial effects of rooibos (Aspalathus linearis), a popular South African herbal tea and some of its 
major polyphenolic compounds in ameliorating metabolic complications associated with DM (Dludla et 
al., 2014, Mazibuko et al., 2015, Muller et al., 2012 and Sanderson et al., 2014,). Aspalathin (ASP), a 
C-glucosyl dihydrochalcone unique to rooibos, can improve glucose and lipid metabolism by 
modulating 5' adenosine monophosphate-activated protein kinase (AMPK) expression in 3T3-L1 
adipocytes (Mazibuko et al., 2015). Similarly, in a recent study we demonstrated that ASP protects 
H9c2 cardiomyocytes against high glucose (HG)-induced oxidative damage by improving myocardial 
substrate metabolism via AMPK regulation (Johnson et al., 2016). While AMPK plays a noticeable role 
in regulating energy metabolism in cardiomyocytes, the control of hyperglycemia-induced oxidative 
stress may be additionally enhanced through other redox-related pathways such as Nrf2 
(Zimmermann et al., 2015). Hence we tested the hypothesis that ASP can prevent hyperglycemia-
induced oxidative injury by up-regulating the transcriptional expression of Nrf2 by using an in vitro 
H9c2 cardiomyocyte model and a leptin receptor-deficient db/db mouse model. 
 
Materials and methods 
Reagents and kits 
H9c2 rat derived cardiomyoblasts (ECACC No. 8809294) were purchased from the European 
Collection of Cell Cultures (Salisbury, Wiltshire, UK), while ASP was synthesized according to Han et 
al., 2014 and obtained from High Force Research (ca. 98%, batch SZI-356-54) (Durham, UK). 
Hematoxylin, eosin, xylene, and formalin were obtained from Merck-Millipore (Billerica, MA, USA), 
halothane was from , Safeline Pharmaceuticals (Johannesburg, RSA), Dulbecco’s Modified Eagle’s 
Medium (DMEM), Dulbecco's phosphate-buffered saline, penicillin and streptomycin from Lonza 
(Verviers, Belgium), and fetal bovine serum and horse serum from Biochrom (Berlin, Germany). High 
Capacity Reverse Transcription Kit, RNAse free water, small interfering RNA (siNrf2) (AM16708), 
scrambled Nrf2 (scrRNA) (AM4615), Trizol reagent, Turbo DNase Kit, Lipofectamine RNAimax 
reagent, and all Taqman gene expression assays were supplied by ThermoFisher Scientific, Inc. 
(Waltham, MA, USA). RT2 SYBR Green qPCR Master Mix, RT2 Array First Strand Kit and RNeasy 
Mini Kit were obtained from Qiagen (Valencia, CA, USA). All other consumables and reagents were 
purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA), unless otherwise specified. 
 
In vitro experiments on H9c2 cardiomyocytes 
Cell culture 
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H9c2 cardiomyoblasts were cultured in supplemented DMEM (10% fetal bovine serum, 100 μg/mL 
penicillin and 100 μg/mL streptomycin) overnight under standard tissue culture conditions (37°C in 
humidified air and 5% CO2). Cells were seeded in a 6-well plate at a seeding density of 2 X 104 
cells/well. Confluent H9c2 cardiomyoblasts were differentiated into adult cardiomyocytes by 
substituting growth media with differentiation media consisting of DMEM supplemented with 10 nM all-
trans-retinoic acid and 1% horse serum for 6 days (Karagiannis et al., 2010). On day seven, 
differentiated cells were exposed to 33 mM glucose for 48 h prior to treatment with ASP (1 µM) for an 
additional 6 h. Cells exposed to either 5.5 mM glucose or 33 mM glucose served as controls for 
normal glucose (NG) and HG, respectively. Cells exposed to 33 mM mannitol were used to rule out 
the effect of osmolarity (Johnson et al., 2016). 
 
Preparation of ASP for cell culture treatment 
A stock solution of ASP (22.1 mM), prepared in dimethyl sulfoxide (DMSO), was diluted using DMEM 
media to give a final solution of 1 µM. The toxic effect of DMSO at a concentration of 0.004% was 
tested and ruled out in all the experiments performed. 
 
RNA isolation and purification 
Total RNA was extracted using Trizol reagent, according to a previously described protocol (Johnson 
et al., 2016). RNA was purified using an RNeasy Mini Kit, while the Turbo DNase Kit was used to 
remove genomic DNA, as per manufacturer’s instructions. RNA integrity was determined using an 
Agilent 2100 Bioanalyser (Agilent Technologies, Inc., Palo Alto, CA, USA), according to 
manufacturer’s instructions.  
 
RT2-PCR array analysis 
cDNA was synthesized from 2 µg RNA using the RT2 First Strand Kit, according to manufacturer’s 
instructions. Rat Oxidative Stress and Atherosclerosis RT2 Profiler PCR Arrays were used (PARN-
065ZA and PARN-065ZA) to analyze the differential expression of multiple genes. Briefly, cDNA was 
added to the RT2 SYBR Green qPCR Master Mix and aliquotted onto each well of the 96-well RT2 
Profiler PCR Array plate. An ABI 7500 Instrument (ThermoFisher Scientific, Inc., Waltham, MA, USA) 
was used for mRNA quantification at the following cycling conditions: 50ºC for 1 min, 1 cycle of 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Analysis of PCR array data 
was done using a Microsoft Excel sheet with macros made available by the manufacturer 
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(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). As controls, each array with 84 
assay genes includes 5 housekeeping genes, as well as a reverse transcription efficiency and DNA 
contamination control. RNA from 3 biological replicates was pooled and repeated only once for each 
condition.  
 
Real-time PCR to confirm oxidative stress and apoptosis markers 
Quantitative RT-PCR was performed on an ABI 7500 Instrument. cDNA was synthesized from 1 µg of 
RNA using the High Capacity Reverse Transcription Kit, as per manufacturer’s instructions. 
Thereafter, the PCR reaction mix was prepared by adding 5 µL Taqman universal PCR master mix, 
0.5 µL Taqman gene expression assay [in vitro study (Casp3, Gpx2, Nox4, Nrf2, Park 7, SOD2 and 
UCP2) and in vivo study (Casp3, Gpx2, Gss, Nox4, Nrf2 and Park 7)], 1 µL of cDNA, and 3.5 µL 
RNAse free water to a final volume of 10 µL. The quantitative RT-PCR protocol was conducted as 
follows: 50°C for 1 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 30 
sec. Gene expression data were normalized to hypoxanthine-guanine phosphoribosyltransferase 
(Hprt). 
 
Knockdown of Nrf2 using small interfering RNA 
Nrf2-siRNA was done using a Lipofectamine RNAimax reagent, according to the manufacturer′s 
instructions. Briefly, H9c2 cells at approximately 70% confluence were transfected with siNrf2 or 
scrRNA for 24 h, respectively. Thereafter, transfected cells were exposed to HG for 24 h before 
treatment with ASP for 6 h. The degree of Nrf2 knockdown after 24 h of transfection was confirmed by 
RT-PCR. Non-transfected cells, exposed to either 5.5 mM glucose or 33 mM glucose served as 
controls for NG and HG, respectively.  
 
In vivo experiments using C57BL/KS mice 
Animals  
Male C57BL/KS leptin receptor-deficient (db/db) mice and nondiabetic heterozygote littermate (db/+) 
controls were obtained and housed at the Primate Unit and Delft Animal Centre (PUDAC) of the South 
African Medical Research Council (SAMRC). Animals were kept in a controlled environment with a 12 
h light/dark cycle and a temperature range of 23-25ºC (relative humidity: ∼50%). The mice received 
standard laboratory chow pellets (Afresh Vention, Cape Town, South Africa) ad libitum and had free 
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access to water. Ethical clearance for the use of animals in this study was granted by the SAMRC 
Ethics Committee for Research on Animals (ECRA no. 07/13), and the Stellenbosch University Ethics 
Committee (SU-ACUM13-00021). 
 
Treatment of mice with ASP 
Nine-week old diabetic (db/db) mice and their non-diabetic (db/+) littermate controls were treated daily 
for 6 weeks through oral gavage with either a low (13 mg/kg) or high (130 mg/kg) ASP dose and 
compared to metformin (MET) at a dose of 150 mg/kg. Dose selection was based on a previous study 
by Kawano et al., 2009. Treatment groups (n=6/group) included; i) db/+ untreated controls (db/+_UC), 
ii) db/db untreated controls (db/db_UC), iii) db/db MET (db/db_MET), iv) db/db ASP low dose 
(db/db_ASP_LD), v) and db/db ASP high dose (db/db_ASP_HD). ASP and MET were prepared fresh 
daily for the duration of the study by dissolving in distilled water, while animals belonging to the 
untreated control groups were given water only. 
 
Heart tissue staining and left ventricular hypertrophic measurements 
After the 6-week treatment period, mice were fasted for 4 h before being weighed and anesthetized 
with halothane. Animals received the anesthetic until no reaction could be recorded by pedal reflex 
before removal of the heart. The heart tissue was weighed and fixed in 10% formalin for a minimum of 
16 h before it was processed using a Leica TP 1020 automated processor (Leica Biosystems, Buffalo 
Grove, IL, USA) and embedded in paraffin wax. Paraffin embedded tissue was cut into sections and 
attached to aminopropyltriethoxysilane coated glass slides. Tissues were then stained with H&E as 
previously described (Page et al., 2004). Stained sections were visualized using a Nikon Eclipse Ti 
inverted microscope (Tokyo, Japan). Micrographs for heart LV and median wall thickness were taken 
in non-overlapping fields of 1 mm2 under 40x magnification and measurements were done using NIS 
Elements imaging software (Tokyo, Japan). 
 
Measurement of fasting plasma glucose (FPG) concentrations 
In mice fasted overnight for 16 h, FPG concentrations were measured by tail prick using a OneTouch® 
Select® handheld glucometer (LifeScan Inc., Milpitas, CA, USA), according to the manufacturer’s 
instructions. 
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Oral glucose tolerance tests (OGTTs) 
After the 6 weeks of treatment, OGTTs were performed. Briefly, after a 16 h fast, a glucose bolus of 2 
g/kg was orally administered through gastric gavage. Plasma glucose levels were determined by tail 
prick at time intervals of 0, 30, 60, and 120 min. 
 
Statistical analysis 
Data were expressed as the mean ± SEM. Results for in vitro experiments were expressed as the 
mean of 3 independent biological experiments with each experiment containing at least 3 technical 
replicates, unless otherwise stated. For in vivo experiments, each treatment group contained 6 mice. 
Statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, 
USA). Comparisons between groups were performed using one-way multivariate ANOVA, followed by 
unpaired Student t-test, and a p-value of ≤ 0.05 was deemed as statistically significant.  
 
Results 
In vitro screening of ASP in H9c2 cardiomyocytes 
ASP maintained cellular homeostasis in vitro 
High glucose exposure decreased endogenous antioxidant capacity of the cells. RT2-PCR analysis 
revealed that ASP post-treatment at a dose of 1 µM was able to enhance mRNA expression of a 
number of antioxidant genes and phase II detoxification enzymes. Results obtained showed that ASP 
increased the expression of catalase (Cat; 11.8 fold), Gpx2 (15.8 fold), peroxiredoxin 1, 3, 4, and 6 
(2.4, 3.0, 2.1, and 2.8 fold, respectively) SOD1 and SOD2 (2.1 and 1.2 fold) (Table 1). The increased 
expression of antioxidant genes correlated with the up-regulation of glutathione-associated and 
reducing genes, including glutamate-cysteine ligase catalytic subunit (Gclc; 6.9 fold), glutamate-
cysteine ligase, modifier subunit (Gclm; 5.8 fold) and glutathione reductase (Gsr; 3.2 fold) (Table 1). 
Increased expression of thiol reducing genes and cytoprotective genes by ASP included sulfiredoxin 1 
(Srxn1; 6.3 fold), thioredoxin 1 (Txn1; 2.0 fold), thioredoxin reductase 1 (Txnrd1; 13.7 fold), thioredoxin 
reductase 2 (Txnrd2; 1.0 fold), heme oxygenase 1 (Hmox1; 3.9 fold), Nqo1 (11.4 fold), and uncoupling 
protein 2 (UCP2; 2.8 fold) (Table 1). Interestingly, the effect of ASP was not only restricted to 
activation of antioxidant-associated genes, but the anti-apoptotic properties of this flavonoid were also 
displayed as it was able to increase the expression of B-cell lymphoma 2 (Bcl2; 2.6 fold) and down-
regulate that of Caspase 8 (Casp8; -1.3) (Table 1). 
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Table 1. Aspalathin treatment (1 µM) increased the expression of antioxidant genes and phase II cytoprotective 
enzymes in H9c2 cardiomyocytes pre-exposed to 33 mM glucose for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASP regulated expression of Nrf2 and its downstream target genes in vitro 
To investigate if ASP activates Nrf2, siRNA was employed. H9c2 cardiomyocytes exposed to siNrf2 
for 24 h resulted in a significantly reduced Nrf2 mRNA expression (0.5 ± 0.05, p ≤ 0.0001) when 
compared to the scrRNA control (2.0 ± 0.2) (Fig. 1A). Furthermore, to define the role ASP plays in the 
activation of Nrf2, HG-exposed H9c2 cells were treated with either siNrf2 or scrRNA. HG exposure 
decreased the expression of Nrf2 when compared to the NG control (0.4 ± 0.12 compared to 1.0 ± 
0.13, p ≤ 0.001) (Fig. 1B). ASP treatment ameliorated this effect compared to the HG control (0.8 ± 
GENE Fold regulation 
after high 
glucose 
exposure 
Fold regulation 
after post-
treatment with 
aspalathin 
Antioxidant genes 
Catalase (Cat) -1.63 11.80 
Glutathione peroxidase 2 (Gpx2) -1.20 15.86 
Peroxiredoxin 1 (Prdx1) -1.33 2.49 
Peroxiredoxin 3 (Prdx3) -1.21 3.09 
Peroxiredoxin 4 (Prdx4) -1.72 2.14 
Peroxiredoxin 6 (Prdx6) -2.65 2.89 
Superoxide dismutase 1 (SOD1) -1.25 2.18 
Superoxide dismutase 2 (SOD2) -1.17 1.22 
Glutathione synthesis genes 
Glutamate-cysteine ligase catalytic subunit 
(Gclc) 
-1.84 6.96 
Glutamate-cysteine ligase, modifier subunit 
(Gclm) 
-1.40 5.89 
Glutathione reductase (Gsr) -1.50 3.29 
Reducing agent genes 
Sulfiredoxin 1 (Srxn1) -3.43 6.34 
Thioredoxin 1 (Txn1) -1.08 2.05 
Thioredoxin Reductase 1 (Txnrd1) -2.88 13.70 
Thioredoxin Reductase 2 (Txnrd2) -3.25 1.08 
Cytoprotective genes 
Heme oxygenase 1 (Hmox1) -2.77 3.98 
NAD(P)H dehydrogenase (quinone 1) 
(Nqo1) 
-4.57 11.45 
Uncoupling protein 2 (UCP2) -3.95 2.83 
Uncoupling protein 3 (UCP3) -2.01 -1.61 
Apoptotic genes 
B-cell lymphoma 2 (Bcl2) -1.8 2.6 
Caspase 8 (Casp8) 3.9 -1.3 
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0.04 compared to 0.4 ± 0.12, p = 0.01) (Fig. 1B). As anticipated, cells treated with siNfr2 + ASP failed 
to increase Nrf2 mRNA expression when compared to the scrRNA control (Fig. 1B). 
 
               A 
 
 
 
 
 
 
 
               B 
 
 
 
 
 
 
 
 
 
Figure 1. Aspalathin (ASP) increased the expression of Nrf2 in H9c2 cardiomyocytes. (A) The degree of Nrf2 
knockdown in H9c2 cardiomyocytes after transfection with either small interfering RNA (siNrf2) or scrambled 
RNA (scrRNA) for 24 h. (B) H9c2 cardiomyocytes transfected with siNrf2 or scrRNA for 24 h were exposed to 33 
mM glucose (HG) for 24 h, followed by treatment with 1 µM ASP for 6 h. Results are expressed as the mean ± 
SEM of 3 independent biological experiments relative to the normal glucose (NG) control, each done in triplicate. 
**p ≤ 0.001, ***p ≤ 0.0001 vs. NG, #p ≤ 0.05 vs. HG, †††p ≤ 0.0001 vs. scrRNA + ASP. 
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Figure 2. siNrf2 inhibited the effect of aspalathin (ASP) in vitro. The relative mRNA expression of antioxidant 
genes, including (A) Gpx2, (B) Park7, (C) SOD2, and (D) UCP2, and oxidative damage associated genes (E) 
Casp3 and (F) Nox4 after transfection of cells with either small interfering RNA (siNrf2) or scrambled RNA 
(scrRNA) for 24 h followed by treatment with 1 µM ASP for 6 h. Results are expressed as the mean ± SEM of 3 
independent biological experiments relative to the normal glucose (NG) control, each done in triplicate. *p ≤ 0.05, 
**p ≤ 0.001, ***p ≤ 0.0001 vs. NG, #p ≤ 0.05, ##p ≤ 0.001 vs. HG, †p ≤ 0.05, †††p ≤ 0.0001 vs. scrRNA + ASP. 
 
The effects of siNrf2 on ASP treatment on mRNA expression of antioxidant and oxidative genes. 
These results show that HG exposure significantly reduced the mRNA expression of oxidative stress 
protective genes, Gpx2 (0.4 ± 0.04, p = 0.01), Park7 (0.3 ± 0.04, p ≤ 0.001), SOD2 (0.1 ± 0.03, p ≤ 
0.001), and UCP2 (0.3 ± 0.33, p ≤ 0.001) when compared to the NG controls (1.0 ± 0.38, 1.0 ± 0.28, 
1.0 ± 0.49, and 1.0 ± 0.30, respectively) (Fig. 2A-D). Treatment with ASP at 1 µM for 6 h was able to 
prevent this by up-regulating the expression of Gpx2 (1.0 ± 0.32, p ≤ 0.02), Park7 (0.85 ± 0.17, p ≤ 
0.001), SOD2 (0.6 ± 0.13, p ≤ 0.001), and UCP2 (0.9 ± 0.15, p ≤ 0.001) when compared to the HG 
controls (Fig. 2A-D). Interestingly, the effect on cells exposed to siNrf2 + ASP was down-regulated 
when compared to scrRNA + ASP and similar to when compared to HG (Fig. 2A-D). 
Moreover, the mRNA expression of genes associated with oxidative damage (Casp3 and Nox4) was 
up-regulated in HG exposed cells (1.6 ± 0.43, p = 0.04; and 1.8 ± 0.4, p = 0.03) when compared to the 
NG controls (1.0 ± 0.61, and 1.0 ± 0.20, respectively) (Fig. 2E and F). ASP treatment was able to 
abolish this effect for both Casp3 and Nox4 (0.9 ± 0.42, p = 0.04; and 0.6 ± 0.06, p = 0.01, 
respectively) when compared to the HG controls (Fig. 2E and F). However, treatment with siNrf2 + 
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ASP failed to reduce expression of both these genes when compared to cells subjected to scrRNA + 
ASP (Fig. 2E and F). The effect was similar to the HG control. 
 
In vivo confirmation studies on db/db mice 
Effect of ASP on FPG and OGTT  
Db/db mice and their db/+ controls were treated daily with either a low (13 mg/kg) or a high (130 
mg/kg) dose of ASP, as well as MET at 150 mg/kg for 6 weeks. The db/db_UC group displayed 
elevated FPG levels from week 9 to week 14 (21.0 ± 1.73, 15.5 ± 1.29, 23.7 ± 1.15, 24.7 ± 2.91, 19.7 
± 1.46, and 22.3 ± 2.85, respectively) when compared to the untreated db/+_UC control group (6.1 ± 
0.30, 5.9 ± 0.50, 6.2 ± 0.38, 5.3 ± 0.44, 6.0 ± 0.20, and 4.3 ± 0.49, respectively) (Fig. 3A). Although 
both the low and high dose ASP treatments did not reduce the increased FPG levels in db/db mice, 
MET was able to reduce the raised FPG levels from week 12 to week 14 (17.3 ± 1.92, 17.0 ± 1.67, 
and 17.4 ± 2.56, respectively), though not significantly (Fig. 3A). 
 
Assessment of OGTTs after administration of a 2 g/kg glucose bolus in mice 
Results obtained showed a marked increase in FPG levels 30 min after glucose administration, and 
this was significantly different when the db/db_UC (33.8 ± 0.40, p ≤ 0.0001) was compared to the 
db/+_UC control (9.6 ± 0.50) (Fig. 3B). High dose ASP treatment at 60 and 120 min (30.8 ± 1.53 and 
28.6 ± 1.63) was comparable to MET (30.2 ± 1.61 and 28.8 ± 2.22) in reducing the increased FPG 
concentrations when compared to the untreated diabetic controls, though not significantly (Fig. 3B). 
Treatment with a low dose of ASP was, however, ineffective. 
 
ASP prevented diabetes-induced LV mass enlargement in vivo 
Heart hypertrophy associated measurements, including heart weight (HW)/body weight (BW) ratio, LV 
wall and interventricular septum thickness, and occurrence of cardiac muscle remodeling were 
assessed after mice were treated with ASP for 6 weeks. Results showed that the db/db_UC group 
presented with increased HW/BW ratio (0.0061 ± 0.00005, p ≤ 0.0001), LV wall and interventricular 
septum thickness measurements ((1588 ± 42, p ≤ 0.0001 and 1556 ± 70, p ≤ 0.001, respectively) 
occurring concurrent to enhanced cardiac remodeling in comparison to the db/+_UC control group 
(HW/BW ratio: 0.0048 ± 0.0001, LV wall: 1151 ± 9; and interventricular septum: 1120 ± 29) (Fig. 4A-
C). Interestingly, treatment with a high dose ASP was able to ameliorate these dysregulations 
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associated with cardiac hypertrophy, including prevention of changes in HW/BW ratio (0.0043 ± 
0.0003, p ≤ 0.001), LV wall (1278 ± 96, p = 0.01) and interventricular septum thickness (1160 ± 42, p ≤ 
0.001) (Fig. 4A-C). Neither MET or a low dose ASP had any effect on the altered cardiac muscle fibers 
or ventricular wall thickness. 
               A 
 
 
 
 
 
 
 
 
 
               B 
 
 
 
 
 
 
 
 
 
 
Figure 3. Aspalathin (ASP) treatment did not reduce increasing fasting plasma glucose (FPG) levels, however a 
high dose of 130 mg/kg of ASP was able to improve oral glucose tolerance in diabetic mice after 60 and 120 
minutes from baseline. (A) FPG levels (B) Oral glucose tolerance tests (-60: baseline reading). Results are 
expressed as the mean ± SEM and each treatment group contained 6 mice. ***p ≤ 0.0001 diabetic control mice 
(db/db_UC) vs. untreated nondiabetic mice (db/+_UC). db/db_MET: diabetic mice treated with metformin (150 
mg/kg); db/db_ASP_LD: diabetic mice treated with aspalathin low dose (13 mg/kg); db/db_ASP_HD: diabetic 
mice treated with aspalathin high dose (130 mg/kg). 
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Figure 4. Aspalathin (ASP) prevented diabetes-induced cardiac muscle structure modifications associated with 
hypertrophy in diabetic mice. (A) Heart weight (HW) to body weight (BW) ratio, (B) left ventricular (LV) wall 
thickness, (C) interventricular septum thickness, and (D) photomicrographs of cardiac remodeling. Results are 
expressed as the mean ± SEM and each treatment group contained 6 mice. **p ≤ 0.001, ***p ≤ 0.0001 versus 
untreated nondiabetic mice (db/+_UC), #p ≤ 0.05, ##p < 0.001 versus untreated diabetic mice (db/db_UC). 
db/db_MET: diabetic mice treated with metformin (150 mg/kg); db/db_ASP_LD: diabetic mice treated with 
aspalathin low dose (13 mg/kg); db/db_ASP_HD: diabetic mice treated with aspalathin high dose (130 mg/kg). 
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ASP regulated the expression of Nrf2 and its target genes in vivo 
In support of the in vitro data on H9c2 cardiomyocytes, we assessed the expression of Nrf2 and its 
associated downstream cytoprotective genes in vivo, and results showed a significant enhancement of 
Nrf2 mRNA expression in the db/db_UC group (2.54 ± 0.63, p ≤ 0.001) in comparison to the db/+_UC 
control group (0.99 ± 1.49) (Fig. 5A). Although MET and low dose ASP treatments were not effective, 
the high dose ASP (4.1 ± 0.93, p = 0.01) significantly increased mRNA expression of Nrf2 when 
compared to both db/db_UC and db/+_UC groups (Fig. 5A).  
Further analyzing mRNA expression of genes activated by Nrf2, it was noted that the expression of 
Gpx2 (0.69 ± 0.11, p = 0.04) and Gss (0.66 ± 0.05, p = 0.03) was reduced in the db/db_UC group 
when compared to the db/+_UC group (1.0 ± 0.15, 1.0 ± 0.11, respectively) (Fig. 5B and C). The 
expression of Park7 was not significantly affected (0.94 ± 0.06). Treatment with MET and the low dose 
ASP did not have any effect, while the high dose ASP significantly up-regulated expression of Gpx2 
(1.56 ± 0.66, p = 0.04), Gss (1.0 ± 0.15, p = 0.03), and Park7 (1.35 ± 0.06, p ≤ 0.001) when compared 
to db/db_UC group (Fig. 5B-D). 
Expression of oxidative damage-associated genes (Casp3 and Nox4) was significantly enhanced in 
the db/db_UC group (1.53 ± 0.24, p = 0.02; and 1.8 ± 0.37, p = 0.01) when compared to the db/+_UC 
group (1.0 ± 0.06; and 1.0 ± 0.07, respectively) (Fig. 5E and F). No effect was observed for MET or 
low dose ASP treatments, while the high dose ASP treatment was able to down-regulate the 
expression of both Casp3 (0.97 ± 0.03, p = 0.01) and Nox4 (0.96 ± 0.10, p = 0.01) when compared to 
db/db_UC group (Fig. 5E and F). 
 
     A                                                                                  B 
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     C                                                                                  D 
 
 
 
 
 
 
 
 
 
     E                                                                                  F 
                             
 
 
 
 
 
 
 
 
 
Figure 5. Aspalathin (ASP) prevented oxidative damage by increasing the expression of Nrf2 and its down-
stream target genes in diabetic mice. The relative mRNA expression of (A) Nrf2 and associated antioxidant 
genes, including (B) Gpx2, (C) Gss, and (D) Park7, and oxidative damage associated genes (E) Casp3 and (F) 
Nox4 after the 6 week treatment period with metformin, and a low or high dose ASP. Results are expressed as 
the mean ± SEM and each treatment group contained 6 mice. *p ≤ 0.05, **p ≤ 0.001 versus untreated 
nondiabetic mice (db/+_UC), #p ≤ 0.05, ##p ≤ 0.001 versus untreated diabetic mice (db/db_UC). 
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Discussion 
Evidence of the antidiabetic properties of ASP, through the use of cell culture and animal models, has 
been increasingly reported (Kawano et al., 2009, Muller et al., 2012 and Son et al., 2013). In addition 
to its robust antioxidant properties (Snijman et al., 2009 and von Gadow et al., 1997), this C-glucosyl 
dihydrochalcone protects the myocardium against HG-induced oxidative stress and subsequent 
metabolic dysregulations (Johnson et al., 2016). Metabolic dysregulations associated with oxidative 
stress are complex, but two cellular signaling processes, namely AMPK and Nrf2 play crucial roles 
and are essential in maintaining cellular homeostasis (Bai et al., 2013 and Johnson et al., 2016). 
Previously, we showed that ASP was able to prevent shifts in substrate preference by decreasing 
AMPK phosphorylation resulting in reduced oxidative damage (Johnson et al., 2013). In addition, 
various studies have shown that activation of Nrf2 decreases oxidative stress by increasing 
intracellular antioxidant defences (Chen et al., 2013 and He et al., 2009). Hence, this study aimed to 
investigate if ASP can improve the bioenergetics of the cell through enhancing Nrf2 expression. 
During accelerated free radical damage that occurs mainly through ROS the cell adapts by 
dissociating Nrf2 from KEAP1. This dissociation results in the translocation of Nrf2 into the nucleus 
and binding to the ARE that activate the endogenous antioxidant defense system (Dinkova-Kostova et 
al., 2015). Accumulative evidence has shown that certain dietary phytochemicals are able to activate 
Nrf2 and thereby increase its cytoprotective response (Chen et al., 2013, Cheng et al., 2015 and 
Granado-Serrano et al., 2012). Presence of a catechol group may be a pivotal structural feature of 
flavonoids that contributes to Nrf2 activation as demonstrated for shogaol derivatives (Zhu et al., 
2016). Furthermore, a dihydrochalcone glycoside, neohesperidin dihydrochalcone, has recently been 
shown to prevent carbon tetrachloride-induced hepatic injury by increasing the expression of Hmox1 
and Nqo1 through activation of Nrf2 in HepG2 cells (Su et al., 2015). In agreement to others (Bai et 
al., 2013, Chen et al., 2013 and Su et al., 2015), our study showed that activation of Nrf2 promoted 
cell survival by increasing the expression of an array of antioxidant genes and enzymes. We showed 
that a 6 h treatment with 1 µM ASP protected cardiomyocytes exposed to HG against oxidative 
damage by up-regulating the expression of antioxidant genes and cytoprotective enzymes such as 
Nqo1 and Hmox1. In addition, by using RNA interference we showed that activation of Nrf2 by ASP is 
crucial for the antioxidant response against hyperglycemia-induced oxidative injury in H9c2 
cardiomyocytes. While it was expected that Nrf2-knockdown may exacerbate susceptibility of such 
cells to oxidative damage, ASP treatment showed an even higher capacity to enhance Nrf2 
expression and its downstream target genes and thus protect against HG-induced stress. 
Following in vitro experiments on H9c2 cardiomyocytes, it was important to confirm such findings in an 
in vivo system. For this we made use of db/db mice, which represent a type 2 diabetic mouse model. 
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These mice display a whole-body phenotype of DM and are frequently used in the pharmacological 
study of compounds including ASP (Kawano et al., 2009 and Zheng et al., 2015). Moreover, they have 
been reported to spontaneously become obese and develop hyperglycemia from the age of eight 
weeks (Ritchie et al., 2008). At the age of ten to eighteen weeks these mice display signs of cardiac 
interstitial fibrosis and hypertrophy as a result of increased LV wall thickness, occurring simultaneous 
to enhanced generation of ROS (Belke et al., 2000 and Ritchie et al., 2008). Accelerated ROS 
production induces deleterious modifications to DNA, proteins and lipids concomitant to the 
pathophysiological state observed within the diabetic heart (Mapanga and Essop, 2016). To support 
this, we showed that, in addition to impaired OGTT, db/db mice presented elevated FPG levels, an 
increased HW/BW ratio that occurred concomitant to a thickened left ventricle and interstitial fibrosis 
when compared to the db/+ control group. An enlarged heart LV wall is a conspicuous sign of DCM 
and is identified as an early defect associated with chronic hyperglycemia in diabetic patients 
(Fonarow, 2005 and Rubler et al., 1972). The latter state has been associated with elevated oxidative 
stress and various studies have reported on the effect of oxidative stress on vascular remodeling and 
how antioxidant therapy prevents progressive remodeling and improves cardiac function (Bai et al., 
2013, Dludla et al., 2014 and Johnson et al., 2016). Correspondingly, in this study we observed that 
morphological derangements within db/db mouse hearts occurred concurrently to accelerated 
oxidative stress and a modest increase in Nrf2 expression. It has been previously reported that the 
expression of Nrf2 is initially elevated in response to stress, and then diminishes at a later stage 
leading to adverse complications such as apoptosis (Bai et al., 2013 and Dinkova-Kostova et al., 
2015).  
Despite inability protective effects displayed by ASP treatment on reducing elevated FPG 
concentrations, this polyphenol at a dose of 130 mg/kg was able to ameliorate oxidative damage via 
Nrf2 activation, resulting in attenuated cardiac hypertrophy and remodeling. However, an unexpected 
finding was the inability of ASP to attenuate increased FPG concentrations, since it has been 
previously reported to have blood glucose lowering effects (Kawano et al., 2009 and Muller et al., 
2012). A similar finding was observed where treatment of streptozotocin (STZ)-induced diabetic mice 
with sulforaphane failed to reduce FPG, but was able to protect the heart against oxidative stress 
associated with heart tissue remodeling (Bai et al., 2013). The inability of ASP to reduce blood glucose 
can also be due to other factors, such as the duration of treatment, as our group has previously 
demonstrated that ASP reduces blood glucose concentrations in STZ-induced diabetic rats over a 
period of 6 h (Muller et al., 2012). In contrast, while current antidiabetic agents including MET 
effectively reduce FPG concentrations, there is still an increasing number of cardiovascular-related 
deaths in diabetic patients (Inzucchi et al., 2015). Correspondingly, this study showed that even 
though MET-treated mice presented with moderately reduced FPG levels, it was unable to prevent 
Stellenbosch University  https://scholar.sun.ac.za
 116 
oxidative stress associated myocardial structural modifications. Therefore, the use of potential 
nutraceutical agents such as ASP, especially in combination with current antidiabetic agents to 
alleviate oxidative injury and protect diabetic individuals at risk of myocardial infarction are of foremost 
importance. 
In summary, consistent with previous findings, ASP displays strong properties to improve myocardial 
ultrastructure by preventing HG-associated complications. However, dose selection remains important 
to induce desired efficacy, since the low dose of 13 mg/kg did not show any effect in protecting the 
heart when compared to the high dose of 130 mg/kg in our study. In addition to its modulatory effects 
of AMPK, the ability of ASP to regulate Nrf2 may be a key factor to protect against DCM. However, 
further studies to assess the impact of ASP on cardiac functional parameters in diabetic rodents are 
required to confirm this exciting proposal.  
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Abstract 
In the pathological condition of type 2 diabetes mellitus, myocardial fatty acid uptake exceeds the rate 
of β-oxidation leading to lipid toxicity. Increased lipid storage within the diabetic heart correlates with 
the development of diabetic cardiomyopathy (DCM). Aspalathin, a C-glucosyl dihydrochalcone, can 
protect cardiomyocytes against hyperglycemia-induced shifts in substrate preference and subsequent 
apoptosis. However, the precise gene regulatory network associated with the protective effect of 
aspalathin remains to be fully elucidated. Db/db mice and their non-diabetic (db/+) littermate controls 
were treated daily for 6 weeks with either a low (13 mg/kg) or high (130 mg/kg) aspalathin dose. 
Results obtained showed that aspalathin significantly lowered plasma lipid levels. To provide insight 
into the molecular mechanisms associated with the improved plasma lipid profile, an in vitro H9c2 
cardiomyocytes model was employed. H9c2 cardiomyocytes were exposed to high glucose for 48 
hours before treatment with or without aspalathin (1 µM) for 6 hours. Thereafter, RNA was extracted 
and RT2 PCR Profiler Arrays were used to profile the expression of 336 genes involved in cardiac 
metabolism. Results obtained showed that among the 336 genes assessed, 57 were differentially 
regulated by more than 2-fold in the high glucose or high glucose + aspalathin treated groups. 
STRING analysis revealed lipid metabolism and molecular transport to be the top two biological 
processes that were altered after high glucose treatment, followed by inflammation and apoptosis. 
Interestingly, aspalathin was able to modulate key regulators associated with lipid metabolism (Acads, 
Adipoq, Apob/e, Cd36, Cpt1, Pparγ, Srebf1/2, Scd1 and Vldlr), insulin resistance (Igf1, Akt1, Pde3 and 
Map2k1), inflammation (Il3, Il6, Jak2, Lepr, Socs3, and Tnf13) and apoptosis (Bcl2, Bbc3 and Chuk). 
Collectively, our results indicate that aspalathin was able to reverse lipid toxicity that can lead to 
subsequent inflammation and myocardial death. 
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Introduction 
In the last decade, there has been much interest in the use of plant-derived polyphenols as 
nutraceuticals to protect against the development of metabolic diseases [1, 2]. Aspalathus linearis 
(commonly known as rooibos) is a rich source of plant polyphenols with known health promoting 
properties. In addition to reversing ischemia/reperfusion injury in the isolated perfused rat heart [3], 
rooibos has been shown to improve lipid profiles as well as oxidative stress in diabetics at risk of 
developing cardiovascular disease [4, 5]. Furthermore, literature has indicated that polyphenols 
specific to rooibos may present strong ameliorative properties against diabetes mellitus and its 
associated complications [6-8]. Of note, aspalathin, a C-glucosyl dihydrochalcone found in rooibos has 
displayed an even greater potency to prevent diabetes-induced cardiovascular complications [9-11]. 
For example, a fermented rooibos extract containing abundant levels of aspalathin protected 
cardiomyocytes isolated from diabetic rats against experimentally-induced oxidative stress and 
ischemia [9]. Moreover, recent data from our laboratory demonstrated that aspalathin protects cultured 
cardiomyocytes exposed to chronic hyperglycemia from shifts in substrate preference and subsequent 
cell apoptosis [10].  
Enhanced intracellular lipid accumulation that results in impaired cardiac substrate metabolism is 
consistently reported in diabetic hearts [10, 12]. For example, obese mice display elevated 
intramyocardial lipid accumulation concomitant to suppressed glucose oxidation that was linked to 
contractile dysfunction [12, 13]. Increased lipid storage in the hearts of diabetic patients correlates with 
the development of diabetic cardiomyopathy (DCM) [14]. DCM is a disease of the myocardium that is 
characterized by a measurable deterioration in the heart function. In animal models of DCM, a 
significant increase in FFA transporter expression alters intracellular signalling pathways and 
promotes apoptotic cell death [15, 16]. Therefore, targeting myocardial metabolism as a therapeutic 
intervention to protect a diabetic heart is a powerful therapeutic strategy. This study made use of RT2 
PCR Profiler Arrays to unravel the transcriptional mechanisms that underlie the cardioprotective effect 
of aspalathin against the development of high glucose-induced cardiomyopathy. 
 
Materials and methods 
Reagents and kits 
Pure aspalathin (ca. 98%, batch SZI-356-54) was synthesized according to a previously published 
protocol [17] and was obtained from High Force Research (Durham, UK) while H9c2 rat derived 
cardiomyoblasts were purchased from the European Collection of Cell Cultures (ECACC No. 
8809294; Wiltshire, UK). Radioimmunoassay Kit was from Linco Research (St. Charles, USA), 
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halothane from Safeline Pharmaceuticals (Johannesburg, RSA), Dulbecco’s Modified Eagle’s Medium, 
penicillin, and streptomycin were obtained from Lonza (Verviers, Belgium), and fetal bovine serum 
was from Biochrom (Berlin, Germany). RNeasy Mini Kit, RT2 First Strand Kit, RT2 Profiler PCR Arrays 
and RT2 SYBR Green qPCR Master Mix were from Qiagen (Valencia, USA), while Trizol reagent and 
Turbo DNase Kit were from ThermoFisher Scientific (Waltham, USA). All other consumables and 
reagents were purchased from Sigma-Aldrich Corp. (St. Louis, USA), unless otherwise specified. 
 
Animal work 
Male C57BL/KS leptin receptor deficient (db/db) mice were obtained from and housed at the Primate 
Unit and Delft Animal Centre (PUDAC) of the South African Medical Research Council (SAMRC) in a 
controlled environment with a 12 h light/dark cycle in a temperature range of 23-25ºC (relative 
humidity: ∼50%). The mice received standard laboratory chow pellets (Afresh Vention) ad libitum and 
had free access to drinking water. The study was performed in agreement with the principles and 
guidelines of the SAMRC (ECRA no. 07/13) as well as Stellenbosch University Ethics Committee (SU-
ACUM13-00021).  
 
Animal treatment with aspalathin 
After acclimatizing for one week, nine-week old db/db mice together with their nondiabetic lean 
littermates (db/+) (n=6 per group), caged in individual cages, were randomly divided in five groups. 
Mice were treated daily for six weeks through oral gavage with either a low (13 mg/kg) or high (130 
mg/kg) aspalathin dose and compared to metformin (150 mg/kg). Treatment groups included: i) 
untreated nondiabetic controls (db/+_UC), ii) untreated diabetic controls (db/db_UC), iii) diabetic 
treated with metformin (db/db_MET), iv) diabetic treated with low dose aspalathin (db/db_ASP_LD) 
and v) diabetic treated with high dose aspalathin (db/db_ASP_HD). Aspalathin and metformin were 
dissolved in water before orally administered at the same time every day for six weeks, while 
untreated animals were given water in place of treatment. 
 
Homeostasis model assessment: insulin resistance (HOMA-IR) determination 
Mice were fasted overnight before plasma glucose levels were measured. This was done on a weekly 
basis by tail pricks using OneTouch Select handheld glucometer (LifeScan, Milpitas, USA). Fasting 
plasma insulin was detected using Radioimmunoassay Kit, as per manufacturer's instruction. HOMA-
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IR was calculated using fasting plasma glucose levels and insulin values, according to an already 
described method [18]. 
 
Organ weight measurements and lipid profiles 
After the 6-week treatment period, mice were fasted for 4 h and body weight (BW) measurements 
documented before being anesthetized with halothane. Animals received the anesthetic until no 
reaction could be recorded by pedal reflex before an average of 1 mL of blood was collected from the 
abdominal vena cava and organs were removed from each mouse. Heart, liver muscle, and fats 
(gonadal and intraperitoneal) were removed and weighed to determine heart weight (HW), liver weight 
(LW) and fat weight (FW), respectively, using an Adventurer analytical balance (OHAUS Corp., 
Parsippany, USA). For lipid profiles, blood was collected and centrifuged at 4000 g at 4ºC for 15 min 
before serum was removed and stored at -80ºC. Serum was sent to PathCare Medical Diagnostic 
Laboratories to screen for total cholesterol, triglycerides, low density lipoprotein (LDL), and high-
density lipoprotein (HDL). 
 
Cell culture and treatment 
Embryonic ventricular rat heart-derived H9c2 cardiomyoblasts were cultured in supplemented 
Dulbecco’s Modified Eagle’s Medium (10% foetal bovine serum, 100 U/ml of penicillin, 100 mg/ml of 
streptomycin) for 48 h under standard tissue culture conditions (37°C in humidified air and 5% CO2). 
Confluent cells (60-80%) were seeded at a density of 2 x 104 in 6-well multi-plates. Thereafter, H9c2 
cardiomyoblasts were differentiated into adult cardiomyocytes for 7 days using retinoic acid according 
to previously described method [19]. On day 8, H9c2 cells were exposed to 33 mM glucose for 48 h 
prior to treatment with aspalathin (1 µM) for an additional 6 h. Cells exposed to 5.5 mM glucose were 
used as a normal glucose control [10].  
 
RT2-PCR array analysis 
Total RNA was extracted using Trizol reagent, according to a previously described protocol [10]. RNA 
was purified using an RNeasy Mini Kit, while the Turbo DNase Kit was used to remove genomic DNA, 
as per manufacturer’s instructions. RNA integrity was determined using an Agilent 2100 Bioanalyser 
(Agilent Technologies, Palo Alto, USA) and cDNA was synthesized from two microgram RNA using 
the RT2 First Strand Kit, according to relevant manufacturer’s instructions. Rat Atherosclerosis (PARN-
038ZA-2), Cytokine (PARN-011ZA-2), Fatty Acid Metabolism (PARN-007Z), and Insulin Resistance 
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(PARN-156ZA-2) RT2 Profiler PCR Arrays were used for mRNA profiling studies using ABI7500 
(ThermoFisher Scientific, Waltham, USA). Analysis of PCR array data was done according to 
manufacturer’s instructions, using a Microsoft Excel sheet with macros 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Each array contained five house 
keeping genes (Actb, B2m, Gapdh, Gusb and Hsp90ab1) against which the sample data was 
normalized. Using the online software, the transcript level of each candidate gene was quantified by 
using the ΔΔCT method. Ant Ct value > 35 was not included in the analysis and considered as 
negative. To determine the gene interaction and network analysis, Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING; http://string-db.org/) database was used to represent information 
of known and anticipated gene interactions [20, 21]. 
 
Statistical analysis 
Data were expressed as the mean ± SEM of three independent biological experiments with each 
experiment containing at least three technical replicas, unless stated otherwise. For in vivo 
experiments, each treatment group contained six mice. Statistical analysis was calculated using 
GraphPad Prism software (La Jolla, USA). Comparisons between groups were performed using one-
way multivariate ANOVA followed by using unpaired Student t-test. P-value of ≤ 0.05 was deemed as 
statistically significant. 
 
Results and discussion 
In vivo effect of aspalathin 
Hyperglycemia, lipidemia and insulin resistance are the key risk factors associated with the 
development of cardiovascular complications. Chronic hyperglycemia results in shifts in substrate 
preference that precede the onset of heart failure. Aspalathin, a C-linked dihydrochalcone glucoside, 
plays an important role in maintaining cellular homeostasis by preventing shifts in substrate preference 
through reducing excess uptake of free fatty acids that may result in lipid toxicity in H9c2 
cardiomyocytes [10].  
 
Effect of aspalathin on biometrical measurements: Results from this study demonstrated that 
leptin receptor deficient db/db_UC mice displayed significantly increased water and food intake when 
compare to the db/+_UC littermate control group (Table 1). Concomitantly, an increase in BW, FW, 
HW and LW was observed. The results obtained were expected as leptin deficient db/db mice have 
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high circulating leptin levels which are actively associated with increased BW, FW, food intake, 
HOMA-IR and decreased adiponectin levels in type 2 diabetic individuals [22-24]. Interestingly, chronic 
treatment (daily for 6 weeks) with a high dose of aspalathin reduced all biometrical measurements 
except for food intake when compared to the db/db_UC mice. Of interest, aspalathin treatment at a 
high dose was more effective than either metformin or a low dose of aspalathin treatment (Table 1).  
 
Table 1. The effect of aspalathin on body weight, fat weight, heart weight, liver weights, food intake and 
water intake. 
Weight 
(g) 
db/+_UC db/db_UC db/db_MET db/db_ASP_LD db/db_ASP_HD 
BW 
 
27.1 ± 0.33 37.9 ± 0.82*** 38.0 ± 0.61*** 37.7 ± 0.74*** 35.0 ± 0.99***
#
 
FW 
 
0.93 ± 0.08 2.6 ± 0.12*** 2.9 ± 0.17*** 2.9 ± 0.19*** 1.9 ± 0.15***
##
 
HW 
 
0.1 ± 0.01 0.2 ± 0.02** 0.2 ± 0.02 0.2 ± 0.03 0.1 ± 0.01
#
 
LW 
 
1.2 ± 0.08 2.5 ± 0.14*** 2.5 ± 0.09*** 2.2 ± 0.09***
#
 1.9 ± 0.15**
#
 
FI 
 
24.9 ± 0.67 45.68 ± 1.87*** 41.12 ± 2.20*** 44.63 ± 1.50*** 40.95 ± 1.59*** 
WI 
 
57.3 ± 4.73 213.9 ± 6.49*** 172.1 ± 7.41***
##
 188.6 ± 3.98***
#
 181.8 ± 9.86***
#
 
 
Results are the mean ± SEM, with each treatment group containing six mice. *p < 0.05, **p < 0.001, ***p < 
0.0001 versus untreated nondiabetic mice (db/+_UC); #p < 0.05, ##p < 0.001 versus untreated diabetic mice 
(db/db_UC). BW: body weight, db/db_ASP_LD: diabetic mice treated with low dose aspalathin (13 mg/kg), 
db/db_ASP_HD: diabetic mice treated with high dose aspalathin (130 mg/kg), db/db_MET: diabetic mice 
treated with metformin (150 mg/kg), FI: food intake, FW: fat weight, HW: heart weight, LW: liver weight, WI: 
water intake. 
 
Effect of aspalathin on lipid profiles: Increased morbidity observed in type 2 diabetes individuals is 
primarily associated with heart failure with lipid toxicity being the key pathological mechanism 
underlying the condition [5, 12, 14]. To investigate if aspalathin can improve lipoprotein clearance, a 
total lipid profile was performed on mice treated with and without aspalathin (Table 2). Interestingly, 
we observed that the db/db_UC mice had increased HDL levels with associated elevated triglycerides, 
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total cholesterol, LDL and no change in HOMA-IR when compared to the db/+_UC group (Table 2). 
Aspalathin treatment at a high dose was able to ablate this response and the effect was better than 
either the low dose aspalathin or the metformin treated groups. However, similar to metformin, 
aspalathin treatment was unable to change HDL cholesterol (Table 2). An unexpected finding was the 
increased HDL levels on untreated db/db mice, while metformin or aspalathin failed to have any effect. 
However, it had been suggested that obese mice display a marked catabolic defect for the major HDL 
apolipoprotein A-1 (Apoa1) [13]. 
 
Table 2. The effect of aspalathin on blood lipid profiles and HOMA-IR. 
 db/+_UC db/db_UC db/db_MET db/db_ASP_LD db/db_ASP_HD 
Total cholesterol 
(mmol/L) 
2.4 ± 0.09 3.5 ± 0.18*** 2.9 ± 0.18*
#
 3.2 ± 0.18** 2.7 ± 0.24
#
 
LDL 
(mmol/L) 
0.1 ± 0.06 0.4 ± 0.07* 0.2 ± 0.04
#
 0.2 ± 0.05 0.1 ± 0.04
##
 
HDL 
(mmol/L) 
1.7 ± 0.06 2.5 ± 0.10*** 2.2 ± 0.13** 2.3 ± 0.13** 2.3 ± 0.14** 
Triglycerides 
(mmol/L) 
0.9 ± 0.04 3.2 ± 0.38*** 2.3 ± 0.46* 2.6 ± 0.19*** 2.3 ± 0.28** 
HOMA-IR 0.1 ± 0.01 0.6 ± 0.28 0.3 ± 0.05 0.4 ± 0.07 0.2 ± 0.03 
 
Results are the mean ± SEM, with each treatment group containing six mice. *p < 0.05, **p < 0.001, ***p < 
0.0001 versus untreated nondiabetic mice (db/+_UC); #p < 0.05, ##p < 0.001 versus untreated diabetic mice 
(db/db_UC). db/db_ASP_LD: diabetic mice treated with low dose aspalathin (13 mg/kg), db/db_ASP_HD: 
diabetic mice treated with high dose aspalathin (130 mg/kg), db/db_MET: diabetic mice treated with metformin 
(150 mg/kg), HDL: high density lipoprotein, HOMA-IR: homeostasis model assessment: insulin resistance, LDL: 
low density lipoprotein. 
 
In vitro effect of aspalathin 
To confirm our in vivo findings and to decipher the molecular mechanism used by aspalathin to 
improve hyperglycemia-associated lipid toxicity in the heart, gene expression profiling was employed 
using H9c2 cardiomyocytes exposed to high glucose. The expression profiles of 336 genes were 
assessed, 57 genes (17%) were differentially expressed and of these, 45 and 12 genes (79% and 
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21%) were hyper-expressed in the high glucose and aspalathin treated groups, respectively (Table 3). 
STRING data analysis confirmed that aspalathin treatment largely improved the expression of genes 
involved in metabolic processes, identifying fatty acid and lipid metabolism as the top two regulatory 
processes. 
 
In vitro effect of aspalathin on fatty acid and lipid metabolism 
Data analysis identified 26 of the 57 (46%) differentially expressed genes to be involved in fatty acid 
and lipid metabolism (Table 3). STRING network analysis identified three clusters encoding interactive 
nodes representing genes associated with fatty acid/lipid transport, lipid metabolism and fatty acid 
metabolism (confidence score, 0.7) (Fig. 1). Lipids are the large and diverse group of naturally 
occurring organic compounds that are essential for energy storage while FFAs are a sub-group of 
lipids that are commonly derived from triglycerides. FFAs are the preferred substrate for energy 
production within cardiomyocytes, contributing up to 70% of ATP when compared to other substrates 
such as glucose and lactate. 
 
Increased β-oxidation: Enhanced FFA uptake and lipid storage are causal factors known to precede 
the development of diabetic heart failure [14, 25]. In this study, we demonstrated that high glucose 
increased the expression of fatty acid transporters including; cluster of differentiation 36 (Cd36; 3.7-
fold), fatty acid-binding proteins 3 (Fabp3; 2.7-fold), solute carrier family 25, member 30 (Slc25a30; 
2.6-fold) and solute carrier family 27, member 1, 3 and 5 (Slc27a1, 3 and 5) by 1.0, 6.3-fold and 2.0-
fold, respectively (Fig. 1 and Table 3). This increased fatty acid transport was concomitant to raised 
expression levels of genes associated with β-oxidation; including carnitine palmitoyltransferase 1b 
(Cpt1b; 3.3-fold), acyl-CoA thioesterase 2 (Acot2, 2.8-fold), acyl-CoA oxidase 2 (Acox2, 2.8-fold) as 
well as lysophospholipase 1 (Lypla1; 3.5-fold) (Fig. 1 and Table 3). Additionally, we observed that high 
glucose exposure upregulated mRNA expression of stearoyl-CoA desaturase 1 (Scd1, 5.5-fold), an 
enzyme crucial for the synthesis and storage of fatty acids. However, aspalathin treatment supressed 
this effect, which was associated with reduced FFA uptake and oxidation (Fig. 1 and Table 3). This 
result was in agreement with our previous findings [10, 26], where we showed that aspalathin and 
phenyl acid-2-O-β-D-glucoside prevented loss of metabolic flexibility by preventing shifts in myocardial 
substrate preference, from an almost compete reliance on fatty acid oxidation towards increased 
glucose utilization. 
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Increased supply of long-chain fatty acids (LCFAs): Chronic hyperglycemia has been associated 
with increased supply of circulating FFAs in cardiomyocytes [10, 26]. When this enhanced supply of 
FFAs exceed the rate of β-oxidation, myocardial triglyceride accumulation occurs, leading to 
lipotoxicity [14, 15]. The latter can subsequently lead to left ventricular dysfunction, a major 
characteristic of DCM. In a study done by Drosatos et al. [25], they showed that mice with cardiac-
specific overexpression of LCFA acyl-CoA synthetase (Acsl) genes developed lipid toxicity and 
diastolic dysfunction, directly implicating LCFAs in the development of cardiac fibrosis and subsequent 
myocardial remodeling [25]. In our dataset, STRING analysis identified a network of genes with nodes 
linking long-chain fatty acyl-CoA synthetase enzymes (Fig. 1). These data confirm previous findings 
[25], where high glucose exposure resulted in increased mRNA expression of acyl-CoA synthetase 
long-chain family member 4 and 6 (Acls4, 5.6-fold and Acls6, 2.4-fold) as well as acyl-CoA synthetase 
medium-chain family member 3 and 4 (Acsm3, 14.2-fold and Acsm4, 6.1-fold) (Fig. 1 and Table 3). 
Results obtained showed that aspalathin treatment was able to attenuate this effect.  
 
Altered lipid metabolism and increased cholesterol flux: Scientific evidence has shown that 
excessive cardiac lipid accumulation may lead to fibrosis and reduced ventricular compliance, 
contributing to the development of cardiac dysfunction [10-13]. Lipid toxicity in the myocardium has 
been associated with the transcriptional factor sterol regulatory element-binding protein 1/2 (Srebf1/2) 
and the transcriptional coactivator peroxisome proliferator-activated receptor-gamma (PPARγ) [25, 
27]. Srebf1/2 and PPARγ are important switches that regulate lipid accumulation and lipotoxicity. In a 
study done by Marfella et al. [27] on biopsies from diabetic patients with left ventricular dysfunction, 
they found that increased cardiac lipid deposits were concomitant with enhanced mRNA expression of 
Srebf1/2, PPARγ as well as genes associated with accelerated β-oxidation. Notably, in this study, 
elevated levels of circulating FFAs were observed after high glucose exposure. This was in parallel to 
enhanced mRNA expression of Srebf1 and 2 (3.4 and 2.0-fold, respectively) as well as PPARγ (8.3-
fold) (Fig. 1 and Table 3). Increased expression of Srebf1 is further linked to the development of an 
artherogenic apolipoprotein profile, a characteristic of cardiac hypertrophy [29, 30]. The main function 
of apolipoproteins is to transport triglycerides and cholesterol in the blood [30]. Apoa1 is the major 
protein component of HDL. HDL promotes efflux of cholesterol, phospholipids, and other lipophilic 
molecules from cells by an active process mediated by a cell-membrane transporter, ATP-binding 
cassette transporter (Abca1) [28, 30]. By contrast, apolipoprotein B (Apob) is the main apolipoprotein 
of chylomicrons and LDL and its elevated levels may cause heart failure [28, 30]. In this study, we 
observed an increased mRNA expression of Apob (7.7-fold), apolipoprotein E (Apoe; 4.4-fold) and 
very low density lipoprotein (Vldlr; 2.0-fold) that was decreased after aspalathin treatment (Fig.1). 
Similar to increased HDL cholesterol in db/db mice, Apoa1 and its transporter Abca1 were increased 
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by 4.2-fold and 2.0-fold, respectively, after high glucose exposure. Aspalathin treatment reversed this 
effect. Of interest, increased Apob has been associated with increased expression of Cd36, the 
receptor for oxidized LDL. Furthermore, insulin sensitivity and improved lipotoxicity have also been 
linked to adiponectin (Adipoq) [29]. Adipoq encodes the circulating protein adiponectin and is 
expressed primarily in the adipose tissue [31], but can also be found in vascular tissue [22, 32]. In this 
study, high glucose exposure resulted in the reduced expression of Adipoq (-6.0-fold), while aspalathin 
was able to reverse this effect. 
Our results support the work of others that increased cardiac lipid toxicity as a result of chronic 
hyperglycemia may lead to heart failure [30, 32]. Aspalathin treatment was able to reverse lipid toxicity 
by modulating key regulatory genes, such as Adipoq and Sreb1/2, that are involved in metabolic, 
hormonal and energy processes. Adipoq plays an important role in controlling lipid metabolism by 
negative regulating Srebf1/2 [29]. Thus, by upregulating Adipoq, aspalathin improved insulin sensitivity 
and suppressed LDL by reducing Srebf1/2 (Fig. 1). We predict that aspalathin can prevent lipid 
accumulation and subsequent death due to cardiac failure.  
 
In vitro effect of aspalathin on the development of insulin resistance 
It is well-known that increased LCFAs result in the intramyocardial accumulation of diacylglycerol that 
activates protein kinase C (theta isoform), leading to the inhibition of insulin receptor substrate 1 (Irs1) 
and development of insulin resistance [10-12]. The latter can have a profound effect on cardiac 
performance, as the heart is an insulin-responsive organ and hyperglycemic-induced insulin 
resistance decreases cardiac performance. Our data analysis revealed that 14 (25%) of the 57 
differentially expressed genes were associated with the development of hyperglycemic-induced insulin 
resistance (Table 3). Network mapping of the differential expressed genes identified two major 
interconnecting clusters (genes associated with protein kinase activity and development of insulin 
resistance) with serine/threonine-protein kinase homolog 1 (Akt1) and mitogen activated protein 
kinase (Mapk) being the major nodes of connection (confidence score, 0.7) (Fig. 2). 
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Figure 1. Aspalathin prevented high glucose-induced impaired cardiac substrate metabolism by reducing the 
uptake and oxidation of free fatty acids. (A) Search Tool for the Retrieval of Interacting Genes (STRING) 
database confirmed a strong interaction between genes associated with lipid toxicity. (B) Representative 
diagram of the proposed protective mechanism of aspalathin against increased lipid accumulation and oxidation. 
Cd36: cluster of differentiation 36; Cpt1: carnitine palmitoyltransferase 1; FFAs: free fatty acids; Fabp3: fatty 
acid binding protein 3; FAO: fatty acid oxidation; Pparɣ: peroxisome proliferator activated receptor gamma; 
Scd1: stearoyl-Coenzyme A desaturase 1; Srebf1/2: Sterol regulatory element binding transcription factor 1/2; 
TAG: triacylglycerides. 
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Insulin signalling and effect on myocardium: Akt1 is a pro-survival protein kinase that plays an 
important role in the regulation of various cellular functions, including metabolism (glucose and lipids), 
growth, migration, proliferation and cell survival [33]. STRING network analysis identified Akt1 as the 
central node associated with 12 of the 14 differentially expressed genes. Akt1 constitutes an important 
node with diverse signalling cascades. In this study, a direct link was observed between 
phosphodiesterase 3B (Pde3b) and Akt1. Studies have demonstrated that cAMP-dependent protein 
kinase signaling is impaired in diabetes and is associated with cardiac dysfunction [34, 35]. Cyclic 
AMP (cAMP) plays a significant role in the thermogenic process as well as potentiating glucose-
stimulated insulin release [34, 35]. In contrast, Pde3b is a negative regulator of cAMP and increased 
expression of this gene has been shown to block and diminish the effect of cAMP [28]. Pde3b is highly 
expressed in the myocardium and is known to decrease myocardial smooth muscle contractility [36]. 
In studies done on isolated rat islets, inhibition of Pde3 was reported to improve insulin release [37]. In 
this study, high glucose exposure resulted in the upregulation of Pde3b by 2.1-fold (Fig. 1 and Table 
3). However, treatment with aspalathin was able to ablate this response, implying that aspalathin 
might act as a possible inhibitor of Pde3 and could be used as a potential therapeutic target to protect 
the diabetic heart. Furthermore, Akt1 was found to be associated with various antioxidant genes 
including superoxide dismutase 2 (Sod2) and uncoupling protein 1 (Ucp1). Although predominantly 
found in the brown adipose tissue, Ucp1 is also expressed in cardiac cells where together with Sod2 
inhibit the damaging effects of reactive oxygen species (ROS) [38]. Aspalathin was able to improve 
Sod2 (3.1-fold) activity while the effect of high glucose on Ucp1 (58.6-fold) expression was decreased 
(-1.7-fold) (Fig. 2). Interestingly, in a study done by Barreto et al [39], where they investigated the 
mechanism of Ucp1 action on stress response, they observed that increased Ucp1 expression 
induced the upregulation of various antioxidant stress-response genes, such as Sod1, glutathione-S-
transferase and glutathione peroxidase, concomitantly reducing ROS. Similarly, in a study by Dludla et 
al. [9], a rooibos extract with abundant aspalathin levels significantly enhanced glutathione levels of 
cardiomyocytes isolated from diabetic rats exposed to ROS. Based on these findings, we speculate 
that the observed increased Ucp1 expression could have been a compensatory mechanism used by 
the cells to prevent the adverse effects of increased FFA and hyperglycemia-induced ROS. 
 
Impaired myocardial energy metabolism, due to aberrant FFA levels and insulin resistance, activates a 
myriad of other maladaptive signaling pathways. This includes activation of insulin-like growth factor 1 
(Igf1), a hormone similar in structure to insulin and known to be a physiological regulator of glucose 
transport and glycogen synthesis [40]. Igf1 activates and phosphorylates Akt1 to attenuate the 
development of diabetes-induced myocardial apoptosis, through inhibiting tumor protein 53 [41]. In this 
study, high glucose moderately reduced the mRNA expression of Igf1 (1.3-fold) and Akt1 (-2.2-fold) 
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(Fig. 2). Conversely, the tumor necrosis factor ligand superfamily member 6 (Faslg) that interacts with 
Akt1 has been shown to induce apoptosis through binding and inhibiting the pro-survival gene Cflar 
[42]. In this study, high glucose treatment increased mRNA expression of Faslg (4.8-fold), while 
aspalathin ablated this response. Thus, our results infer that aspalathin protected cardiomyocytes 
exposed to chronic hyperglycemia against Faslg-induced apoptosis by activating the Igf-PI3K-Akt pro-
survival pathway (Fig. 2). Additionally, STRING data analysis showed that an interactive network was 
formed between Igf1, Akt1, serpin peptidase inhibitor, member 1/2 (Serpin1/2) and vascular 
endothelial growth factor A (Vegfa) (Fig. 2). High glucose treatment increased the expression of Vegfa 
by 2.0-fold while reducing that of Serpinb2 and Serpine1 by -2.7 and -46.1-fold, respectively (Fig. 2 
and Table 3). Similarly, Xue et al. [43] as well as Natarajan et al. [44] observed that chronic 
hyperglycemia upregulates Vegf and accelerates diabetic-induced cardiac fibrosis. They further 
speculate that the observed increase in high glucose-induced Vegf expression may be due to elevated 
inflammation consistent with a hyperglycemic state. The role of Serpine1 in cardiac fibrosis remains 
controversial however; Serpine1 deficient mice display cardiac fibrosis, enhanced inflammation, along 
with increased microvascular permeability and haemorrhage [45]. Thus, concluding that Serpine1 is 
cardio protective, and functions in maintaining normal microvasculature integrity. Thus, based on the 
latter findings we would speculate that increased expression of Serpine1 might be cardioprotective. 
However, this hypothesis requires further investigation.  
 
Protein kinases and mitochondrial function: Damaged structural components of the heart as a 
result of insulin resistance are known to activate signaling pathways such as p38 mitogen-activated 
protein kinases (Mapk) [46]. STRING network analysis identified three distinct nodes within this 
network, including dynamin 1-like (Dnm1l), Map2k1 and cAMP-dependent protein kinase catalytic 
subunit (Prkacb), which is known to be involved in the process of mitophagy. Mitophagy is responsible 
for the removal of damaged mitochondria proteins as a result of lipotoxicity and defects in this process 
have been linked to cardiovascular dysfunction [47]. Dnm1l is a mitochondrial protein that is involved 
in the apoptotic process and is crucial for maintaining mitochondrial function through increased Dnm1l-
dependent mitophagy. Roy et al. [48] showed that mice lacking Dnm1l demonstrate impaired heart 
contraction with an associated reduction in mitochondrial fission, concluding that Dnm1l is critical for 
sustaining mitochondrial morphology and heart function. Interestingly, Dnm1l was increased 2.8-fold 
after aspalathin treatment. Furthermore, mitophagy induction can be regulated/activated through the 
Prka-MTOR-ULK1 mediated signaling pathway [48]. STRING analysis showed a strong interaction 
between protein kinase, AMP-activated, gamma 1 non-catalytic subunit (Prkag) and Mapk. Activation 
of Mapk has been implicated in FFA-induced cardiac toxicity and subsequent cardiac failure [49]. In 
this study we observed that high glucose resulted in enhanced expression of Map2k1 (2.3-fold), with 
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an associated decrease in the mitophagy activator Prkag1 (-2.6 fold). However, aspalathin treatment 
reversed this effect (Fig. 2). Thus, we speculate that aspalathin might possibly protect the myocardium 
from chronic hyperglycemia through enhanced cAMP-mediated mitophagy, thereby alleviating FFA-
induced-MAPK toxicity and subsequent intracellular lipid accumulation in vitro. 
 
In vitro effect of aspalathin on inflammation 
In a diabetic state, a complex interplay between impaired cardiac substrate metabolism, insulin 
resistance and inflammation underlies the progression of DCM. Furthermore, accumulating evidence 
is available on the important role inflammation plays in the development of cardiac hypertrophy and 
failure. Aberrant and/or prolonged suppressors of cytokine signaling (Socs) proteins and JAK-induced 
signaling is detrimental and can give rise to a number of inflammatory pathologies known to affect 
cardiac function [50, 51]. Accordingly, 11 of the 57 (19%) differentially expressed genes were 
associated with cytokine signaling (Table 3). STRING analysis identified a network with five distinct 
nodes that include interleukins, Cd3e antigen (Cd3e), Socs3, and leptin receptor precursor (Lepr), with 
Janus kinase 2 (Jak2) being the predominant interactive node (Fig. 3).  
 
Leptin action: Leptin is an adipokine that is mainly expressed in adipose tissue, but is also expressed 
in cardiac heart muscle cells [22]. Accumulative evidence suggests that leptin impairs myocardial 
energy metabolism by favouring a complete reliance on FFAs as an energy source leading to cardiac 
hypertrophy [22, 50]. Leptin is known to bind to the leptin receptor to activate the JAK/Signal 
Transducers and Activators of Transcription (STAT) pathway. Activation of this pathway results in the 
translocation of STAT to the nucleus where it can activate Socs3, inhibiting leptin action as well as 
insulin signaling [51]. A meta-analysis of our data showed that the Lepr was increased (7.2-fold) after 
high glucose treatment. Interestingly, this increase was concomitant with an upregulation in the mRNA 
expression of both Jak2 (3.9-fold) and Socs3 (4.5-fold). This result is of interest as increased Lepr 
expression is known to enhance Socs3 with an associated altered β-oxidation [51], as observed in this 
study.  
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Figure 2. Aspalathin prevented high glucose-induced insulin resistance. (A) Search Tool for the Retrieval of 
Interacting Genes (STRING) database confirmed a strong interaction between genes associated with insulin 
resistance. (B) Representative diagram of the proposed protective mechanism of aspalathin against insulin 
resistance and resultant oxidative stress. Akt1: v-akt murine thymoma viral oncogene homolog 1; cAMP: cyclic 
adenosine monophosphate; Dnm1l: dynamin 1-like; Faslg: fas ligand (TNF superfamily, member 6); Igf: insulin-
like growth factor 1; Map2k1: mitogen-activated protein kinase kinase 1; Prkag: protein kinase, AMP-activated, 
gamma 1 non-catalytic subunit; Serpine1: serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1; Sod2: superoxide dismutase 2; Vegfa: vascular endothelial growth factor A. 
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Cytokine signaling: In the diabetic heart, increased lipotoxicity and insulin resistance triggers the 
recruitment of macrophages and leukocytes before the release of pro-inflammatory cytokines such as 
interleukin 3 and 6 (Il3 and Il6), tumour necrosis factor superfamily (Tnf) and cluster of differentiation 
(Cd). Il6, Tnf and Cd cause the endothelial cells of blood vessels to express cellular adhesion 
molecules, such as Selectin E (Sele) and Cd44, resulting in an acute localized cellular inflammation. 
Both Cd44 and Sele are cell-surface glycoproteins that mediate neutrophil, monocyte, lymphocyte and 
platelet rolling in the ventricular wall. These glycoproteins have also been found to play an important 
role in atherosclerotic lesion development and calcification of the lesion [52, 53]. Studies 
demonstrated that Cd44 as well as Sele null mice display increased atherosclerosis plaque formation 
[52, 53]. Our results showed that high glucose treatment increased the expression of various pro-
inflammatory cytokines including, Il3 (2.3-fold), Il6 (2.7-fold), Tnsf13 (4.7-fold) and Tnfsf13b (2.1-fold), 
Sele (13.8-fold) and Cd44 antigen (Cd44, 2.3-fold) (Fig. 3 and Table 3). Based on our gene 
expression data, we propose that during chronic hyperglycemia, pro-inflammatory cytokines (Il3, Il6 
and Tnf-α) are activated. This increased inflammatory cytokine response releases Sele and Cd44 from 
the storage granules in activated platelet and endothelial cells and recruits them to mediate the first 
step of leukocyte extravasation. Additionally, Il6 and Tnf activate the JAK/STAT and Map kinase 
pathways respectively, resulting in increased hypertrophy and apoptosis. Increased expression of 
Socs3 has been linked to inflammation-induced insulin resistance and enhanced JAK/STAT signaling 
as observed in this study [54]. However, aspalathin treatment was able to reverse this effect (Fig. 3).  
 
In vitro effect of aspalathin on apoptosis 
Chronic hyperglycemia, insulin resistance and inflammation have been shown to exacerbate oxidative 
stress and cardiomyocyte apoptosis [23, 26]. In this study, 6 of the 57 (11%) differentially expressed 
genes were associated with apoptosis signaling. STRING data analysis identified one network with 
five interactive nodes, centralized around B-cell lymphoma 2 (Bcl2). 
Genes identified in this network included Bcl2, Bcl2 binding component 3 (Bbc3), mitogen activated 
protein kinase 3 (Mapk3) and optic atrophy 1 homolog (Opa1) (Fig. 4 and Table 3). The Bcl2 family of 
proteins are known to be strong modulators of apoptosis and can induce either pro-apoptosis or cell 
survival depending on the cell’s fate [10, 26]. Two pro-survival genes were identified (Bcl2 and Bcl2a1) 
and their expression was reduced after high glucose exposure (Fig. 4 and Table 3). Contrary, four pro-
apoptotic proteins (Bbc3, Chuk, Mapk3 and Opa1) were identified. Activation of Mapk3 together with 
pro-apoptotic proteins such as Bbc3 has been associated with myocardial dysfunction [23, 55], while 
upregulation of Opa1 is directly linked to the reversal of mitochondrial fragmentation [56]. Furthermore, 
in vivo and in vitro data has confirmed that activation of Mapk proteins, including Mapk3 together with 
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pro-apoptotic proteins is associated with hyperglycemia induced myocardial dysfunction [23, 55]. 
Hence, this emphasises the importance of ameliorative strategies that target apoptosis to alleviate 
myocardial structural remodeling. Increased Bcl2 expression has an inhibitory effect on Mapk3. Thus, 
we proposed that aspalathin prevents myocardial apoptosis through the inhibition of Mapk3 while 
simultaneously increasing Bcl2-mediated cardiomyocyte survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Aspalathin prevented high glucose-induced inflammation. (A) Search Tool for the Retrieval of 
Interacting Genes (STRING) database confirmed a strong interaction between genes associated with 
inflammation. (B) Representative diagram of the proposed protective mechanism of aspalathin against high 
glucose induced inflammation. Cd44: cluster of differentiation 44; Il3: interleukin 3; Il6: interleukin 6; Map2k1: 
mitogen-activated protein kinase kinase 1; Socs3: suppressor of cytokine signaling 3; Tnf: tumor necrosis 
factor; Vegfa: vascular endothelial growth factor A. 
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Figure 4. Aspalathin limited high glucose-induced apoptosis. (A) Search Tool for the Retrieval of Interacting 
Genes (STRING) database confirmed a strong interaction between genes associated with high glucose induced 
apoptosis.  
 
 
Conclusion: Results obtained in this study lead us to propose that aspalathin could protect the 
myocardium against lipid toxicity in two ways. In the first instance, such treatment significantly 
improves the blood lipid profile to a far less damaging one therefore attenuating fuel substrate 
availability to the diabetic heart. It is likely that aspalathin mediates such effects by acting on targets in 
the liver, although this was not further investigated in the current study. Secondly, our data 
demonstrate that aspalathin also exerts direct, protective effects within the myocardium to protect the 
heart against excess fuel substrate availability. Here our data indicate that aspalathin may protect the 
myocardium against lipotoxicity and subsequent cell apoptosis by increasing the expression of Adipoq 
and subsequently decreasing the expression of Cd36 and Cpt1. Furthermore, aspalathin reduced lipid 
transport via Slc27a3/5, which together with reduced PPARγ and Srebf1 resulted in decreased total 
cholesterol and subsequent cell apoptosis. Moreover, we proposed that the reversal of lipid toxicity 
results in a decreased inflammatory response via the Il6/Jak/Stat pathway, which together with an 
observed increase in Bcl2 prevents myocardium cell apoptosis. Together, these findings propsed a 
probable mechanism by which aspalathin reverses metabolic abnormalities associated with the failing 
myocardium (Fig 5). However, this warrants further investigation. 
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Table 3 Aspalathin improves gene expression derangements associated with hyperglycemia in H9c2 
cardiomyocytes. 
 
    Gene fold regulation 
Gene name Gene 
symbol 
High 
glucose 
(33 mM) 
Aspalathin 
(1 µM) 
Lipid metabolism 
 
      
ATP-binding cassette, subfamily A (ABC1), member 1 Abca1 2.0776 -1.1921 
Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain Acads -1.6611 -2.425 
Acyl-CoA thioesterase 2 Acot2 2.8239 -1.2178 
Acyl-Coenzyme A oxidase 2, branched chain Acox2 2.0959 1.8895 
Acyl-CoA synthetase bubblegum family member 2 Acsbg2 4.3205 -1.5973 
Acyl-CoA synthetase long-chain family member 4 Acsl4 5.6547 1.7361 
Acyl-CoA synthetase long-chain family member 6 Acsl6 2.465 -1.5973 
Acyl-CoA synthetase medium-chain family member 3 Acsm3 14.2353 5.697 
Acyl-CoA synthetase medium-chain family member 4 Acsm4 6.1301 3.1806 
Adiponectin, C1Q and collagen domain containing Adipoq -6.0324 3.2588 
Apolipoprotein A-I Apoa1 4.2006 2.9178 
Apolipoprotein B Apob 7.7651 -3.0228 
Apolipoprotein E Apoe 4.4207 -1.0317 
CD36 antigen Cd36 3.7512 1.7387 
Carnitine palmitoyltransferase 1b, muscle Cpt1b 3.3366 2.0449 
Fatty acid binding protein 3, muscle and heart Fabp3 2.7003 -1.5135 
Lysophospholipase 1 Lypla1 3.5198 1.6047 
Peroxisome proliferator activated receptor gamma Pparγ 8.3847 -1.6135 
Stearoyl-Coenzyme A desaturase 1 Scd1 5.5982 1.0879 
Solute carrier family 25, member 30 Slc25a30 2.6123 1.6634 
Solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 1.0514 -2.2919 
Solute carrier family 27 (fatty acid transporter), member 3 Slc27a3 6.323 2.2207 
Solute carrier family 27 (fatty acid transporter), member 5 Slc27a5 2.0184 -1.5973 
Sterol regulatory element binding transcription factor 1 Srebf1 3.4573 -4.544 
Sterol regulatory element binding factor 2 Srebf2 2.0208 -26.826 
Very low density lipoprotein receptor Vldlr 2.0148 1.3077 
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Insulin resistance 
 
      
V-akt murine thymoma viral oncogene homolog 1 Akt1 -2.2173 1.2477 
Dynamin 1-like Dnm1l 1.4367 2.8522 
Fas ligand (TNF superfamily, member 6) Faslg 4.8622 -1.4856 
Insulin-like growth factor 1 Igf1 1.3447 2.4477 
Mitogen-activated protein kinase kinase 1 Map2k1 2.3446 -2.1822 
Phosphodiesterase 3B, cGMP-inhibited Pde3b 2.1481 1.5951 
Protein kinase, cAMP dependent, catalytic, beta Prkacb 1.687 2.4466 
Protein kinase, AMP-activated, gamma 1 non-catalytic subunit Prkag1 -2.6381 1.3516 
Serpin peptidase inhibitor, clade B (ovalbumin), member 2 Serpinb2 -2.7789 1.8746 
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
Serpine1 -46.1814 -1.4005 
Superoxide dismutase 1, soluble Sod1 2.8805 1.0032 
Superoxide dismutase 2, mitochondrial Sod2 -1.5522 3.1195 
Uncoupling protein 1 (mitochondrial, proton carrier) Ucp1 58.6622 -1.7821 
Vascular endothelial growth factor A Vegfa 2.0015 1.2082 
Inflammation 
 
      
CD3 antigen, epsilon polypeptide Cd3e 5.4019 1.3557 
Cd44 molecule Cd44 2.3883 1.322 
Interleukin 3 Il3 2.3815 -1.1606 
Interleukin 6 Il6 2.7362 1.9106 
Janus kinase 2 Jak2 3.9723 1.721 
Leptin receptor Lepr 7.2781 -1.6135 
Selectine E Sele 13.8787 -1.5233 
Suppressor of cytokine signaling 3 Socs3 4.5848 -2.4959 
Tumor necrosis factor receptor superfamily, member 1b Tnfrsf1b 1.0099 -3.114 
Tumor necrosis factor (ligand) superfamily, member 13 Tnfsf13 4.7142 1.2849 
Tumor necrosis factor (ligand) superfamily, member 13b Tnfsf13b 2.0522 1.8583 
Apoptosis 
 
      
Bcl-2 binding component 3 Bbc3/puma -1.3703 -3.1586 
B-cell CLL/lymphoma 2 Bcl2 -2.6947 1.8312 
B-cell leukemia/lymphoma 2 related protein A1d Bcl2a1 -7.13 1.8085 
Conserved helix-loop-helix ubiquitous kinase Chuk 4.2959 2.1502 
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Mitogen-activated protein kinase 3 Mapk3 1.2583 -3.0871 
Optic atrophy 1 homolog (human) Opa1 1.3949 2.0255 
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Chapter 6: General conclusions 
Summary of findings 
Urbanization and obesity remain important causal factors responsible for the dramatic rise in cases of 
diabetes mellitus (DM) worldwide (International Diabetes Federation, 2015). The rising incidence of 
DM has been associated with an increase in cardiovascular mortality. Currently, insulin and metformin 
remain the leading first line antihyperglycemic drug therapies (Jonassen et al., 2001; Yin et al., 2011). 
However, these drugs have a limited capacity to protect the diabetic myocardium against the 
development of cardiovascular complications. Currently, researchers are increasingly exploring the 
use of plant-derived materials as an adjunct to current drug treatment (Chellan et al., 2014; Mazibuko 
et al., 2015; Muller et al., 2016). Numerous edible plants are known to contain plant polyphenols, 
flavonoids, terpenoids and other constituents, which may contribute to the reduction of blood glucose 
levels as well as counteract oxidative-induced tissue damage through their robust antioxidant effect 
(Kawano et al., 2009; Bai et al., 2013; Ezuruike et al 2014). Previously, our group and others have 
demonstrated that Aspalathus linearis, a plant indigenous to South Africa and commonly known as 
rooibos, displayed protective properties against the development of obesity, insulin resistance and 
cardiovascular disease in various experimental models (Muller et al., 2012; Son et al., 2013; Dludla et 
al., 2014; Sanderson et al. 2014). In a study done by Dludla et al 2014, we showed that a fermented 
rooibos extract with abundant levels of phenyl pyruvic acid-2-O-β-D-glucoside (PPAG) and aspalathin 
was able to decrease oxidative stress and subsequent cell apoptosis in primary rat cardiomyocytes 
from diabetic rats. However, the protective mechanism afforded by PPAG and aspalathin to modulate 
oxidative-induced myocardial damage remained to be fully elucidated. Therefore, in this study we 
aimed to unravel the mechanisms by which PPAG and aspalathin protect against the development of 
hyperglycemia-induced myocardial injury.  
 
PPAG protected against hyperglycemia-induced cardiac apoptosis 
The mitochondrial apoptotic pathway is largely mediated through the B-cell lymphoma 2 (Bcl2) family 
of proteins. Bcl2, a human proto-oncogene, protects against mitochondrial permeability and 
subsequent programmed cell death. Following a death signal, pro-apoptotic proteins such as Bax 
undergo a conformational change that enable it to integrate into the outer mitochondrial membrane 
and initiate cell death. In contrast, anti-apoptotic proteins such as Bcl2 are important for protecting the 
mitochondrial membrane against Bax translocation, making Bcl2/Bax ratio crucial for cell survival. In 
this study, we observed that PPAG treatment led to an enhanced Bcl2/Bax ratio thus preventing 
mitochondrial depolarization and subsequent cell apoptosis as observed by a reduced caspase 3/7 
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activity and inhibition of DNA fragmentation (Fig. 1). We further observed that PPAG treatment 
resulted in increased glucose uptake with a concomitant decrease in oxidative phosphorylation. It is 
well-known that tumor suppressor 53 (p53) plays an important role in energy metabolism by activating 
TP53-inducible glycolysis and apoptosis regulator (TIGAR), resulting in the blockade of glycolysis and 
accelerated apoptosis. Thus, we speculate that PPAG may protect the myocardium from cell death 
through an increased Bcl2/Bax ratio as well as improved glucose uptake by inhibiting p53. However, 
this mechanism will be further explored in a follow up study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pyruvic acid-2-O-β-D-glucoside (PPAG) protects H9c2 cardiomyocytes against hyperglycemia-induced 
damage by reducing mitochondrial membrane depolarization and inhibiting apoptosis through increasing Bcl-
2/Bax ratio. ΔΨm: mitochondrial transmembrane potential, Bax: Bcl2-like protein 4, Bcl2: B-cell lymphoma 2. 
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The role of aspalathin in preventing shifts in energy substrate preference, oxidative damage 
and subsequent lipid toxicity 
The role aspalathin plays in modulating fatty acid oxidation (FAO) and glucose oxidation (GO): 
An important feature of the failing heart is the observed shift in substrate preference that precedes the 
onset of oxidative damage. The myocardium has a high-energy demand that is primarily achieved 
through FAO, accounting for 60-80% of ATP production at the expense of glucose. In a diabetic heart, 
an adaptive response is observed where there is diminished utilization of glucose with an increase in 
FAO. This results in a shift in substrate preference with an almost complete reliance on FAO as an 
energy source, with an associated decrease in glucose oxidation. This compensatory shift is believed 
to be involved in impaired cardiac function of the failing heart. In this study we showed that aspalathin, 
via 5' AMP-activated protein kinase (AMPK) was able to efficaciously decrease myocardial FAO, 
causing a reciprocal increase in glucose oxidation. Shifting energy substrate preference away from 
FAO towards glucose utilization is a promising therapeutic approach that could possibly slow down the 
progression of heart failure (HF) in a diabetic state. However, there is a fine line in the balance of 
substrate preference. Decreasing the cell’s capacity for FAO may result in the accumulation of long-
chain fatty acyl intermediates and triglycerides, which may in turn lead to the generation of toxic lipid 
build-up and potentially accelerate the progression of HF (Lionetti et al 2011). However, as will be 
discussed below, we showed that aspalathin was able to decrease lipid toxicity as a result of reduced 
FAO. Additionally, we showed that aspalathin was able to enhance endogenous antioxidant defense 
genes and protect against hyperglycemia-induced membrane depolarization and subsequent cell 
apoptosis (Fig. 2). 
 
Aspalathin decrease oxidative damage by increasing the expression of Nrf2: Impaired 
myocardial energy substrate utilization and increased oxidative stress are linked to the onset of 
cardiac hypertrophy. In this study, we demonstrated that in addition to impaired substrate preference, 
cardiomyocytes exposed to a simulated hyperglycemic state displayed increased generation of 
reactive oxygen species and reduced expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
(Fig. 2). Nrf2 plays a crucial role in the cells ability to response to endogenous oxidative stress, by 
increasing the expression of an array of cytoprotective and antioxidant defense genes. 
Correspondingly, in this study, after high glucose exposure, we observed accelerated oxidative stress 
concurrent to heart tissue morphological derangements and increased apoptosis. However, aspalathin 
treatment was able to abolish the observed myocardial injury by upregulating the expression of Nrf2 
and its associated down-stream cytoprotective and antioxidant genes (Fig. 2).  
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Aspalathin role in lipid metabolism: DM has been associated with an increase in FFA availability 
with a concomitant increase in lipid toxicity. This lipid overload is known to decrease respiratory 
efficiency of the heart resulting in increased hypertrophy and subsequent HF. In this study, we showed 
that aspalathin was able to reverse lipid toxicity by increasing the expression of Adipoq and 
subsequently decreased Cd36 and Cpt1 mRNA expression (Chapter 5, Fig. 1B). We speculate that 
Adipoq negatively regulates FFA synthesizing genes, such as sterol regulatory element binding 
transcription factor 1 (Srebf1) and stearoyl-Coenzyme A desaturase 1 (Scd1), leading to a decrease in 
lipid accumulation. Moreover, aspalathin reduced intracellular FFA uptake via solute carrier family 27 
(fatty acid transporter), member 3/5 (Slc27a3/5) which together with reduced Srebf1 result in the 
decrease of total cholesterol, hypertrophy and subsequent HF. Moreover, reversal of lipid toxicity was 
associated with an observed decrease in inflammatory markers, such as interleukin 3 and 6 (Il6 and 
Il3), tumor necrosis factor receptor superfamily, member 1b and 13 (Tnfrsf1b and Tnfsf13), Janus 
kinase 2 (Jak2) and mitogen-activated protein kinase 3 (Mapk3) (Fig. 2).  
 
In summary, in this study showed that while PPAG and aspalathin were able to reduce hyperglycemia-
induced apoptosis, only aspalathin could ameliorate lipid toxicity and oxidative stress-associated with 
the insulin resistances state by activating Nrf2 expression. In conclusion, this study was able to prove 
the hypothesis that rooibos-specific compounds (PPAG and aspalathin) can protect the myocardium 
against hyperglycemia-induced oxidative injury by activating Nrf2 antioxidant response pathway.  
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Figure 2. Aspalathin protects against hyperglycemic-induced myocardial injury. A leptin receptor-deficient (db/db) 
mouse model displayed increased food intake and body weights that was concomitant to elevated lipid profiles. 
Similarly, cultured cardiomyocytes exposed to a simulated hyperglycemic state demonstrated impaired 
myocardial energy substrate preference (that was associated with increased inflammation, insulin resistance and 
subsequent apoptosis. However, aspalathin treatment was able to prevent these complications, with activation of 
AMPK and Nrf2 the most prominent mechanisms of protection involved. ΔΨm: mitochondrial transmembrane 
potential, AMPK: 5' AMP-activated protein kinase, Bax: Bcl-2-like protein 4, Bcl-2: B-cell lymphoma 2, Casp3: 
caspase 3, CPT1: carnitine palmitoyltransferase 1, FAO: fatty acid oxidation, FFAs: free fatty acids, Gss: 
glutathione synthetase, Il3: interleukin 3, Il6: interleukin 6, Jak2: Janus kinase 2, Mapk3: mitogen-activated 
protein kinase 3, Nox4: NADPH oxidase, Nrf2: nuclear factor (erythroid-derived 2)-like 2, Opa1: Optic atrophy 1 
homolog (human) 4, PPARɣ: peroxisome proliferator-activated receptor gamma, ROS: reactive oxygen species, 
Socs3: suppressor of cytokine signaling 3, Sod1/2: superoxide dismutase 1 or 2, Srebf1/2: sterol regulatory 
element-binding protein 1 or 2, TAG: triacylglycerides, Tnfrsf1b: tumor necrosis factor receptor superfamily, 
member 1b, UCP1: uncoupling protein 1, VLDL: very low density lipoprotein. 
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Study limitations and future work 
Limitations of study: 
1. Due to financial constraints, we were unable to investigate the precise gene regulatory network 
used by PPAG to decrease hyperglycemia-induced apoptosis. 
2. To establish a successful animal model for DCM, it is crucial to detect the precise age at which 
animals develop left ventricular dysfunction. A Tissue Doppler Imaging echocardiography (TDI) 
would have been a more precise and relevant technique to detect such changes. However, this 
technique could not be used due to the unavailability of a TDI echocardiography sensitive 
enough to detect left ventricular dysfunction in rodent animals. 
3. The combinational use of metformin with either PPAG or aspalathin was effective in enhancing 
the cardioprotective effect of these polyphenols in vitro. However, the in vivo potential of 
metformin in combination with both PPAG and aspalathin was not investigated. 
 
Future work: 
PPAG 
 Targeting the role of p53, the known modulator of apoptosis within a diabetic heart.  
 We will also make use of an in vivo model, e.g. type 2 diabetic (db/db) mice to confirm the 
protective mechanisms of PPAG in relation to apoptosis. 
 We will perform additional studies where we treat db/db mice with a combination of metformin 
and either PPAG or aspalathin before measuring relevant markers associated with 
hyperglycemia-induced myocardial injury. 
 
Aspalathin 
 Although aspalathin was expected to prevent oxidative-induced injury due to its known 
abundant antioxidants, an unexpected finding was its effect to act as a lipid lowering agent by 
significantly decreasing cholesterol related markers such as very low density lipoprotein and 
triglycerides both in high glucose-induced cardiomyocytes and diabetic mice. Thus, it is of 
interest to further employ more robust in vitro techniques such as lentiviral vector gene 
silencing to unravel the mechanism linked to its ameliorative effect of lipid toxicity and to 
confirm such findings in an in vivo model. 
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ADDENDUM 1: Animal ethical clearance 
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